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Abstract 
Phenylketonuria (PKU) is the most common inborn error of human amino acid 
metabolism. The disorder is characterized by elevated levels of phenylalanine (Phe) in the 
blood, due to a deficiency in phenylalanine hydroxylase (PAH), the hepatic enzyme 
oxidizing Phe to tyrosine (Tyr) in the presence of O2 and the cofactor tetrahydrobiopterin 
(BH4). The accumulated Phe is neurotoxic, leading to CNS Tyr deficiency and disturbed 
neurotransmitter synthesis. If not treated early in life by dietary restriction of essential Phe, 
the metabolic phenotype is severe resulting in disturbances in brain development and 
cognition.  
PKU is inherited in an autosomal recessive manner with a broad mutational spectrum 
leading to heterogeneity among PKU patients. Many patients are compound heterozygous 
with the genotype being the main determinant for the phenotype and not the single allele 
alone. The variation of dietary protein combined with genetic alteration lead to a 
multifactorial cause for hyperphenylalaninemia. However, there are many unsolved aspects 
between the patient’s genotype, its predicted effect on enzyme function, and the associated 
metabolic phenotype.  
Oral supplementation of the PAH natural cofactor BH4 is the first pharmacological 
therapy for patients with PKU, but there is still limited information on the molecular basis of 
BH4 responsiveness. About 20 - 30% of PKU patients are known to respond to BH4 
administration by a significant reduction of their blood phenylalanine levels, i.e. they can be 
treated with BH4 instead of a low Phe diet or in combination with the diet.  
In this work, we aimed at gaining further insight into the metabolic and molecular 
mechanisms of determining BH4 responsiveness. The thesis project outlines a molecular, in 
vitro analysis of several common, and also new PKU mutations and testing of their response 
to BH4 in a mammalian cell system.  
In order to gather more genotype information and select mutation combinations for 
analysis, two patient studies are described. They include the large-scale genotyping of PKU 
patients previously tested for BH4 responsiveness. Phe levels as well as loading test data were 
available from most of the 750 patients from Turkey and Croatia. The large dataset permitted 
the division into several smaller groups to discriminate between distinct BH4 loading test 
protocols and BH4 formulation used. 
Based on these data we calculated correlations of the genotypes with response to BH4, 
phenotype, and with in vitro residual PAH activities. The correlations showed a relative high 
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residual PAH activity is required for response to BH4 supplementation. Among the Turkish 
PKU patients, a relatively high proportion (22%) of potential candidates for the BH4 therapy 
was detected. Furthermore, the studies highlighted that single allele mutations are not reliable 
for the selection of potential PKU candidates for pharmacological therapy with BH4. 
Considering both studies, twenty-four novel mutations were detected. The assembly of more 
than 700 genotypes, phenotypes and BH4 loading tests data further extended the BIOPKU 
database. The database is public and new patients with documented non-responsive genotype 
may not need to undergo BH4 testing.  
The quantification of PAH activity expressed in cultured cells or in animal tissues is 
performed by a novel tandem mass spectrometry assay. Mass spectrometry allows the use of 
stable isotopes for Phe and Tyr quantification and PAH activity measurement. Among the 
discordances reported with effective prediction of a mutation’s effect on enzyme function 
and residual PAH activity, is the use of various assay protocols and quantification methods. 
Therefore, a validated, reproducible, and more specific method compared to previously used 
approaches for determining in vitro PAH activity was established. LC-MSMS is a powerful 
technique where low detection limits were found for both amino acids and thus it requires 
lower sample amounts for accurate determination of PAH activity.  
Furthermore, several particular mutations found in Turkish PKU patients were selected 
for detailed molecular analysis. The study included investigating the association of an 
intronic mutation in PAH intron 10 with BH4 responsiveness and two other mutations in PAH 
exon 11. Discordant PAH activity results were found for these mutations, as well as their 
location in important splicing regulatory elements pointed to an implication on PAH exon 11 
mRNA processing. PAH minigene constructs and EBV-transformed PKU patient cell lines 
harboring these mutations were established and analyzed. More than one transcript was 
detected upon amplification of exons 10 to 12 from the minigenes and the patient cells 
carrying the mutations of interest. Sequencing confirmed skipping of PAH exon 11 during 
mRNA processing. Affinity purifications showed abolished binding to specific SR proteins 
of RNA oligonucleotides, carrying the two missense mutations investigated. PAH exon 11 is 
vulnerable and recognition of exon 11 is subtle with mutations in splicing regulatory sites.  
Only the combination of the two mutant PAH alleles that determines residual PAH 
activity in vivo, and the individual mutations of a patient should not be viewed by 
themselves. The final section of this thesis presents the setup and validation of a mammalian 
cell test system with engineered plasmid vectors. The system allows transient co-expression 
of wild type or mutant PAH variants of previously selected genotypes and measurement of 
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PAH activity by LC-MSMS and expression levels, in presence or absence of exogenous BH4. 
The selection of genotype combinations was done referring to the previously mentioned 
patient studies and the BIOPKU database. The co-expression of two distinct PAH mutant 
alleles revealed possible dominance effects (positive or negative) by one of the mutations on 
residual activity as result of interallelic complementation. Treatment of the transfected cells 
with sepiapterin as BH4 precursor showed an increase in residual PAH activity with several 
mutations co-expressed.  
In summary, the results presented herein provide additional information and elucidation 
on PKU genotypes, phenotypes, and response to BH4 as a reference available for clinicians, 
health care professionals, and researchers for diagnosis and establishment of tailored 
treatment of patients. 
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Zusammenfassung 
Die Phenylketonurie (PKU) gehört zu den häufigsten, angeborenen Störungen im 
menschlichen Stoffwechsel der Aminosäuren. Durch einen Defekt im Leberenzym 
Phenylalanin Hydroxylase (PAH) wird die essentielle Aminosäure Phenylalanin (Phe) 
unvollständig zu Tyrosin (Tyr) umgewandelt. Dieser Vorgang führt, unter der Beteiligung 
von Tetrahydrobiopterin (BH4, Kofaktor) und O2, zur Anreicherung von Phe im Blut. Daraus 
resultieren Störungen im Tyrosinstoffwechsel sowie auch in der anschließenden 
Neurotransmittersynthese. Bei strenger, von Anfang an eingehaltener Phe-reduzierter Diät 
können die neurotoxischen Schäden von Phe und der Mangel an Folgemetaboliten in der 
Hirn- und Wahrnehmungsentwicklung vermindert werden.  
Die Vererbung von PKU erfolgt autosomal rezessiv mit einem breiten Mutationsspektrum 
und führt zu einer Vielfalt an metabolischen Phänotypen. Die meisten Patienten haben einen 
gemischt heterozygoten Genotyp, welcher für die Ausprägung des Phänotyps im Gegensatz 
zum einzelnen mutierten Allel bestimmend ist. Die Schwankungen in der 
Nahrungsproteinaufnahme in Kombination mit der Genänderung sind multifaktorielle 
Ursachen für Hyperphenylalaninämie. Diese Faktoren führen zu verschiedenen 
Unstimmigkeiten in der Vorhersage des assoziierten metabolischen Phänotyps, aufgrund des 
Einflusses der Mutationen und deren vorhergesagten Effekts auf die Enzymfunktion.  
Die erste pharmakologische Behandlung für PKU Patienten besteht in der Einnahme von 
BH4, dem natürlichen Kofaktors von PAH. Es gibt allerdings nur wenig Information über die 
molekularbiologischen Hintergründe bezüglich des Ansprechverhaltens auf BH4. Etwa 20 bis 
30% der Patienten reagieren auf diese Einnahme durch eine Abnahme der 
Blutphenylalaninkonzentration und können somit mit BH4 anstelle der niedrigen Phe-Diät 
behandelt werden. 
Das Ziel der vorliegenden Arbeit ist die weitere Aufklärung der metabolischen und 
molekularbiologischen Mechanismen der BH4-Sensitivität. Das Projekt behandelt die 
molekulare, in vitro Untersuchung von mehreren bekannten PKU Mutationen, sowie auch 
von neuen Varianten. Außerdem wurden die Mutationen auf ihre Sensitivität gegenüber BH4 
in einem Zellkultursystem getestet. 
Zusätzliche Genotypdaten und Allelkombinationen für eine detaillierte Studie wurden in 
zwei Patientenstudien gesammelt. Hierbei wurden 750 PKU-Patienten aus der Türkei und 
Kroatien genotypisiert, die vorher auf ihre BH4-Sensitivität getestet wurden. Phe-Werte 
sowie auch BH4-Belastungstestdaten wurden miteinander korreliert. Die große Datenmenge 
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erlaubt die Einteilung in kleinere Gruppen, um zwischen unterschiedlichen 
Belastungstestvorgängen und BH4-Formulierungen zu unterscheiden. Zusätzlich wurden die 
Genotypen mit dem Phänotyp, der BH4-Sensitivität und in vitro PAH-Restaktivitäten 
korreliert. Die Auswertung zeigte, dass erhöhte Restaktivität notwendig für das Ansprechen 
auf BH4 ist. Bei den türkischen Patienten wurden mit 22% relativ viele mögliche Kandidaten 
für die Therapie mit dem Kofaktor gefunden. Zusätzlich zeigten diese beiden 
Patientenstudien, dass einzelne Allelvariationen nicht ausreichend sind um zuverlässig 
Patienten für diese Therapie auszuwählen. Weiterhin wurden 24 neue PAH-Mutationen 
gefunden. Die Zusammenstellung von den Genotypen, Phänotypen und BH4-
Belastungstestdaten wurde in die öffentliche BIOPKU Datenbank eingetragen. Patienten mit 
dokumentiertem, nicht-BH4-sensitiven Genotyp müssen keinem Belastungstest mehr 
unterzogen werden.  
Die Quantifizierung von PAH-Aktivitäten in Zellkulturen oder Tiergewebeproben wurde 
mit einer neuen Tandem-Massenspektrometriemethode durchgeführt. In der 
Massenspektrometrie (MS) können stabile Isotope von Phe und Tyr zur Quantifizierung und 
somit für PAH-Aktivitätsmessungen eingesetzt werden. Verschiedene PAH-
Aktivitätsmessungsprotokolle und Quantifizierungsmethoden führen immer wieder zu 
unterschiedlichen Ergebnissen bezüglich Mutationen und deren Effekt auf die 
Enzymfunktion und Restaktivität. Aufgrund dessen haben wir eine auf LC-MSMS-basierte, 
validierte, reproduzierbare und im Vergleich zu anderen gängigen Messmethoden 
spezifischere Methode zur in vitro Bestimmung von PAH-Aktivitäten entwickelt. Diese neue 
Methode benötigt kleinere Probenmengen und zeichnet sich durch niedrige 
Detektionsgrenzen für beide Aminosäuren aus. 
Eine detaillierte, molekularbiologische Analyse wurde an drei ausgewählten Mutationen 
aus der türkischen Patientenstudie durchgeführt. Hierbei handelt es sich um eine intronische 
PAH Mutation (Intron 10) mit BH4-Sensitivität, sowie zwei Punktmutationen im Exon 11 die 
zum Austausch von Aminosäuren führen. Für diese Mutationen fanden wir widersprüchliche 
PAH-Aktivitäten. Zusätzlich deutete die Lage dieser beiden Mutationen in Elementen der 
Spleissregulierung auf einen möglichen Einfluss auf die Prozessierung der PAH mRNA. 
PAH-Minigene und EBV-transformierte Zelllinien von PKU Patienten mit diesen Mutationen 
wurden hergestellt und untersucht. Die Analyse der cDNA Sequenz ergab zwei 
unterschiedlich lange Transkripte nach der PCR-Amplifikation von PAH Exon 10 bis 12. Die 
Sequenzierung bestätigte, dass es sich hierbei um das Fehlen von Exon 11 handelte. 
Weiterhin zeigte die Affinitätschromatographie von RNA Oligonukleotiden (tragen die 
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untersuchten Mutationen in der Sequenz) eine fehlende Bindung zu spezifischen SR 
Proteinen. Zusammenfassend ist PAH Exon 11 labil und Mutationen in spleissregulierenden 
Elementen führen leicht zu einer verminderten oder ausbleibenden Exonidentifizierung.  
Das Zusammenwirken zweier, mutierter PAH-Allele bestimmt die PAH-Restaktivität in 
vivo. Daher sollten auch in vitro die Mutationen nicht nur einzeln untersucht werden. Im 
letzten Teil dieser Arbeit wird der Aufbau und die Validierung eines Zellkulturtestsystems 
mit gentechnisch veränderten Plasmidvektoren beschrieben. Das System ermöglicht die 
transiente Co-Expression von Wildtyp oder mutierten PAH-Varianten aus ausgewählten 
Allelkombinationen, sowie die Bestimmung der PAH-Aktivität mittels LC-MSMS und die 
Menge der PAH-Expression, in Gegenwart oder Abwesenheit von exogenem BH4. Die 
Auswahl der Genotypen basierte auf den Daten der Patientenstudien und der BIOPKU 
Datenbank. Die Co-Expression von zwei unterschiedlichen PAH-Allelen wies mögliche 
dominierenden Effekte (positive oder negative) durch eine der beiden Mutationen auf die 
PAH-Restaktivität aufgrund der interallelischen Komplementierung auf. Die Behandlung von 
transfektierten Zellen mit sepiapterin als BH4-Vorstufe zeigte einen Anstieg der Restaktivität 
bei einigen der untersuchten Mutationen.  
Zusammenfassend bieten die hier gezeigten Studien zusätzliche Informationen und 
Aufklärung bezüglich PKU Genotypen, Phänotypen und BH4-Sensitivität. Diese Arbeit dient 
als Referenz für Mediziner, Therapeuten und Forscher zur Diagnose und zur Erstellung einer 
auf den Patienten zugeschnittenen Behandlung. 
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1.1 Phenylketonuria and Hyperphenylalaninemia 
1.1.1 History of Phenylketonuria (PKU) 
In 1930 phenylketonuria (PKU) was acknowledged as an inborn error of metabolism, a 
concept not widely known at that time. It was the first inherited metabolic disorder found to 
lead to mental retardation and seriously affecting individuals. PKU is the most common 
defect in amino acid metabolism and nowadays figures as a model system in genetics, 
clinical medicine and biology.  
The disease was discovered by the Norwegian physician Asbjørn Følling upon analysis of 
urine from two mentally retarded children presenting with several other clinical symptoms 
and was later renamed to phenylketonuria (1, 2). The abnormally excreted substance in urine 
of these children was identified as phenylpyruvic acid, a transamination product from 
Phenylalanine (Phe). Further investigations lead to the conclusion that the defect is due to 
elevated concentrations of Phe in the blood. In addition, it was noted that very often siblings 
were affected, together with consanguinity among parents, suggesting an autosomal recessive 
inheritance (3, 4).  
Phe is an essential amino acid for humans taken up with nutrition. The evidence 
 soon emerged that Phe-low diet could prevent the metabolic phenotype, namely 
hyperphenylalaninemia (HPA), and thus mental retardation (5, 6, 7, 8). The knowledge that 
PKU can be treated successfully greatly improved patients’ and families’ lives. This was also 
the urge of the bacteriologist Robert Guthrie, successfully trying to develop a more accurate 
test for PKU and promoting the need to test all newborns, hereby saving many individuals 
from brain damage. Initially, the detection of alternative metabolites like phenylpyruvic acid 
was used for diagnosis of PKU using a ferric chloride test (2, 9). Robert Guthrie developed 
the first practical screening test for PKU in the early 1960s (10). The Guthrie test is a 
bacterial inhibition assay using a drop of blood from a heel prick spotted on filter paper. The 
filter paper is applied to an agar gel containing Bacillus subtilis, which requires Phe for 
growth. Bacterial growth only appears in samples with elevated Phe levels and the size of the 
bacterial colony gives a rough estimate of the Phe concentration in the sample. This test was 
cheap, reliable and robust. The ‘Guthrie cards’ are still commonly used today and as Bob 
Guthrie already suggested, they can be used for testing other metabolic conditions. A 
newborn screening program for PKU was established in the United States during the late 
1960s. Since then, it was further developed and applied in many other countries, improved 
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with new technologies and expanded to other inherited diseases for the purpose of early 
diagnosis and treatment. 
The enzyme deficient in PKU patients, phenylalanine hydroxylase (PAH, phenylalanine 
4-monooxygenase, EC 1.14.16.1) was described in 1953 (11). PAH catalyzes the conversion 
from Phe to Tyrosine (Tyr) and is mainly active in the liver and kidneys. Since the mapping 
and cloning of the gene sequence of human PAH cDNA in the 1980s (12), much progress in 
mutation analysis was reported. Finally, a locus-specific database has been set up to maintain 
and centralize mutation data on PAH gene (Phenylalanine Hydroxylase Locus 
Knowledgebase, PAHdb, www.pahdb.mcgill.ca). Once updated, around 600 mutation 
records can be found in the continuously expanding PAHdb. 
Tetrahydrobiopterin (BH4) is the essential cofactor in the catalytic conversion of Phe to 
Tyr (13). In 1974, S. Milstien and S. Kaufman reported on the stimulation of PAH with 
increase in activity by the addition of exogenous BH4 added to the medium containing liver 
slices for the study of PAH (14). H. - Ch. Curtius and A. Niederwieser suggested ten years 
later that Km mutants in the PAH gene lead to responses to the cofactor and lowering of Phe 
levels (15) But it was not until 1999 that Kure et al. described patients treated by the oral 
administration of BH4. This option significantly changed the field, increased activities in 
further characterizing BH4-response and greatly improved treatment for some PKU patients.  
PKU emerged as the prototype for treatable human inherited genetic diseases by early 
diagnosis and showed that a simple Mendelian phenotype can also be a complex disorder (5). 
The understanding of the links between gene, mutations, enzyme function, metabolism and 
clinical phenotype provide opportunities to better understand the pathophysiology of disease.  
1.1.2 Epidemiology of PKU 
The prevalence of PKU varies widely around the world (16). The ethnic background is 
probably the most predominant factor influencing the incidence of PKU. However, 
differences in cutoff values and definitions of PKU may lead to inconsistencies in population 
statistics. 
In Europe, depending on the area, the prevalence of PKU is in average 1 in 10’000 live 
births with highest prevalence in Northern Ireland (1 case in 4’500) and lowest in Finland (1 
in 100’000) (17, 18). In the United States, ethnic differences correlate with varying 
prevalence. The incidence is higher in Caucasians and Native Americans and lower in 
African Americans, Latinos and Asians (19). This relates to the distribution among those 
continents of origin (20). Africa has a very low incidence of PKU (21), while in Spain 
especially mild HPA is predominant (22). In Asian populations, differences in occurrence 
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can be found within China (between one per 15’000 and one per 100’500) (23, 24), but also 
Japan and Thailand exhibit lower prevalence than Europe (one per 70’000 and one per 
200’000 respectively) (25, 26).  
1.1.3 Diagnosis and Classification of Hyperphenylalaninemias  
PKU is caused by different disease-causing alleles in the PAH gene, and thus deficiency 
in PAH enzyme function. However, this does not account for all hyperphenylalaninemias and 
not all degrees of HPA’s are identical risk factors for impaired cognitive development (see 
below, 1.3.2). Treatment of PKU patients by dietary Phe restriction diminishes the toxicity of 
excess Phe to the brain and enables an almost normal development and cognitive function. 
Until the mid 1980s, the most specific method in diagnosing and classifying PKU was 
considered to be the direct measurement of PAH activity in a liver biopsy (27, 28, 29). 
However, this method is ethically unjustifiably and no longer used. 
Today, the diagnosis is based on neonatal screening results of blood Phe levels. Blood 
Phe concentrations are determined by analysis of dried blood spots (DBS) from a filter paper 
(Guthrie card) obtained by heel prick, in general around day three after birth. Tandem mass 
spectrometry (TMS) is nowadays an alternative to the bacterial Guthrie test used for the 
determination of Phe and Tyr levels from small volumes of blood (30, 31). TMS 
simultaneously allows the detection of other inborn errors of metabolism, as many amino 
acids and metabolites can be measured from the same sample. Other fluorimetric and 
chromatographic screening methods are regularly used as well in PKU newborn screening 
(32). Blood Phe levels in newborn range between 30 and 120 µM and levels higher than 120 
µM are considered as pathological and require further investigation (33). A second test is 
required for confirmation of HPA and to eliminate the possibility of transient HPA. Delayed 
maturation of PAH can lead to transiently elevated levels in non-PKU infants (34).  
The report by Kure et al. in 1999, which describes several patients to respond to oral 
administration of the cofactor BH4 by lowering Phe levels led to a new subgroup in 
classifying HPA’s. Those patients generally present with mild to moderately elevated Phe 
levels. The diagnosis, properties and mechanisms underlying BH4 responsiveness will be 
described in more detail in section 1.7.   
After the introduction of newborn screening, PKU became viewed as a complex disorder 
with variable degrees of severity depending on blood Phe levels and daily dietary Phe 
tolerance. The recognition that the phenotype varies relative to the degree of HPA led to 
classification schemes that influence the stringency of treatment (35, 36, 37, 38, 39). 
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Regulations across countries vary about the start of the treatment, but the following current 
classification (according to the recent 2012 NIH consensus conference) has been elaborated 
for the types of PKU (Table 1). 
Molecular genetic testing is not primarily performed for diagnosis or treatment, but can 
be used for genetic counseling, disease classification and genotype-phenotype correlations. 
The genotype is the main determinant for the metabolic phenotype (40). However, the 
identification of mutant PAH alleles cannot be used alone for classification of HPA, as many 
inconsistencies are reported (41, 42). Mutation scanning by denaturing high-performance 
liquid chromatography and cDNA sequence analysis are methods of choice in molecular 
genetic testing. New methods like whole genome or exome sequencing are on the way (43, 
44, 45).  
Table 1: Classification of hyperphenylalaninemias according to blood Phe levels. 
Blood Phe levels below 120 µmol/L are considered normal (16).  
 Blood Phe µmol/L 
Mild HPA (no treatment required) 120 - 360 
Mild HPA (gray zone for treatment) 360 - 600 
Mild PKU 600 - 900 
Moderate PKU 900 - 1200 
Classic PKU > 1200 
BH4-responsive HPA/PKU > 360 
 
PAH deficiency is not always the underlying cause for elevated Phe levels. Upon a 
positive screening result, further diagnostic tests must be performed in all newborns with 
even slightly elevated blood Phe levels. In 1 - 2% of HPA cases, mutations in the genes 
coding for enzymes in BH4 biosynthesis or regeneration pathways lead to disturbed Phe 
metabolism. An HPA is confirmed by full amino acid analysis in plasma or blood. The 
differentiation of a PAH defect and a defect in BH4 metabolism is done by analysis of urinary 
or blood pterins and determination of dihydropteridine reductase (DHPR). The differential 
diagnosis for elucidating BH4 deficiencies is described in more detail in section 1.3.2. 
1.1.4 Clinical Presentation and Pathophysiology  
Symptoms of untreated or late-diagnosed PKU patients are generally summarized as 
mental retardation, but the clinical effects of HPA/PKU are highly variable. Although mental 
retardation is greatly prevented by an early start of diet, patients treated from birth are often 
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not completely protected from cognitive impairment. Slowed reaction times, reductions in 
executive functioning, non-executive functions (speed of information processing, fine motor 
skills, and perception/visual-spatial abilities), and increased hyperactivity and impulsivity, 
are among the neuropsychological impairments described in individuals with PKU benefiting 
from early treatment (46, 47, 48). For example, the IQ in treated children with PKU well 
reaches average range, but always remains little lower than IQ from siblings and peers. An 
IQ level reduction was even found to correlate with an increase in Phe levels and leading to a 
reduced mental processing speed. Children with PKU are often found to perform less well in 
school (49). Despite a lifelong dietary treatment, some degree of neurocognitive deficit 
always occurs in most patients with PKU (50). 
In untreated or late-treated PKU individuals, clinical symptoms are more severe and 
range from severe intellectual disability, seizures, ataxia to motor deficits, dermatological 
and behavioral problems (51). In adults, anxiety disorders and depression have been reported 
(52, 53, 54). Microcephaly and impaired growth were revealed in adult non-treated PKU 
patients (55). A characteristic of classic PKU already known from 1930s is a mousy odor that 
results from the excretion of phenylketone bodies in the urine. Hypopigmentation in PKU 
patients is a result of deficient melanin synthesis inhibited by the elevated Phe levels (56). 
Many of these symptoms are only rarely observed nowadays because of the introduction of 
neonatal screening. Children with a late diagnosis and start of treatment can still markedly 
benefit from dietary treatment. Cognitive performances may improve in children as well as 
intellectual functioning, behavior and improved quality of life (57). Nevertheless, intellectual 
disabilities remain and chronic neurotoxic consequences from high Phe levels are 
irreversible.  
All these symptoms led to the conclusion that a PAH deficiency mainly affects the central 
nervous system and leads to impaired brain development and function. A broad concordance 
was found between the metabolic phenotype (determined by the mutant genotype) and the 
cognitive phenotype (40). PAH alleles with a severe effect are likely to cause PKU with low 
IQ scores in the untreated state, whereas mild PAH alleles are likely to cause mild HPA with 
higher IQ scores (58). Thus, high plasma Phe levels do not always lead to high brain Phe 
levels and brain abnormalities (59), as shown by noninvasive in vivo 1H-magnetic resonance 
spectroscopy (60, 61). These studies imply that interindividual variation in brain Phe 
transport is another factor to explain interindividual intellectual abilities in PKU. Some 
patients with high blood Phe, but normal brain Phe levels just escape brain dysfunction (62, 
63).  
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A general agreement arises that the blood-brain barrier (BBB) plays an important role in 
neurologic consequences of PKU.  
The pathogenesis of brain dysfunction is not completely known. Nevertheless, increased 
concentrations of Phe in the brain are neurotoxic and cause a disturbance of transport 
processes of other large neutral amino acids (LNAA), resulting in abnormal homeostasis in 
the brain. Several mechanisms were analyzed for their involvement in neuropsychological 
dysfunctioning of the brain (64, 65, 66).  
Amino acid transport from blood to brain is a dynamic process, involving a set of amino acid 
transporters each with specific affinity for a set of amino acids. Phe is entering the brain via 
binding to the LNAA type 1 transporter (LAT1, SLC7A5). The other LNAA, valine, leucine, 
isoleucine, methionine, threonine, histidine, tryptophan and tyrosine, are also using this route 
in a competitive manner (67). In addition, for each LNAA taken into the brain, the LAT1 
transporter excretes one LNAA. Moreover, the LAT1 transporter shows highest affinities for 
Phe among all the LNAA’s (68, 69, 70). High concentrations of Phe were found to impair the 
function of the LAT1 carrier and neuronal uptake of non-Phe LNAA is reduced, leading to 
low intracellular concentrations of these amino acids. This increases the potential for 
neurotransmitter dysfunction and their availability for protein synthesis (71, 72). In addition 
to the high neurotoxic Phe concentrations, deficient LNAA also contribute to pathogenesis in 
PKU. In general, decreased availability of these LNAA (which are now essential amino 
acids) results in decreased protein synthesis (73, 74). Regulation of cerebral protein synthesis 
is essential for brain development and function (75, 76). Myelin is a cerebral protein often 
found abnormal in PKU and associated with white matter abnormalities detected in PKU 
patients (77, 78). Reduced myelination was also found in two animal models, in the Pahenu2 
genetic mouse model with PAH deficiency (see also section 1.1.5 below) and in the 
pharmacologically induced HPA rat model (79, 80). Oligodendrocytes had adopted a non-
myelinating phenotype in the animals, which was also confirmed in cell culture (81, 82), 
possibly appearing secondary to an increase in Phe. Diffuse white matter pathology was 
found in treated and untreated PKU patients. In untreated patients, this is likely to reflect 
hypomyelination while in early-treated patients this pathology is likely to reflect 
intramyelinic edema. Research demonstrated that this pathology is associated with metabolic 
control and can be reversed with adherence to the strict diet (78). However, impaired myelin 
function may not completely account for the principal pathophysiological defect in PKU 
(83). 
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Oxidative stress is possibly also involved in the pathology of PKU. Causes of oxidative 
stress are often not well understood. However, it is assumed to result from the accumulation 
of toxic metabolites leading to the induction of free radical production (84). Oxidative stress 
is known to be associated with obesity, cardiovascular disease and stress. The low-Phe diet 
may be a risk factor and lead to deficiencies for example of zinc, selenium, ubiquinone-10 
and L-carnitine (85). In addition, the excessive production of reactive species and associated 
metabolites may increase the risk of oxidative stress of tissue damage in PKU. Several 
studies in PKU animal models, but also in PKU patients have analyzed oxidative stress 
parameters (antioxidant enzymes, e.g. Glutathione peroxidase, Superoxide dismutase, 
catalase, and also non-enzymatic antioxidants, e.g. some vitamins, glutathione, minerals, 
carotenoids, but also high and low density lipoproteins, summarized in ref. (85)). Especially 
in late-diagnosed PKU patients, these markers seemed evident, probably associated with the 
long exposure to high Phe (86). Early diagnosed and diet compliant PKU patients seem more 
protected from oxidative damage. Further studies in PKU patients are required to confirm 
results from animal models (87). It is however suggested to maintain patients on follow-up 
and make them aware of good metabolic control (85, 88).  
Figure 1 summarizes different cascades and probable interactions with each other 
resulting in brain dysfuntion in PKU. Reduced activity of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMG-CoA reductase) and the function of monoamine oxidase B as a 
modifying gene were studied in relation with potential pathological mechanisms for HPA-
induced damage to the brain (89, 90). HMG-CoA reductase is a rate-limiting enzyme in the 
metabolic synthesis pathway of cholesterol.  
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Figure 1: Different cascades and their interaction with each other as a concept of the 
pathophysiology of brain dysfunction in PKU (Figure modified from ref. (94)). 
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Myelin, which contains a high content of lipids especially cholesterol, connects these two 
mechanisms as potential pathogenic factors in brain dysfunction in PKU. It is however not 
clear, whether impaired cholesterol synthesis leads to reduced myelination in PKU or 
whether synthesis of HMG-CoA reductase is reduced, suggesting that reduced cerebral 
protein synthesis may affect enzymes in myelin formation (90). Impairment and reduced 
activities of several other key enzymes are mentioned, like glutamatergic synaptic 
transmission, synaptogenesis, and activity of pyruvate kinase, that are still subjects of debate 
and where the clinical consequences for PKU are poorly understood (91, 92, 93). 
Reduced blood Tyr concentrations do not to correlate with cognitive outcome in PKU, 
and Tyr supplementation alone does not prevent mental retardation (95, 96). However, 
reduced Tyr and Trp concentrations lead to insufficient synthesis of catecholamines and 
serotonin in the central nervous system. The metabolic relationship between Phe, Tyr and Trp 
and their oxidation to neurotransmitter precursors is depicted in Figure 4. Lower levels of 
dopamine, catecholamine, and serotonin were found in the PKU mouse model Pahenu2 
compared to non-HPA mice. A reduction in the synthesis of these precursor metabolites was 
also shown in urine and CSF in humans with PKU (97, 98, 99, 100). However, the dietary 
supplementation of Tyr and Trp restores reduced neurotransmitter synthesis (101). These 
neurotransmitters are normally concerned with executive functions of the brain and the 
initiation of movement. In addition, cerebral serotonin deficiency may explain the increased 
occurrence of anxiety and depression disorders in PKU patients. High Phe concentrations 
were even shown to inhibit the activity of the other two monooxygenases TH and TPH (102, 
103, 104). In contrary, Fernstrom and Fernstrom (105) negate high Phe levels as inhibitors 
for TH and these findings alone are still matter of debate. Burlina et al. showed, that in 
untreated PKU patients, i.e. at high blood Phe levels, both dopamine and serotonin 
metabolites are extremely low in CSF (106). In summary, although dopamine and serotonin 
are involved in postnatal brain development and maturation, these findings do not explain the 
severe mental retardation of PKU patients, but they are likely to explain certain cognitive 
deficiencies.  
1.1.5 Treatment Options for PKU 
Since the discovery of Phe-low diet, resulting in near-normal cognitive development in 
PKU, dietary management has emerged as effective treatment for 60 years. It is an easy and 
straightforward treatment. Nevertheless, alternative strategies are required and advancing, as 
adherence to natural protein restriction is often compromised at several stages of life. In 
addition to dietary food, other nutritional deficits may occur through PKU resulting in 
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variable neurological outcomes (94, 107). Diet imposes a burden on patients and families, 
economical and social, which is a downside of the therapy (108) and compliance is often a 
problem (109). Reasons reported for low compliance with diet include lack of time, impact 
on social life and stress associated with food preparation (110, 111).  
It is still debated whether plasma Phe concentrations lower than 600 µmol/L require 
dietary treatment (63, 112). These individuals were not found to be at higher risk for 
developing neurological impairment than non PAH-deficient individuals. In addition, Phe 
levels often change between newborn and later age, so that the diet should also be adjusted 
according to stage of life. Phe can only reach its full potential biological value in non-
restricted dietary status, which has to be considered when analyzing test results. The Phe 
level during dietary treatment is often considered as a tolerance level and an estimate for 
residual PAH.  
The main focus of new treatment approaches is the decrease of the blood Phe levels. The 
increasing knowledge on the genetic basis of PAH deficiency has allowed for the 
investigation of novel pharmacologic therapies to directly ameliorate the effects of the 
mutant enzyme (113). PKU is targeted at the different levels, from nutritional intake and 
intestinal uptake to the liver and the BBB, where toxic effects of high Phe levels have been 
observed. The dietary management, as well as promising alternatives in development will be 
discussed in the following paragraphs. 
Relevance of PKU animal models 
PKU animal models provide a great basis for characterizing different aspects of Phe 
metabolism and kinetic properties of PAH protein. Many early studies were performed in a 
pharmacologically induced rat model (79), but a better opportunity to obtain a mammalian 
counterpart of human PKU now exists in mice. The access to a model of the human disease 
in an orthologous animal has greatly advanced work of therapies for PKU (114). Two 
homoallelic and one heteroallelic orthologous mouse models are frequently used in the pre-
clinical investigations: Pahenu1/1 (ENU1) and Pahenu2/2 (ENU2), and the hybrid strain Pahenu1/2 
(ENU1/2), respectively. The models have been created by chemical mutagenesis with the 
ENU mutagen (N-ethyl-N-nitrosourea) (115), which induces point mutations. Mice with 
various Phe levels were found, corresponding to mild and classic PKU phenotypes. The 
homozygous ENU1 mouse is classified as non-PKU HPA type (116), whereas the ENU2 
mouse exhibits a PKU phenotype with no PAH activity (117), very similar to human classical 
PKU. The mutations were characterized later by DNA sequence analysis (118). The Pahenu1/1 
mutation was identified as c.364T>C leading to p.V106A missense change on protein level. 
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The Pahenu2/2 model harbors the c.835T>C (p.F263S) mutation. In the human PAH sequence, 
this mutation corresponds to p.F263L (c.789C>G) amino acid substitution as was once 
reported in a PKU patient (119). The ENU1/2 mouse orthologue is hyperphenylalaninemic 
with moderate, intermediate phenotype of the other two strains (p.V106A/p.F263S) (120). 
With these three models, all phenotypic levels of human PKU can be represented. The 
heteroallelic ENU1/2 model was reported particularly useful for the assessment of alternative 
therapies for PKU (120) and pharmacological chaperone mechanism, as it is also a model for 
BH4-responsive PKU (121, 122).  
Dietary therapy 
The substantial effect of dietary restriction is due to the fact that Phe is not synthesized in 
the body and that the concentration of Phe in the blood can be controlled by dietary intake. 
Although there are no common dietary guidelines around the world, consensus is found that 
dietary therapy is started early after the positive newborn screening results and that treatment 
in infancy is highly important (123, 124).  
Phe is present in all naturally existing proteins. This means that meat, fish, cheese, eggs, 
seeds with flour, milk, tofu or soya for example cannot be readily eaten or even need to be 
completely avoided, depending on the type of severity. The protein content of vegetables and 
potatoes needs to be analyzed before consumption. Foods are classified according to their 
Phe content and the amount of each to be eaten can be calculated. But this also means that 
protein substitutes need to be consumed with the food for avoiding other nutritional deficits. 
Much progress has been made in those chemically manufactured food mixtures to provide 
good taste and smell and all nutritional components required, but they might never reach the 
status of normal food. This is another drawback on treatment of PKU making it less palatable 
and reducing good compliance over a long period of time.  
The stringency of the diet can vary widely, according to the severity of the PAH 
deficiency and the stage of life. In general, cutoff values rise from the age of 4 or 8 and later 
in adolescence with an upper limit of 600 µmol/L accepted in some countries. But individual 
goals are often set (see Table in (16)). Constant blood Phe monitoring and intensive guidance 
by a healthcare team, as well as training for self-management, follow-up and good 
communication with the patient belong to successful approaches for treatment of PKU.  
There is a rationale from several studies for lifelong treatment to minimize neurological 
damage that can still occur at later stages of age. Also upon discontinuation of treatment, 
severe symptoms can return like seizures and anxiety disorders. Restoration of metabolic 
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control ameliorates these symptoms and improved emotional functioning and quality of life 
were noticed (125).  
Treatment with large neutral amino acids (LNAAs) 
All non-Phe LNAAs become essential amino acids for the brain in a PAH-deficient 
individual when Phe blocks transport across BBB and need to be provided through other 
pathways. As these amino acids share common transport mechanisms with Phe, several 
hypotheses emerged for beneficial LNAA supplementation. These ideas have been 
investigated already early on (126). LNAA administration was shown to reduce toxic Phe 
levels in the brain of patients despite constantly elevated serum concentrations (71, 127, 
128). In this way, other amino acids with high affinity for the BBB transport system keep 
high plasma Phe concentrations from entering the brain. This strategy could help to protect 
the brain in non-compliant patients. In addition, LNAA supplementation was shown to result 
in improvement of neuropsychological functions without decrease of cerebral Phe 
concentrations (129, 130). Higher doses of Tyr and Trp also lead to increased synthesis of 
dopamine and serotonin in HPA patients (101). The effect of LNAA is also influencing 
intestinal tract transport, as decreased blood Phe concentrations were determined upon 
supplement administration (129). 
These supplements may not replace Phe-low diet, but may help to relax dietary restriction 
of treated individuals or help in management of untreated adults with classic PKU. However, 
further clinical trials and data are required to examine safety and efficacy of LNAA therapy 
still in development.   
Glycomacropeptide 
Another strategy for targeting the intestinal tract by development of medical food is 
supplementation of glycomacropeptide. Glycomacropeptide is a natural protein from cheese 
whey that is rich in specific essential amino acids but contains no Phe, Tyr, or tryptophan 
(Trp) (131). Food enriched with this protein and supplemented with Tyr and Trp can be given 
as an additional measure and patients may need less amino acid mixture. However it needs to 
be assured that purity is sufficient and that it is absolutely free of Phe. Studies have given 
promising results in terms of palatability, safety and improved compliance, but further 
evidence is still required (132, 133, 134).  
Enzyme substitution therapy 
Enzyme therapy can be addressed in two different ways, either by replacing PAH or by 
substitution with a foreign protein capable of metabolizing Phe. Replacement of PAH is 
highly challenging, as the whole, intact multi-enzyme complex for PAH catalysis including 
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BH4-cofactor is required. In addition, PAH regulation is complex and high amounts of stable 
PAH are tedious to isolate and purify.  
The enzyme of choice for substituting PAH is phenylalanine ammonia lyase (PAL, EC 
4.3.1.5) (135, 136), derived from plants and compared to PAH, sufficiently more stable as 
oral formulation. PAL targets the intestinal system and is also involved in Phe metabolism, 
capable of lowering blood Phe in humans. This exogenous enzyme converts Phe to trans-
cinnaminic acid and negligible amounts of ammonia without the need of a cofactor, making it 
catalytically less complex than PAH. In humans, trans-cinnaminic acid is safely and rapidly 
converted to hippuric acid, which is then excreted in the urine (137, 138).  
The efficacy of PAL was tested in the PKU mouse model ENU2 (see above) and yielded 
complete correction of blood Phe concentrations in blood and brain with a sustained effect 
for up to one year with weekly injections (139). The optimal source of PAL was later found 
in the algae Anabaena variabilis (140). The PEGylation (attachment of polyethylene glycol 
polymers to lysine side chains) diminished immune-mediated detection and elimination of 
the injected enzyme (141). Clinical trials have been initiated in PKU patients and no severe 
adverse events were recorded, but a significant decrease in Phe blood levels after a single 
injection. A phase II clinical trial is in progress in addition to development of an orally 
administrable PAL form (142). PAL would probably be used in addition to a less stringent 
Phe diet. 
Gene therapy 
Gene therapy approaches for treating PKU could be a permanent therapy, which is highly 
desired for alleviating the need of complicated diet. Unfortunately, PKU can only be a 
candidate when gene therapy is safe and an efficient delivery system for lasting correction of 
PKU phenotype is developed. Promising investigations in PKU murine models are on their 
way, but still several years away from clinical trials in humans. Recently, much success has 
been achieved with use of recombinant adeno-associated viral (rAAV) vectors for gene 
transfer targeting the liver in correcting HPA for up to one year in mice (143, 144). However, 
the vector’s genome is gradually eliminated as it is not integrated into the hepatocyte’s DNA 
and re-injection was not effective due to immunological responses.  
Another attractive target organ for gene therapy is skeletal muscle. It is easily accessible 
and does not undergo cell division. For efficient PAH metabolism, local production of BH4 is 
required and so enzymes involved in BH4 metabolism need to be expressed likewise. A 
promising outcome of this strategy of mimicking the role of a second phenylalanine 
metabolism has also been reported (145). 
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Liver- and muscle-directed gene therapy need to be further optimized with improved 
sustainability (146). Promising results were found upon application of non-viral gene therapy 
with increased efficacy and less adverse effects (147). Successful gene therapy might then 
lead to human trials in PKU in the next few years. Not only PAH gene transfer, but also 
therapeutic liver repopulation with wild type hepatocytes and even liver transplantation have 
been investigated as potential approaches for treating PKU (148). Clinical evaluations for 
these treatment alternatives are still required.  
Tetrahydrobiopterin (BH4) 
An oral BH4 loading test was introduced in the 1980s to discriminate between patients 
with PAH deficiency or with a BH4 deficiency (149). With BH4 formulations of higher purity 
(only 6R-BH4), doses in the loading test were increased from 7.5 to 20.0 mg/kg body weight. 
Kure et al. (150) reported in 1999 a group of patients carrying mutations in the PAH gene 
with decreasing blood Phe values several hours after oral administration of the PAH cofactor 
BH4. Around 30% of patients with PKU are now thought to respond to BH4 treatment (151), 
and there is wide range in the extent of response. While the most rapid Phe reduction of up to 
90% after 4 - 8 hours is highly indicative for a BH4-deficiency, in PKU patients responding 
to BH4 administration, blood Phe reduction of 30 - 80% is evident after 24 - 48 hours. 
Therapy with BH4 as an alternative approach to the Phe-low diet was introduced in 2001 
(152).  
Different test protocols have been developed for the oral loading test as well as different 
guidelines among countries for time of testing and cutoff levels. This again leads to 
heterogeneity among loading test results and inconsistencies in predicting response, 
justifying requirement of further testing. BH4-responsive patients generally present with 
milder forms of PKU, which is also illustrated from several studies, displayed in of Figure 2. 
Panel A shows the outcome of the 24-hour loading test in European PKU population with 20 
mg/kg BH4 and a 30% responsiveness cutoff (A). In B, a number of patients in the USA who 
responded to commercial BH4 formulation sapropterin (10 mg/kg per day) on day 8 with at 
least a 30% reduction of blood Phe concentrations are displayed. The proportion of BH4-
sensitive patients increases as the severity of the phenotype decreases (153), which is due to 
the mechanistic action of administered BH4, requiring sufficient active hepatic PAH protein 
(residual enzyme activity). However, this eliminates the need for challenging every patient. 
The mechanistic details and explanations for BH4 responsiveness are described in section 1.7. 
Two different forms of BH4 have been used in clinical investigations. Since 2008, sapropterin 
dihydrochloride (Kuvan® or Biopten®, BioMarin Pharmaceutical Inc), the synthetic analogue 
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of BH4, has been market approved for treatment and is commercially available in the US, 
Japan and Europe, whereas the older form, 6R-BH4 dihydrochloride is unregistered (Schircks 
Laboratories, Jona, Switzerland). However, both forms are chemically identical. 
 
Figure 2: Responsiveness to tetrahydrobiopterin in patients with phenylketonuria according 
to initial blood phenylalanine concentrations (Figure adapted from ref. (16)) 
Generally accepted as the threshold of BH4 responsiveness is a reduction of blood Phe 
levels of at least 30% during the first 8 - 24 hours after oral administration of BH4. Test 
durations may be even up to 4 weeks. Several late responders can be detected in longer test 
periods. The test dose is typically 20 mg/kg bodyweight and is administered once a day with 
regular blood sampling. The detailed comparison of test protocols is described elsewhere 
(154).  
In clinical trials, BH4-treatment was mostly well tolerated with no severe side effects and 
long-term efficacy was found. A successful treatment leads to a higher Phe tolerance and 
allows these patients benefit from a relaxation of the strict diet. A modification of the diet 
and constant monitoring of Phe values is, however, required. Eventually, patients with mild 
phenotypes and good responsiveness can attain a normal unrestricted diet (155, 156, 157, 
158). Responsiveness testing and treatment with BH4 is rather expensive and not available 
for all patients. This might change in the future when the prediction of response to BH4 
treatment is ameliorated. Some PAH mutations could be associated with a BH4-responsive 
phenotype (159, 160) and a combination of genotyping with the BH4 challenge may be the 
method of choice for prediction of BH4 responsiveness. The online BIOPKU database 
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(www.biopku.org) tabulates available data on almost 800 genotypes, phenotypes and BH4-
response in patients previously tested and is used as a reference tool in consulting whether to 
challenge a patient based on previous similar genotype results.  
Pharmacological Chaperones 
BH4 induces a gain-of-function in PAH in a multifactorial response mechanism with a 
notable stabilization of PAH structure (subchapter 1.7). However, efficacy studies of 
treatment with BH4 revealed that it is not able to significantly lower blood Phe levels in all 
milder PKU genotypes and other potential ligands as therapeutic agents are investigated. 
Pharmacological chaperones are compounds of low molecular weight that promote folding 
by stabilizing the native state of a target protein without actually binding to them, or by 
facilitating the folding of nonnative intermediates (161, 162). The pharmacological 
chaperone-induced stabilization of protein conformations corrects protein misfolding 
otherwise leading to loss of function. They showed their potential in the treatment of several 
genetic disorders in successfully reducing clinical symptoms, for example in lysosomal 
storage diseases and cystic fibrosis. Pharmacological chaperones are either developed by 
optimization of natural or synthetic substrates with increased affinity or by screening 
procedures. Two screening studies revealed several promising candidates for further drug 
development. Pey et al. employed a high-throughput screening of a thousand compounds by 
fluorescence monitoring for PAH stabilizing ligands (163). The efficiency was demonstrated 
in cell and animal models and the molecules present a basis for drug optimization. Santos-
Sierra et al. performed a virtual screening in a chemical library to identify potential 
candidates for further testing in vitro and in vivo in a PKU mouse model (164). Their results 
present another class of molecules for further development into a more effective drug 
treatment for PKU. 
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1.2 The Phenylalanine Hydroxylase System 
1.2.1 Aromatic Amino Acid Monooxygenases in the Mammalian 
Phenylalanine Metabolism  
The concentration of Phe in the blood is determined by dietary intake and the balance 
between protein synthesis and catabolism (including free amino acid pool) (165). The 
hydroxylation to Tyr through PAH is the limiting step and major pathway for catabolizing 
dietary Phe. In addition, it is the only metabolic pathway through which Phe can be 
completely catabolized to carbon dioxide and water (166).  
PAH gene expression is observed at the transcriptional and translation levels not only in 
liver, but also in the kidney. Up to 45% of enzyme activity, compared to the liver, were 
reported in the kidney and therefore, PAH function also plays a physiological role in this 
organ and adds to the phenotypic heterogeneity in PKU (167). It has been shown that kidney 
can influence Phe and Tyr homeostasis as well (168, 169), although slight differences in 
activation mechanisms and enzyme conformation were found (166). 
PAH is an iron-containing enzyme depending on 6(R)-L-erythro-tetrahydrobiopterin 
(BH4) as cofactor and molecular oxygen for efficient catalysis. During the reaction, BH4 is 
oxidized to 4a-hydroxypterin and needs to be regenerated for continuous catalysis (Figure 3). 
The regenerating enzymes pterin-4a-carbinolamine (PCD) and dihydropteridine reductase 
(DHPR) complete the phenylalanine hydroxylating system (170). 
 
Figure 3: Overview of the reaction catalyzed by phenylalanine hydroxylase (Figure adapted 
from ref. (154)) 
The phenylalanine hydroxylating system provides an endogenous source of Tyr, making 
Tyr a non-essential dietary component (171). PAH together with tyrosine hydroxylase (TH, 
EC 1.14.16.3) as well as tryptophan hydroxylase (TPH, EC 1.14.16.4) constitute a family of 
aromatic non-heme iron monooxygenases that use BH4 as cofactor (172, 173). All three of 
them are involved in metabolic pathways critical for normal functioning of the nervous 
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system (170) with similar catalytic and structural properties as well as high sequence 
similarity. The C-terminal region of the three hydroxylases (monooxygenases) is more 
conserved, containing the determinants for hydroxylating activity and BH4 binding, whereas 
the N-terminal domains are more divergent leading to the different substrate specificities 
(174). TH catalyzes the hydroxylation of Tyr to L-dihydroxyphenylalanine (L-DOPA), 
whereas Trp is oxidized to 5-hydroxy-Trp by TPH (Figure 4). The subsequent 
decarboxylations of L-DOPA and 5-OH-Trp are catalyzed by the aromatic L-amino acid 
decarboxylase (AADC, EC 4.1.1.28). 
Phenylalanine Tyrosine Tryptophan 
PAH TH TPH 1,2 
Tyrosine L-DOPA 5-OH-Trp 
Dopamine 5-Hydroxytryptamine 
(Serotonin) 
Epinephrine 
(Adrenaline) 
BH4 BH4 BH4 
AADC AADC 
 
Figure 4: BH4-dependent hydroxylation of aromatic amino acids by the aromatic amino acid 
monoxygenases. The next step reaction is catalyzed by aromatic amino acid decarboxylases 
(AADC). 
The biosynthesis of the neurotransmitter monoamines dopamine, norepinephrine and 
serotonin is dependent upon the availability of the precursor amino acids Tyr and Trp within 
the brain and the presence of a normal Phe concentration (64). A defect in PAH system 
leading to excess Phe and a relative lack of Tyr and Trp in the brain has consequences for the 
subsequent enzymatic reactions. High Phe concentrations compete with the transport of other 
LNAA through the BBB and lead to a lack of reaction products of Phe, Tyr and Trp. Tyr and 
Trp now become essential dietary components required for the synthesis of dopamine and 
serotonin.  
In PAH deficiency, accumulating Phe is partially degraded through alternative pathways. 
Derivatives formed by transamination and decarboxylation reactions are excreted through 
urine and can be detected in non-treated PKU patients. Phenylpyruvic acid, obtained through 
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transamination of Phe is a phenylketone from which the name of the disease was derived. 
Initially, the detection of these alternative metabolites was used for diagnosis of PKU using a 
ferric chloride test (2, 9). However, phenylketone accumulation can be delayed and is even 
not observed in partial deficiencies of PAH with low degrees of blood Phe elevation resulting 
in non-PKU HPA. Figure 5 describes possible breakdown routes of Phe with major inputs 
and runouts. Phe decay can take place via three major routes: (1) by hydroxylation to Tyr 
(catalyzed by PAH, and followed by oxidation); (2) by incorporation into bound 
(polypeptide) pools; and (3) by the chemical reaction pathways of transamination (A) and 
decarboxylation (B). The transamination pathway becomes only functionally significant 
when the Phe concentration is much increased. 
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Figure 5: Major inputs and runout of free Phe in human metabolism (Figured based on ref. 
(175))  : major reaction.  
The oxidation of Phe to Tyr and further combustion to CO2 and H2O are the only possible 
reactions by which the phenyl ring can be ruptured (166). Nevertheless, under normal 
conditions, the conversion of phenylalanine to non-tyrosine derivatives constitutes only a 
minor alternative. In case of inadequate nutrition for example, protein catabolism occurs and 
free Phe is released. But these endogenous peptide-bound pools contribute only little to the 
input of plasma Phe.  
Another consequence of PAH deficiency is a decrease in melanin synthesis by the 
enzyme tyrosinase (EC 1.14.18.1), which uses Tyr as substrate (56). In addition, tyrosinase is 
competitively inhibited by high Phe concentrations.  
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1.2.2 The PAH Gene and the Diversity of Mutations 
The human phenylalanine hydroxylase gene (PAH) is located on chromosome region 
12q22 - 12q24.2 containing the nucleotide sequence coding for the hepatic enzyme 
phenylalanine hydroxylase (PAH, phenylalanine 4-monooxygenase, EC 1.14.16.1). The PAH 
gene sequence consists of 13 exons and their requisite introns (12), adding up to 171 kb 
including the flanking regions, encoding a 51.9 kDa polypeptide sequence with 452 amino 
acids. The exonic sequences in PAH take up less than 1% of the genomic sequence. The 
complete sequences have been catalogued in GenBank under NM_000277 (mRNA, 2680 
bp), U49897.1 (cDNA, 1359 bp), AF404777 (gDNA, 171 kb) and NP_000268.1 (protein, 
51.9 kDa) or in Ensembl under the reference number ENSG00000171759. 
The PAH gene is the only gene associated with PAH deficiency, which results from 
mutations in both alleles disturbing enzyme function. Isolation and sequencing of PAH 
cDNA (176, 177) opened new fields for intense exploration of the molecular causes of PKU. 
Over 550 pathogenic mutations have been detected distributed over all 13 exons as well as in 
introns and flanking regions. The phenotypic severity of PKU is characterized by the type of 
mutation, and thus by residual enzyme activity. An important resource for information on 
allele variants is the online relational locus-specific knowledgebase PAHdb, originated in the 
PAH Mutation Analysis Consortium (178, 179). The database provides information on 
mutations and associated phenotype, gene and enzyme structure, relation to other species, 
clinical guidance and much else, reported by clinicians and laboratories from around the 
world (180). Since the latest updates of this database roughly 61% of all mutations listed are 
missense mutations, followed by small deletions (13%), splice mutations (11%), silent and 
nonsense mutations (5 - 6%), and small insertions (2%).  
Next to the disease-causing alleles, the PAH gene contains at least 25 recognized non-
pathogenic single nucleotide polymorphisms (SNPs) with many probably still unrecognized. 
Multiallelic tandem repeat sequences and biallelic restriction fragment length polymorphisms 
(RFLPs), embedded in the genomic sequence, provide signatures of multiple haplotypes with 
particular associations for a wide range of disease-causing mutations. Repeat sequences like 
tetranucleotide short tandem repeats (STR), variable number of tandem repeats and Alu 
repeat elements are also annotated on the gDNA sequence, that all served to describe 
haplotypes, facilitate population genetics and led to discovery of large deletions (180).   
The DNA and amino acid sequences of mouse, human and rat are highly similar with 
over 90% identity on protein level (181). Mouse and rat PAH proteins consist of 453 amino 
acids, which is one amino acid longer than human PAH and differ in ten amino acids, 
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compared to 36 amino acid variations between the mouse and the human PAH. Even though 
physiological and regulatory differences were reported, PAH from rodents served as an 
efficient basis for animal studies (166, 182).  
1.2.3 Structural Basis and Regulation of Phenylalanine Hydroxylase  
The success of a large-scale production of recombinant human PAH in 1995 (183) finally 
led to the crystallization of a truncated form of the enzyme. The rat liver PAH structure had 
already been reported (184), but could not be used for correlating structure and function due 
to molecular heterogeneity compared to the human version. Until now, the best model 
available is a composite model, as the crystal structure of the fully active form of PAH is still 
not yet available.  
Human PAH is a cytosolic protein and exists in solution as a pH-dependent equilibrium 
between functional tetramers and dimers (185, 186) (which also accounts for recombinantly 
produced human PAH (183)). The composite model of the tetramer is depicted in Figure 6 
panel A, assembled from several truncated forms that were structurally characterized. A shift 
from predominantly dimer to predominantly tetramer was found in the presence of Phe (183, 
187). Like the other two aromatic amino acid hydroxylases TH and TPH, mammalian PAH 
consists of three domains: the regulatory domain (residues 1-142) at the N-terminal part of 
the protein, the catalytic domain (residues 143-410) and the tetramerization domain (residues 
411-452) (Figure 6 panel B). The model was generated using the structures of 
catalytic/tetramerization domains (188, 189) and regulatory/catalytic domains (190) and 
superimposing the catalytic domains of the two models.  
The catalytic and C-terminal domains of the three hydroxylases are highly homologous 
(191). The catalytic domain of PAH contains the active site with the iron center and the 
binding sites for Phe and BH4. The secondary structure of the tetramerization domain is 
essential for dimer and tetramer formation. The C-terminal domain of PAH is involved in 
subunit-subunit interactions leading to a dimer of dimers associated asymmetrically (189). In 
the dimer, the two catalytic domains closely interact with each other and with one of the 
regulatory domains. In order to maintain Phe homeostasis in vivo, PAH is highly sensitive to 
changes in substrate concentrations and its activity is tightly regulated. In normal cases, the 
exposure of tissues to high levels of Phe should be limited, but in parallel, Phe stores should 
not be depleted in order not to compromise protein synthesis. 
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Figure 6: (A) Perpendicular view of the full-length human PAH model structure, colored 
from red (N-terminus in monomer A) to blue (C-terminus in monomer D). The iron is shown as 
a gray sphere in all four monomers. (B) Structure of human phenylalanine hydroxylase full-
length composite model. The regulatory domain is shown in purple, the catalytic domain in 
yellow, and the tetramerization domain in green. The iron is shown as a red sphere. (Structures 
from (192)) 
The molecular mechanisms described for this regulated enzyme are reversible 
phosphorylation, substrate activation and relevance of the cofactor (175). The first 30 
residues of PAH act as an autoregulatory sequence that includes the Ser16, a substrate for 
cAMP-dependent protein kinase (193, 194), as well as is essential for the expression of 
positive cooperativity induced by the substrate and the inhibitory effect caused by the natural 
cofactor BH4 (190, 195, 196). This sequence region is termed autoregulatory, as it sterically 
limits substrate access unless the enzyme is activated by Phe binding to the regulatory 
domain. The properties of the complex PAH regulation were intensively studied from the 
1970s till the 1990s by Seymour Kaufman and Ross Shiman (166, 197, 198). Purified rat 
liver enzymes were initially mainly used, for availability reasons (185, 199).  
The activation by the Phe substrate results in a significant increase in the initial rate of 
Tyr formation and positive cooperativity in response to the Phe concentration was found 
(200). Activation and cooperativity are probably related to a conformational change induced 
in the PAH protein upon substrate binding that alters the spectroscopic properties (187). One 
monomeric PAH unit contains only one binding site for Phe, located in the catalytic domain 
(201). These reversible conformational changes upon binding are transmitted throughout the 
enzyme, displacing the autoregulatory sequence and leading to the propagation of the 
activating process to the adjacent subunit in the dimer and finally to the other dimer through 
the oligomerization domain (202). In contrast to Phe, the cofactor BH4 acts as an allosteric 
inhibitor, keeping the enzyme in a low activity state and blocking the substrate-activating 
conformational change (166). BH4 interacts with the N-terminal autoregulatory sequence and 
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leads to a dead-end PAH-BH4 complex, closing the entrance to the active site and leaving the 
enzyme in a latent, low-activity state (198, 203, 204). Phe binds with lower affinity to PAH 
than the cofactor BH4 (205). The high affinity binding of BH4 and the inhibitory regulatory 
effect in non-Phe activated PAH are associated with specific interactions of the BH4 side 
chain with residues from the catalytic and regulatory domain (203). Several analogs of BH4 
have been shown to effectively catalyze the PAH reaction, but with much lower affinity and 
only BH4 is a negative regulator of the PAH system (183). Novel studies with a continuous 
PAH assay (206), as well as with a high-throughput isothermal titration calorimetry-based 
activity assay (207), have further characterized BH4 kinetics and showed that PAH activation 
by Phe leads to positive cooperativity in BH4 binding. A Hill kinetic model displays a better 
fit than previously reported Michealis-Menten kinetics. As a result of cooperative BH4 
binding, different conformational alterations propagating cooperativity than found for Phe 
binding were reported. An influence of the patient’s metabolic phenotype may therefore have 
a significant effect in drug response. These results are important in developing the oral 
therapy with BH4. Several mutations in these regions involving sensitive PAH regulation can 
lead to different interactions and activation patterns and result in varying hydroxylation 
mechanisms.  
The iron atom is also essential for catalytic activity (208). It is coordinated to two 
histidine residues (H285 and H290), as well as to one oxygen from E330. The rest of the 
coordination sites of iron are occupied by water molecules, which are all displaced upon 
substrate and cofactor binding. This leaves an open coordination site for the reaction with O2 
and generates an activated intermediate in the hydroxylation of the Phe and BH4 (209). 
The composite model of full-length PAH provided an important basis for analysis of the 
numerous mutations resulting in deficient PAH activity. These structures lead to the 
elucidation of the catalytic mechanism (210, 211, 212), and the explanation of the regulatory 
behavior towards the substrate, the cofactor and phosphorylation (201, 203, 204, 213, 214). 
In addition, 3D structural studies and mapping of mutations can help predict the likely effects 
of a particular mutation upon protein structure or function in some cases, or generate 
hypotheses which can then be further tested by functional assays. Many mutations detected in 
PKU patients were tabulated according to their location and predicted effects on protein 
structure. If available, the structural changes are compared to in vitro expression data and 
phenotype information. PAH mutations were classified in five categories according to their 
location in the monomer: active site mutations, residues at the dimer or tetramer interfaces, 
deletion and insertion mutations, interdomain structure mutations and residues interacting 
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with the N-terminal autoregulatory sequence (192, 215). Most recently, the evaluation of 
BH4-responsive PKU/HPA was greatly aided by the analysis of relevant mutations in a 
structural context (216, 217). The relevant structural details for mutations associated with 
BH4 responsiveness will be further discussed in section 1.7. 
1.3 The Cofactor Tetrahydrobiopterin (BH4) 
1.3.1 Cofactor Biosynthesis and Functions 
BH4 belongs to a group of chemicals known as the pteridines, natural heterocyclic 
compounds widely distributed. Gowland Hopkins first reported them at the end of the 19th 
century in relation to the wing pigment in certain butterflies (218). The pteridines are the 
molecular basic moieties of the pterins, flavins and folates, which are substituted derivatives 
commonly found in biomolecules in different forms depending on the function (Figure 7 
panel A). Substitution with a dihydroxy propyl chain gives the biopterin molecular skeleton 
(Figure 7 panel B). The pteridine ring systems can occur in several different oxidation states, 
i.e. in the fully oxidized, dihydro, and tetrahydro forms. But only the fully reduced biopterin 
form i.e. BH4 exhibits biological activity. 
 
  Figure 7: A: Basic structures of pteridine and pterin; B: Biopterin and 
Tetrahydrobiopterin (BH4) (Molecular structures adapted from ref. (219)) 
BH4 is the short name of its correct chemical name 2-amino-4-hydroxyl-6-[L-erythro-1’, 
2’-dihydroxypropyl]-tetrahydrobiopterin (13). BH4 is essential for many diverse processes 
and ubiquitously present in all tissues of higher organisms. The de novo synthesis of BH4 is a 
highly regulated process that restores the oxidized forms. It is synthesized endogenously in 
several enzymatically-controlled steps from guanosine triphosphate (GTP) via two pterin 
intermediates (Figure 8). The enzyme that catalyzes the conversion of GTP to 7,8-
dihydroneopterin triphosphate (NH2TP) is GTP cyclohydrolase I (GTPCH I, EC 3.5.4.16) in 
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a Mg2+, Zn2+, and NADPH-dependent reaction (220). This primary step is rate limiting and 
GTPCH-activity is regulated through several factors in both directions on transcriptional and 
post-translational levels. These include proinflammatory cytokines and hormones. In Phe 
metabolism for example, the GTP cyclohydrolase feedback protein (GFRP) exerts feedback 
inhibition by BH4 (negative) and feedforward stimulation by Phe (positive) through complex 
formation (221, 222). This leads to the physiological consequence of high BH4 plasma 
concentrations in HPA patients (223).  
The subsequent conversion of NH2TP to 6-pyruvoyl-5,6,7,8-tetrahydropterin (PTP) is 
catalyzed by 6-pyruvoyl-tetrahydropterin synthase (PTPS, EC 4.6.1.10) and is Mg2+and Zn2+-
dependent. The final step leading to BH4 is a succession of side-chain reductions of PTP 
catalyzed among other enzymes by sepiapterin reductase (SR, EC 1.1.1.153). This reduction 
is NADPH-dependent.  
 
Figure 8: Biosynthesis, regeneration and functions of BH4. The chemical structures, 
reactions and regulation details have been extensively reviewed (224, 225). 
BH4 itself is hydroxylated during the aromatic amino acid reactions of PAH, TH and 
TPH. It is therefore essential that the cofactor be regenerated to ensure a continuous supply 
of reduced cofactor and to prevent accumulation of harmful metabolites. BH4 is oxidized to 
BH4-4a-carbinolamine and via two further catalytic reactions and quinoid dihydrobiopterin 
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(qBH2) intermediate reduced to BH4. The enzymes involved are PCD and DHPR (red 
pathway in Figure 8). SR has an alternative function in BH4 metabolism, namely in the pterin 
salvage pathway (pathway in blue in Figure 8). This alternative synthesis of BH4 consists of 
the conversion of sepiapterin to 7,8-dihydrobiopterin (BH2) and then via dihydrofolate 
reductase (DHFR, EC 1.5.1.3) catalysis to the cofactor. Both steps are NADPH-consuming. 
Sepiapterin is formed from PTP non-enzymatically. PTP can be reduced to BH4 through 
several possible routes catalyzed by a family of aldose and carbonyl reductases (AR; CR) via 
the 6-lactoyl tetrahydropterin intermediate (225, 226).  
Intensive research has been performed in BH4 metabolism and all genes, sequences and 
structures involved in BH4 synthesis and regeneration have been described (224). This has 
greatly contributed in characterization of the genetic disorders in the BH4 metabolic 
pathways, which are described in section 1.3.3.  
BH4 acts not only as a cofactor of the aromatic amino acid monooxygenases as described 
above. Additional functions on the cellular level were found upon the discovery that BH4 is 
essential for all three isoforms of nitric oxide synthase (NOS) (227). Nitric oxide synthases 
convert L-arginine to nitric oxide and L-citrulline (228) in two-step reactions. The role of 
BH4 in these reactions is different from aromatic amino acid monooxygenases. BH4 is not 
involved in oxygen activation, donates only one electron, and is regenerated without the need 
for external enzymes. Werner E. et al. recently compared the mechanisms involving BH4 in 
hydroxylases and NOSs (225). The synthases are ubiquitously involved in vascular and 
cardiac functions, establishing a role for BH4 in diseases like hypertension, diabetes, 
atherosclerosis, cardiac hypertrophy and failure, but also Parkinson’s and Alzheimer’s 
disease (229, 230).  
A BH4-requiring enzyme system for the oxidation of glyceryl ethers was described 
shortly after the structure of the PAH cofactor had been elucidated (231). However, progress 
in this field has been limited because the enzyme cannot be produced and purified in 
sufficient amounts (232). A membrane protein was predicted, named alkylglycerol mono-
oxygenase (AGMO, EC 1.14.16.5) and Watschinger et al. (233) recently reported on the 
sequence assignment of AGMO activity to transmembrane protein 195. AGMO is the only 
enzyme known to cleave the O-alkyl ether bond in alkylglyercols, using BH4 to generate an 
aldehyde and a glycerol derivative and leaving BH4 in quinoid form. In addition, it is the only 
enzyme described with a fatty acid hydroxylase motif depending on BH4 and defining a third 
group of BH4-dependent enzymes, next to the aforementioned amino acid hydroxylases and 
NOSs (225, 233). The physiological significance of AGMO remains to be elucidated.  
Introduction 27 
 
 
The many functions and physiological process involvements of BH4 make the 
homeostasis of BH4, bioavailability and regulation highly complex. 
1.3.2 Differential Diagnosis of Hyperphenylalaninemias 
As already mentioned above, not all individuals with a positive newborn screening result 
for PKU suffer from a PAH deficiency. An inherited variation in gene coding for one of the 
enzymes in BH4 biosynthesis or regeneration pathways also leads to disturbed Phe 
metabolism and is detected in approximately 1-2% of all HPA patients. The fast response in a 
BH4 loading test further pinpoints to BH4-deficiency and differentiates from non-responsive-
HPA/PKU. All neonates with even slightly elevated blood Phe levels need to be screened for 
the BH4 deficiencies in order to initiate an early and efficient treatment. The DBS from the 
Guthrie cards allow the measurement of pterins (neopterin and biopterin), DHPR activity, 
and amino acids (Phe and Tyr) from a single specimen. The pterin pattern is identical in DBS 
and urine (234). This leads to the differentiation of all BH4 defects except SR deficiency. SR 
deficiency does not present with elevated Phe levels in humans. Biopterin and neopterin are 
the most important diagnostic metabolites for these disorders. Oxidized pterins are highly 
blue-fluorescent and can be detected with high specificity and sensitivity after high-
performance liquid chromatography (HPLC) in blood, urine, CSF, and amniotic fluid (235). 
The pterin analysis delivers a characteristic pattern for BH4 deficiencies, except some 
patients with DHPR deficiency (234, 236). For example, patients with classical PKU excrete 
more pterins in urine compared to healthy controls and the amount of excreted metabolite is 
directly proportional to blood Phe levels (223).  
 
Figure 9: Diagnostic flowchart for differentiation of hyperphenylalaninemia variants (219)  
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In addition to the pterin measurements, determination of DHPR activity from the blood 
spots is mandatory in every patient with HPA for differentiation of the underlying defect. The 
following diagnostic flowchart illustrates the algorithm to follow for diagnosis of some BH4 
deficiencies. An analysis of the biogenic amine neurotransmitter metabolites and folates in 
CSF adds to the diagnosis of a specific BH4 disorder and hints to severity. 
Table 2 depicts the biochemical markers used in differential diagnosis and discriminates 
between blood, urine and CSF markers. Whereas the patients with HPA are already detected 
in neonatal screening programs, those presenting without HPA are recognized either by the 
typical clinical signs and symptoms or by analysis of neurotransmitter metabolites and 
pterins in CSF. Further characterization of the disorders can be obtained by measuring 
GTPCH, SR, PTPS, and DHPR enzyme activities in cultured fibroblasts and by mutation 
analysis for all variants (237, 238). 
Table 2: Inherited disorders of BH4 metabolism and biochemical markers for 
differential diagnosis (Table from ref. (225)). 
  Blood Urine  Cerebrospinal Fluid 
Disease OMIM # Phe Neo Bio Pri  Neo Bio Sep 5HIAA HVA Folates 
GTPCH deficiency 
(autosomal recessive) 233910    n    n   n 
PTPS deficiency 261640    n    n   n 
PCD deficiency 264070   n -    n n n n n n 
DHPR deficiency 261630  n n -  n  n * n    
GTPCH deficiency 
(autosomal dominant) 
128230 n n n n    n n -   n 
SR deficiency 612716 n n n n  n *    n 
*7,8-dihydrobiopterin 
Abbreviations: : elevated; : lowered; Neo: neopterin; Bio: biopterin; Pri: primapterin (7-
biopterin); Sep: sepiapterin; 5HIAA: 5-hydroxyindoleacetic acid; HVA: homovanillic acid; 
GTPCH: GTP cyclohydrolase I; PTPS: 6-pyruvoyl-tetrahydropterin synthase; PCD: pterin-4a-
carbinolamine dehydratase; DHPR: dihydropteridine reductase; SR: sepiapterin reductase. 
1.3.3 Inborn errors in Tetrahydrobiopterin Metabolism  
BH4 deficiencies arise from mutations in the genes coding for the enzymes in BH4 
biosynthesis and regeneration pathways. Due to the secondary disturbance in aromatic amino 
acid hydroxylase metabolism, they also affect central nervous system neurotransmitter 
biosynthesis and generally lead to severe and heterogeneous phenotypes. BH4 deficiencies 
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are treatable diseases although with variable outcomes. The clinical signs and symptoms of a 
BH4 deficiency largely arise from neurotransmitter depletion and compromised nitric oxide 
synthesis (239). The few patients that present with a mild phenotype generally show normal 
brain neurotransmitter metabolism and require only BH4 monotherapy. Symptoms of BH4 
deficiency may develop only after a few weeks or months of life. Therefore, most patients are 
initially maintained on a low-Phe diet until final diagnosis. All BH4 deficiencies associated 
with elevated Phe levels are inherited in an autosomal recessive manner and often share 
common clinical symptoms. Clinical features manifested with GTPCH, PTPS and DHPR 
deficiencies are abnormal movements together with impaired tone and posture, convulsions, 
seizures, mental retardation, as well as light pigmentation and microcephaly (16). 
Upon deficiency of in GTPCH I, the first step in BH4 biosynthesis, almost no pterins can 
be formed and consequently detected in urine or blood. The same accounts for neopterin and 
biopterin in the CSF and neurotransmitter metabolites are very low (240).   
The PTPS deficiency is the most prevalent and heterogeneous form of BH4 deficiency. 
Dihydroneopterin triphosphate (NH2TP) accumulates in tissues of patients, as it cannot be 
converted to 6-pyruvoyl-tetrahydropterin (PTP). NH2TP is rapidly dephosphorylated and 
high amounts of its oxidation product neopterin together with almost no biopterin can be 
found in patients’ samples. In severe forms of PTPS deficiency, patients present with high 
Phe levels and very low neurotransmitter levels in CSF (219).  
In contrast to defects in the BH4 biosynthesis, higher levels of biopterin are detected in 
some patients with DHPR deficiency. Some patients with DHPR deficiency can present with 
completely normal DBS or urinary pterins and DHPR activity measurement is thus 
mandatory in all HPA patients. Enzymatic activity is completely absent or very low in most 
reported cases. As BH4 is not regenerated, feedback inhibition mechanism is disturbed as 
well. In the absence of DHPR activity, BH4 cannot be regenerated and 7,8-dihydropterin 
(BH2, rearrangement product) accumulates. 
 Patients with PCD deficiency were initially diagnosed as mildly PTPS-deficient as high 
neopterin, low biopterin and normal neurotransmitter levels were detected, together with an 
unknown metabolite in urine. The metabolite was resolved as a 7-isomer of biopterin, namely 
primapterin, leading to primapterinuria. HPA is only a transient appearance in this condition 
with only minor clinical abnormalities, such as alterations in tone in the newborn period 
(219).  
Another defect associated with heterozygous mutations in GCH1, coding for GTPCH is 
known as Dopa-responsive dystonia or Segawa disease. Unlike classical GTPCH deficiency, 
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this disease is not associated with HPA. Mutations are detected only on a single allele of the 
gene and thus, it is inherited in an autosomal dominant manner with sex-influenced reduced 
penetrance. Biochemically, neopterin and biopterin levels are reduced in CSF, although not 
as low as in recessively inherited GTPCH deficiency. Markedly in this disease is a fast 
clinical response to low doses of L-dopa.  Clinical symptoms’ onset is in average at age 5 to 
6 years. They include muscle dystonia in the extremities and Parkinsonism, hyper- and 
hypotonia and spasticity later in the age (225, 237).  
Characterization of defects in SR was achieved only twelve years ago (241). Diagnosis of 
patients with this disease was probably missed because of lack of HPA and normal pterin 
excretion in blood or urine. Biochemical features are rather similar to DHPR deficiency and 
compensation is possible due to the peripheral salvage pathway to produce BH4 in the liver. 
The biochemical abnormalities can only be found in CSF with low levels of homovanillic 
and 5-hydroxyindolacetic acids, as well as high levels of total biopterin, BH2, and 
sepiapterin. Clinical features of SR deficiency include microcephaly, dystonia, progressive 
psychomotor retardation and extrapyramidal symptoms (219, 242).  
In the non-hyperphenylalaninemic BH4 deficiencies, the production of the cofactor in 
peripheral tissues is sufficient for normal PAH activity. However in a Phe-loading test, it can 
be observed that tyrosine production is compromised (219).  
Due to the similar features among the BH4 disorders, therapies may also be similar, 
generally including supplementation of L-dopa/carbidopa (peripheral decarboxylase 
inhibitor) as well as 5-hydroxytryptophan. BH4 serves as well as a treatment component, 
depending on the variant. Clinical and biochemical outcomes vary with age of diagnosis, so 
that a careful follow-up and fine-tuning of treatment is required (154).  
Two online resources are available at the www.biopku.org website, BIODEF and 
BIOMDB databases, which catalogue clinical, biochemical and molecular data of almost 700 
patients with BH4 deficiencies. Information is also given about severity, phenotype, and 
origin. BIOMDB is linked to BIODEF and lists mutations causing BH4 deficiencies and 
some other pediatric neurotransmitter diseases.  
1.4 In Vitro Expression of PAH Mutations 
The three major approaches have proven very fruitful in exploring the molecular causes 
of PKU: 1) Patient-based investigations analyze the effect of mutations on enzyme function 
in human organism. Many aspects from mutation detection, population studies, and clinical 
data are combined for the phenotype definition. 2) Three-dimensional protein structural 
Introduction 31 
 
 
studies consider the examination of the isolated recombinant mutant enzyme. 3) Analysis of 
mutation effects on enzyme activities by in vitro functional assays links the patient data with 
the protein. This is probably the closest available in vitro approximation to the in vivo hepatic 
PAH, which is not readily available (243).  
The main goals of in vitro expression (IVE) and co-expression studies are: 1) the 
confirmation of a disease-associated mutation and its pathology; 2) the severity of a 
mutation’s impact and predicting the corresponding metabolic phenotype; and 3) the 
understanding on how a mutation exerts its deleterious effects (study of molecular 
mechanisms). In principle, IVE analysis involves the introduction of the human wild type 
PAH cDNA into a plasmid vector, then its introduction into host cells lacking endogenous 
PAH, and the characterization of resultant enzyme. PAH missense mutations can be 
introduced by site-directed mutagenesis into the plasmids for the study of mutations’ effect 
on protein function. The report demonstrating that the recombinant gene product preserves 
most of the biological characteristics of the native protein, and the facilitation of producing 
greater amounts of high purity of recombinant hPAH variants, promoted tremendous 
advancements in characterizing PAH deficiency (183, 244). Depending on the aims and 
downstream analyses of the study, several expression systems have been applied to study 
PAH mutations. There is no perfect single expression system, but many mutations have been 
studied in different systems and only combined results give useful information on their 
effects on enzyme function.  
The expression of PAH in bacterial systems like Escherichia coli has been intensively 
employed. PAH is generally expressed as a fusion protein that is less susceptible to 
proteolytic degradation. The high amounts of pure PAH protein allows detailed 
enzymological studies in terms of kinetics, stability, and oligomerization. In addition, they 
created the source for the crystallization and modeling of the PAH structural details. These 
models greatly help in analyzing structural implications of mutations. A drawback of high 
amounts of protein expression in bacteria is their tendency for aggregation. This requires 
further analysis of the isolated dimeric and tetrameric forms of PAH to distinguish them from 
such bacterial artifacts. Unfortunately, although seemingly identical expression systems are 
used, different labs observed different catalytic, physical and regulatory properties of the 
wild type PAH. These can probably be explained by experimental discrepancies.  
Oligomeric structures of wild type and mutant PAH enzymes were evaluated in a cell-free 
in vitro transcription-translation system (245, 246). Rabbit reticulocyte lysates are used as 
host instead of intact cells. These provide a mammalian cell milieu containing the necessary 
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cellular components for protein synthesis. An RNA polymerase specific for the promoter in 
the expression system is added to allow high levels of transcription from the cDNA. This is 
directly coupled to translation and inserts labeled methionine into the nascent protein for 
rapid quantification. Experimental additions of cofactors, inhibitors or other compounds are 
facilitated. Enzyme activity as well as time-course experiments can be performed with these 
lysates (216, 247, 248). However, the levels of PAH protein produced are rather low and 
limit broader applications of this system. Gjetting et al. (249) mentioned inconsistent 
correlation of results determined with an in vitro transcription-translation system and a 
mammalian system. They concluded that differences in the environments of the two systems, 
including phosphorylation and control protein quality, might affect some mutant forms more 
than others.  
Transient overexpression of PAH cDNA integrated into a plasmid vector in mammalian 
cells was the first type of system used to analyze mutant forms of PAH. It is nowadays still 
the closest approximation to the in vivo milieu and first-line approach to studying disease-
causing effects of mutations. The host cells are generally COS (monkey kidney) or Hek293 
(human embryonic kidney) cells, because they do not possess endogenous PAH activity, but 
otherwise resemble the hepatic and renal cells in which PAH is naturally expressed. PAH 
activity measurements in protein lysates reveal differences in activity for the various mutants 
expressed. Analysis of immunoreactive PAH protein, as well as quantitation of mRNA 
compare mutant and wild type expression levels. The expression level of a mutation 
compared to wild type PAH indicates whether the main effect of a mutation is only on 
residual activity or also on reduced protein amounts. Therefore, mammalian expression 
systems require a certain number of controls for example for transfection efficiency, 
endogenous amino acids and eventual normalization of mRNA levels.  
All of the above described expression systems lead to the production of homomeric forms 
of PAH protein, in which all subunits are identical. As most PKU patients are compound 
heterozygotes with each PAH allele carrying a different mutation, two-hybrid analysis is 
applied. This methodology allows the semi-quantitative assessment of protein-protein 
interactions occurring in living cells. Co-expression systems were reported with bacteria, 
yeast, and mammalian cells as host (250, 251, 252). These systems allow the study of 
disease-causing mutations upon normal assembly of the tetrameric PAH enzyme. The PAH 
monomers are expressed as fusion proteins; one with a DNA-binding domain (BD) and the 
other with a transcriptional activator domain (AD). Interactions between PAH monomers 
bring the two domains into close proximity, leading to activation of reporter genes. Reporter 
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activities are decreased compared to wild type upon influence of mutations on normal 
interactions. However, two-hybrid systems are not the best available milieu for studying 
PAH enzyme activities (250).    
In many cases the different expression systems complement each other. For example, 
mammalian systems fail to explain the instability of mutant proteins, concluded from lower 
levels of mutant protein generally observed compared to wild type expression. But, for 
example the question of proteolytic degradation was successfully addressed in bacterial 
systems (253). In conclusion, in vitro expression studies have greatly contributed to today’s 
knowledge of PAH deficiency and understanding of molecular mechanisms involved.  
1.5 PAH Misfolding as Cause of PKU 
Mutations that affect the stability of a protein’s 3D structure or interfere with the folding 
process are commonly found in many inherited diseases. These effects can lead to increased 
aggregation and destabilized native conformation, causing loss-of-function pathologies (or 
eventually gain-of-function). These aggregates or nonfunctional conformations are no longer 
removed by the cells quality control systems like proteases. Replacements in amino acid 
sequence can abolish native interactions between atoms or create novel non-native 
interactions, changing the topology of the energy landscape and lead to misfolded 
conformations (254). Many of the point mutations on the PAH sequence leading to missense 
in translation were found to affect protein folding and assembly leading to secondary effects 
on enzyme function. The protein architecture of PAH is very sensitive to single point 
mutations throughout the protein sequence. The successful cloning of PAH cDNA and 
isolation of recombinantly expressed PAH allowed thorough studies of biochemical and 
physicochemical properties of wild type and mutant PAH proteins (12, 183, 244). The 
molecular mechanisms of many mutations causing PAH deficiency were analyzed either in in 
vitro expression studies or through three-dimensional protein structural studies. In summary, 
these studies demonstrated decreased stability, disturbed oligomerization, formation of 
aggregates and accelerated degradation of variant PAH proteins (246, 249, 255, 256, 257). 
All these processes are likely to be mutually dependent and their combined actions lead to 
impairment of the phenylalanine hydroxylase system. As there is still a general lack of 
knowledge in protein folding, it is not yet predicable whether a variant leads to misfolding of 
the protein or not (258). The results obtained from analysis of many PAH mutations in IVE 
systems are compatible with a unifying model. This model is shown schematically in Figure 
10 and depicts the various pathways in protein folding. Any newly-synthesized polypeptide 
has the potential to be partitioned between correct and aberrant pathways for folding and 
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oligomeric assembly (259). This is because the monomeric folding intermediate is in 
equilibrium with one or more misfolding intermediates.  
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Figure 10: Model of competing pathways for correct versus aberrant protein folding and 
assembly.  (Figure based on ref. (260)) 
Mutations and/or environmental factors can adversely affect rates of correct monomer 
folding, or can oppose the correct assembly of monomers into native-state oligomers. In 
either case, this will result in a greater proportion of protein entering the aberrant pathway, 
where it is more susceptible to proteolytic degradation in human cells than is protein 
proceeding through the pathway of correct folding and assembly (260). Significant efforts 
were made in recent years to establish a consistent relationship between the clinical 
phenotype, PAH genotype and in vitro residual enzyme activity. The view on global 
conformation of PAH was clarified in a more recent study by Pey et al. (261) using the 
algorithm resource FoldX and predicting the effects of missense mutations on stability. They 
confirmed that the decrease in protein stability is the main molecular pathogenic mechanism 
in PKU and the determinant for phenotypic outcome. In addition, they demonstrated 
substantial overall correlations between the mutational energetic impact and both, in vitro 
residual activities of 80 mutations in eukaryote systems and patient metabolic phenotype 
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(261). Additional results were also reported by Gersting et al. (262) who studied the 
molecular basis of structural mechanisms leading to loss-of-function in PKU by recombinant 
mutant analysis. Their findings are well in agreement with the computational analyses by Pey 
et al. (261). These studies emphasize that mutations impair catalysis, but also aberrant 
folding and conformational destabilization at different degrees are causes of PAH deficiency. 
The mutations were shown to impair molecular motion needed for regulatory processes such 
as substrate and cofactor binding, activation and inhibition, as well as promoting changes in 
the oligomeric state. The PAH enzyme should be regarded as an entity of functional units 
with crucial networks of amino acid interactions being disrupted in the tertiary and 
quaternary protein structure and not only disturbance of the three domains of the primary 
structure (262).  
These structural data confirm that molecular chaperones, like BH4, can be an efficient 
treatment option for PKU. Molecular chaperones assist the folding by protecting the protein 
during the folding process and keeping it away from misfolding which may lead to 
aggregation. The targets for chaperones are unfolded and partially folded polypeptide chains 
with exposed stretches of hydrophobic amino acids that are usually sequestered in the core of 
folded proteins (258).  
1.6 Splicing Defects in PKU 
RNA splicing is the process of removing introns in a typical mammalian gene for the 
subsequent precise joining of exons. In mammalian cells, the production of several isoforms 
from the same transcription unit by various types is a common event known as alternative 
splicing. Alternative splicing is responsible for much of the complexity of the proteome. It 
leads to the expression of different variants in different tissues, in different cells within the 
same tissue, or in the same tissue at different stages of development or in response to 
pathological processes. The understanding of the biological function and abundance of splice 
variants contributes to elucidating alterations in disease states. It is estimated that 94% of 
human genes are alternatively spliced and that as many as 50% of disease-causing mutations 
affect splicing (263, 264). Mutations that affect splicing can cause disease directly or 
contribute to the susceptibility or severity of disease. For example, the disease mechanisms of 
cystic fibrosis, spinal muscular atrophy and medium chain acyl dehydrogenase complex have 
been extensively studied and determined as splicing defects (265). 
Splicing is carried out by spliceosomes, which are ribonucleoprotein complexes that 
recognize the exon-intron junctions and catalyze the precise removal of the introns. The 
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splicing process and alternative splicing can be disrupted both by mutations within the target 
gene sequence (cis-acting elements) required for correct pre-mRNA processing as well as by 
mutations that affect trans-acting components necessary for splicing regulation. The cis-
acting elements are small pre-mRNA sequences recognized by the spliceosome and they are 
referred to as either intronic or exonic splicing enhancers (ISE or ESE) or splicing silencers 
(ISS or ESS). The trans-elements are specialized protein families that either positively or 
negatively regulate exon recognition and inclusion in the product. A critical balance between 
these antagonistic regulators is necessary for controlling the level of exon inclusion in the 
mRNA transcript (266). 
The cloning of the PAH cDNA led to the identification of PAH mutations leading to 
aberrant mRNA processing and deletions. Before the era of polymerase chain reaction (PCR) 
techniques and sequencing of all 13 exons of PAH, population studies using RFLP haplotype 
characterization of the PAH locus were efficient in defining a few splicing mutations in 
common haplotypes. The first PKU mutation identified was a single base substitution in the 
canonical 5’-splice donor site of intron 12, known today as IVS12+1G>A (c.1315+1G>A) 
(267, 268). At present, the McGill PAH database lists 65 splicing mutations in almost every 
region of PAH, leading to insertions and deletions. Splice mutations are generally point 
mutations occurring in introns and affecting the classical consensus splice site signals. They 
are often located close to the exon-intron boundaries, namely in the 5’- and 3’- splice regions 
of each exon. These sites are particularly important for exon recognition in the splicing 
process, so that these mutations deleterious effects in the gene processing are the 
consequence. Four out of the 65 splice mutations are located within one of the PAH exons. 
Particularly, the three exonic PAH splicing mutations in the database are even silent 
mutations resulting in PKU phenotypes. Silent mutations may act on mRNA level and are 
probably under-reported, because they might be incorrectly assumed to be neutral 
polymorphisms that do not merit further characterization.  
The discovery of illegitimate transcription greatly facilitated the detection of PAH 
mutations and of allelic variants leading to alternative gene transcripts (269). This 
phenomenon explores the low transcription levels of tissue-specific genes in non-specific 
cells. Circulating lymphocytes give easy access to PAH gene transcripts with identical 
sequence to that reported in liver. The transcripts are amplified by PCR, reverse-transcribed 
and sequenced (270, 271). The transformation of lymphocytes with Epstein-Barr virus (EBV) 
creates an immortalized cell line, ‘frozen’ at the stage in differentiation achieved when the 
transformation occurred (272). Such cell lines can be used for extensive molecular genetic 
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studies permitting analysis of cDNA as well as genomic DNA, possibly revealing mutations 
buried deep in introns not detected by other commonly used methods.  
As can be seen in the following examples, exonic PAH mutations were also shown to 
affect the splicing process. The study of the p.Y204C mutation represents a strong example 
of the importance of mRNA processing studies. The mutation was detected in patients with 
classical PKU phenotype, but in vitro residual enzyme activities and immunoreactivities did 
not correlate with the severe damage found in patients. Analysis of mRNA from cultured 
lymphocytes by RT-PCR revealed a 96 base pair deletion in exon 6 and the generation of a 
novel 5’ donor splice site. The mutation was thereafter renamed to Ex6-96A>G (273).  
Similarly designed studies using cultured lymphocytes as a source for PAH transcript 
analysis were employed to explain discrepancies in correlating in vitro expression data with 
patients phenotypes in nonsense, p.G272X and p.Y356X, and missense, p.P281L and 
p.R408Q, mutations (274).  
In addition to the lymphoblast analysis, transient expression of minigenes is used in in 
vivo assays for further assessment of a mutation’s effect on splicing mechanism (275). The 
c.1197A>T silent mutation (p.V399V) proved pathogenic and results in a PKU phenotype by 
inducing PAH exon 11 skipping and resulting in an altered reading frame. The mutation leads 
to an unfavorable situation in exon recognition and stresses the influence of splice donor and 
acceptor sequence conservation (276) as well as the probability of affecting ESEs. It is now 
re-classified as disease-causing mutation.   
The consequences of a synonymous mutation influencing splicing signaling sites is 
demonstrated by Dobrowolski et al. (277). An in vivo minigene approach is used together 
with the analysis of splicing proteins, so-called trans-factors, to identify splicing regulation 
upon c.30C>G neutral variation. Several lines of evidence are presented that this benign 
change is a pathological mutation. The c.30C>G mutation is shown to create an exonic 
splicing silencer site and interacts with the hnRNPH, known as a splicing inhibitory protein 
and leads to disruption of mRNA processing and aberrant protein production. The authors 
state that such observations are relevant for interpretation of other PAH exonic mutations and 
implications need to be considered for potential response to BH4 therapy.  
However, these are not the only examples and therefore it should not be generally 
assumed that full-length transcripts are produced from silent and especially also missense 
mutations (260, 278, 279, 280). This effect has long gone unnoticed in mutation analysis. The 
PAH gene has over 400 recognized exonic mutations and it is with certainty that a significant 
portion of these will realize their molecular pathology by disrupting mRNA splicing despite 
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the fact that they ostensibly create missense, nonsense, single codon deletions, or neutral 
changes according to the genetic code (277, 281, 282). This phenomenon may add another 
complication in genotype-phenotype correlations, resulting from unexpected effects of 
mutations in the coding region on the splicing process. The effects of nonsense, missense and 
silent mutations should be more routinely evaluated to assess their possible consequences on 
pre-mRNA processing. The identification of abnormal splicing as the primary mechanism of 
disease raises the possibility of therapeutic approaches that target splicing.  
1.7 Biochemical and Molecular Mechanisms of Tetrahydrobiopterin 
Responsiveness 
Since the initial observation of decreasing Phe levels after oral intake of BH4 by Kure et 
al. (150), an increasing number of patients have been reported. BH4 responsiveness is defined 
as the response to 10 - 20 mg/kg body weight of the natural cofactor BH4 with a reduction of 
more than 30% of plasma Phe levels during the first 8 - 24 hours after administration. Of 
course, BH4-deficiencies in cofactor synthesis or recycling must be excluded. Kure et al. 
initially proposed that PAH mutants are formed exhibiting reduced binding affinity for BH4. 
The increase in BH4 upon supplementation would lead to the restoration of the residual 
activity and is likely to stabilize mutant PAH proteins. Many reports followed presenting 
similar efficiency of BH4 treatment in patients with mild and moderate phenotypes, often 
compound heterozygote with one mild mutation (151). It was emphasized from these studies 
that a significant residual PAH activity is a prerequisite for BH4 responsiveness. This was 
further characterized on biochemical, molecular and physiological levels and several possible 
mechanisms for BH4 responsiveness were proposed based upon results of in vitro expression 
studies and structural implications of the mutations (283). Many mutations and genotypes 
were found associated with responsiveness and are listed in the BIOPKU database 
(www.biopku.org).  
Initially, it was thought that mutations in the catalytic domain, especially residing in one 
of the four cofactor-binding regions (CBR) or in locations that directly interact with these 
regions, would be responsive to BH4. This correlated with the BH4-responsive mutations 
found in previous patient studies. The cofactor binding regions are depicted in Figure 11 
highlighted in dark blue. The cofactor binding regions include amino acid residues 246 to 
266, 280 to 283, 322 to 326 and 377 to 379 (283).  
The mutations have been analyzed in in vitro kinetic studies on recombinantly expressed 
mutant PAH and compared to wild type data (216, 285, 286, 287). Several of the mutations 
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were found to exhibit lower binding affinities towards BH4 compared to the wild type (Table 
3).  
 
Figure 11: Backbone structure of a monomer of the composite model of PAH (Figure from 
ref. (284)) 
 
Table 3: Binding affinities for BH4 in mutant PAH fusion proteins expressed in E.coli 
(Km or Kd defects). Data compiled from (216, 285, 287) 
PAH proteins Kma (BH4) µM Kdb (BH4) µM 
Wild type 26 ± 3 2.7 ± 0.1 
p.F39L 44 ± 2 8.4 ± 0.8 
p.I65T 39 ± 3 3.9 ± 0.4 
p.R68S 30 ± 3 9.0 ± 1.0 
p.D129G 37 ± 3 ND 
p.P244L 39 ± 4 ND 
p.R261Q 25 ± 2 2.7 ± 0.1 
p.L308F 44 ± 8 ND 
p.A309V 38 ± 3 ND 
p.V388M 24 ± 3 ND 
a, Obtained by steady-state kinetic analysis 
b, Obtained from equilibrium binding measurements by isothermal titration calorimetry 
ND, not determined 
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This is represented in higher values of the Michaelis-Menten constant Km, which is a 
measure of the binding affinity of an enzyme for its ligand (substrate or cofactor) and is 
defined as the concentration of ligand required to fill one-half of ligand-binding sites (217) in 
steady-state kinetics. The dissociation constant Kd is also a measure of affinity for a given 
ligand to a protein. For most of the mutations displayed inTable 3, Kd is elevated compared to 
the wild type, representing reduced affinities of mutant PAH and BH4. The BH4-responsive 
mutations in Table 3 proven to be Km mutants (p.F39L, p.I65T, p.R68S and p.D129G), are 
rather located in the regulatory domain of the PAH protein than in the cofactor binding 
regions. In addition, the p.D143G mutation was rigorously studied in multiple systems and 
significant increases in Km were found, concluding a pure kinetic variant (288). As the initial 
hypothesis of only Km mutants being BH4-responsive does not hold for all the currently 
characterized mutants, other effects must play a role and another mechanism emerged, based 
on the results from in vitro studies. Kure et al. later suggested from results obtained in a PKU 
mouse study, that responsiveness to BH4 was probably due to suboptimal physiological 
concentrations of the cofactor in hepatocytes (289). A hepatic concentration of BH4 of 5 - 10 
µM has been measured. However, as Michaelis constant varies between 12 and 44 µM for 
wild type PAH, the enzyme is not saturated at this concentration of cofactor (285).  
Pey et al. (207) showed that PAH activity, in physiological concentrations of Phe, is 
almost not sensitive to the concentration of BH4 when varying from physiological to 
superphysiological levels (Figure 12).  
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Figure 12: PAH activity dependence on the concentration of BH4 at different concentrations 
of L-Phe (Figure adapted from ref. (207)) 
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However, this was shown to change at increased pathological Phe concentrations, mainly 
due to a 5-fold increase in Km (BH4). This remarkable regulation of wild type activity by Phe 
and BH4 is highly susceptible and easily disturbed by conformational changes provoked by 
mutations (207). PAH is known to undergo conformational changes upon Phe binding 
leading to activation, whereas BH4 is a negative regulator, leading to an inactive PAH-BH4 
complex. However, Phe binding can surpass this closed conformation and lead to increased 
conversion of Phe to Tyr. In this sense, BH4 loading would prevent the mutant enzyme from 
structural changes caused by mutations and prevent from misfolding and proteolytic 
degradation. A reduction or loss of the cooperative substrate-dependent activation has been 
seen with many mutations kinetically characterized. This stabilizing effect of BH4 on PAH 
mutants was determined by thermal denaturation studies with increased melting temperatures 
and half-lives for the mutant proteins in the presence of the cofactor. In the absence of the 
cofactor, mutant proteins show increased rates of degradation, indicating a folding defect 
(248). The cofactor may prevent wild type and mutant PAH from degradation by the 
ubiquitin-proteasome-dependent pathway (253). These observations attribute BH4 a 
chaperone-like protective effect for PAH by stabilizing the functional forms. This hypothesis 
is supported by an increase in enzyme activity and protein amount with BH4 content in vivo 
in mice (290). However, BH4 does not have an effect on PAH gene transcription or mRNA 
stability (291, 292). In addition, a chaperone effect of BH4 also explains highest efficiency 
with milder phenotypes, as sufficient residual liver PAH protein must be present to interact 
with the cofactor.  
The establishment of activity landscapes by Pey et al. (207) and Staudigl et al. (293) of 
PAH wild type and mutants supports the influence of kinetics in response to the cofactor. 
They allow the analysis of a wide range of substrate and cofactor concentrations, also 
relevant for diagnosis and treatment of patients with PAH deficiency. This highlights the 
interplay of both kinetic and chaperone effects varying with the genotype and influencing the 
therapeutic effect. However, the interindividual differences in pharmacokinetic properties can 
still lead to different degrees of responsiveness associated with identical genotypes. In 
conclusion, the response to BH4 therapy is multifactorial, and can be explained by a 
combination of proposed mechanisms attributing correction of kinetic and stability defects to 
the favorable action of BH4. Continuous characterization of PAH mutations and BH4 
responsiveness testing leads to the identification of new BH4-responsive mutations and the 
improvement of current models for the molecular basis of cofactor-responsive PKU. 
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1.8 Genotype-Phenotype Correlations 
The compilation of all information about PAH mutations and establishment of genotype-
phenotype correlations is highly useful in predicting the course of disease for a patient’s 
diagnosis. The ability to predict the phenotype already in a newborn with PAH deficiency not 
only enables the design and early implementation of an optimal dietary regimen, it also 
greatly improves counseling of the patient’s family. However, contrary to initial beliefs, a 
simple correlation between PAH genotype and metabolic phenotype could not be confirmed.  
The enormous allelic heterogeneity in PAH deficiency with almost 600 known mutations 
seems to be a severe constraint for attempts to establish genotype-phenotype correlations. 
The number of mutations has doubled over the past decade. The genotype is not always the 
best predictor for the clinical phenotype (58) and many inconsistencies were reported in 
correlating genotype with phenotype. Nevertheless, it was also possible to document clear 
correlations between the allelic variants and the metabolic phenotype in some studies (294, 
295). Despite of the many factors influencing phenotypes, the specific PAH genotype is the 
main determinant of metabolic phenotype in most cases (40, 42).  
Differing clinical phenotypes were reported in some cases with identical genotypes, even 
in siblings. Mechanisms leading to such interindividual variations in Phe kinetics and brain 
Phe content are still unclear and under investigation. Moreover, as seen above, the usage of a 
different IVE system may lead to different conclusions of a mutation’s impact and even the 
results from similar systems are sometimes difficult to compare (249). The cellular 
environment in IVE experiments is an important component in terms of folding, oligomer 
assembly, and aggregation of the mutant enzyme. Therefore varying patient phenotype data 
upon identical genotypes need to be included in databases and considered when establishing 
correlations with a mutation’s outcome. However, as there exists no consensus in 
classification of phenotypes and Phe tolerance, alleged genotype-phenotype inconsistencies 
can be a result of phenotype misclassification. In a large multicenter study, inconsistencies 
were attributed to the various phenotype categories among countries, various genotyping 
methods between centers as well as different treatment guidelines (42). The moderate 
phenotype category, relating to Phe levels between 900 and 1200 µmol/L, is not routinely 
considered by every center. However, most phenotypes not correlating to genotypes belong 
to this category, which adds additional confusion in assigning a patient’s phenotype.    
In vivo residual PAH activities are often calculated based on averaging in vitro expression 
activity data. The activity of both alleles in percent of wild type is averaged to account for the 
full genotype. Some variability in the data is not inevitable when different expression 
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systems are used and these values tend to overestimate the in vivo situation (252). In addition, 
predicted residual activities do not account for interactions between the two alleles 
influencing enzyme activity, so that dominant effects of one of the alleles may lead to a 
different phenotype than expected from prediction. Negative interallelic complementation 
has been demonstrated for a few genotypes, but heteromeric enzyme activities are difficult to 
determine (250, 296). Thus, they allow ranking a mutation in mild, moderate or severe 
phenotype. Combining predicted residual activities with patient data might lead to useful 
correlations, but one has to be aware of the limitations of IVE systems, that might fail in 
reflecting the complete in vivo situation. In patients with new or rare mutations, little 
knowledge is available and IVE thus leads to fast informative data.  
A few common PAH mutations have been repeatedly reported in inconsistent genotype-
phenotype correlations. These mutations were mostly classified with more than one 
phenotype category and include: p.L48S, p.I65T, p.R158Q, p.R261Q, p.V388M, p.E390G, 
and p.Y414C. When differences in classification between participating centers were 
excluded, explanations were ascribed to the position of the mutations. In detailed studies of 
these mutations, the position within the protein was found to influence activity because of 
interference with binding of the substrate or the cofactor. This hinders efficient cooperativity 
or leads to severe folding defects (255, 285). The co-overexpression with chaperonins GroES 
and GroEL (247, 255, 297) revealed different results for activity and oligomerization patterns 
in some of these mutant proteins. Increased levels of protein and residual activity with 
chaperonin overexpression rather point to folding defects. In addition, the influence of Phe 
levels on activity modulated conformational changes happening typically after substrate 
binding in PAH (298). Enzyme activity may therfore be subject to regulation by substrate 
concentration. The recording of an activity landscape for the p.R261Q mutation showed that 
Phe levels greatly influence residual activity and BH4-response in this mutant (293). In these 
cases, standard PAH activity protocols would not efficiently reflect the in vivo situation, as 
only one substrate and cofactor concentration is applied.  
These examples prove that not only the implications of a mutation on activity and 
structure, but also the levels of substrate and cofactor need to be considered in genotype-
phenotype correlations. The combination of all these effects might lead to more consistent 
correlations and confirms the need for continuing in vitro expression studies and further 
characterization of PAH mutations. 
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1.9 Objectives of the Thesis 
PKU has been listed in the McKusick Catalog of Mendelian Inheritance in Man (OMIM, 
# 261600) since 1986 as a monogenic disorder with known straightforward pattern of 
inheritance. The OMIM compendium focuses on the relationship between phenotype and 
genotype, adding value to prognosis and treatment. However, the preceding subchapters have 
illustrated that PKU is not a simple trait but it is a highly heterogeneous disorder with a broad 
spectrum of biochemical and metabolic phenotypes. Figure 13 summarizes the factors adding 
to the complexity of monogenic PKU resulting in challenging genotype-phenotype 
correlations. 
Hyperphenylalaninemia 
Phenylketonuria 
Mendelian trait 
Defect in PAH gene and enzyme 
Complex trait 
(1) Cognitive phenotype, affected 
by transport of Phe into the brain 
(2) Metabolic phenotype, affected 
by Phe disposal/transport 
(3) Enzyme phenotype, affected by 
protein degradation 
Allelic variation 
Different PAH alleles 
associated with different 
phenotypes; 
Prevalent compound 
heterozygosity and 
possible dominant 
negative effects 
Locus heterogeneity of HPA 
Loci for BH4 enzymes, synthesis 
and recycling 
Multifactorial trait 
Genetic alteration combined 
with variation in dietary protein 
 
Figure 13: Factors influencing phenotype in phenylketonuria (Figure adapted from (299)) 
The prediction of the ‘monogenic’ phenotype from the PAH genotype is severely 
challenged by the fact that patients, even siblings, with identical PAH genotypes could have 
greatly different cognitive and metabolic phenotypes. Most probably, this results from other 
genetic contributions to the phenotype (e.g., modifier genes), which are complex and sparsely 
investigated in PKU. Many of the features mentioned in Figure 13 also greatly influence the 
prediction of BH4 responsiveness and often lead to inconsistent results. But as 20 - 30% of 
PKU patients are known to respond to oral supplementation of BH4 and can therefore benefit 
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from this pharmacological therapy, information on genotype, potential residual activity, and 
likely Phe tolerance are relevant for therapeutic approaches. 
The aim of this work was the metabolic characterization of genotypes associated with 
BH4 responsiveness. The thesis project outlines the molecular, in vitro analysis of several 
common, but also new PKU mutations and testing of their response to BH4 in a mammalian 
cell system for better prediction of BH4 responsiveness.  
In Chapter 1, we aimed at characterizing the diversity of genotypes in Turkish PKU 
population. Genotyping of patients with elevated Phe levels detected in newborn screening is 
often performed to complete diagnosis of a PKU patient. A higher prevalence of PKU is 
found in Turkey with 1 in 6’500 newborns. Only two studies reported on mutations prevalent 
in Turkey. Blood and urine samples from many of the patients selected for genotyping were 
previously registered in our division and a BH4 loading test was performed. Phe levels as 
well as information on BH4 formulation used during the loading test were therefore available. 
From these data, we planned to correlate genotypes with response to BH4-loading, 
phenotypes, and predicted residual activities from in vitro expression tabulated in PAHdb. 
The results will be added to the BIOPKU database, which is public and new patients with 
documented non-responsive genotype may not need to undergo BH4 testing. 
The aim of the patient study in Chapter 2 was to determine the predictive value of BH4-
responsive PAH mutations in Croatian PKU population. The prediction facilitates the 
selection of potential PKU candidates for pharmacological therapy with BH4. Null mutations 
for example are generally not associated with response to BH4. Many inconsistent results 
have been reported on single PAH mutations in relation to BH4 responsiveness in milder 
phenotypes. It was envisaged to select patients according to substantial residual activity of 
one allele and evaluate BH4-response after the loading test.    
Chapter 3 describes the quantification of PAH activities expressed in cultured cells or in 
animal tissues by a novel tandem mass spectrometry assay. The measurement of PAH 
activities was usually achieved by the amino acid analyzer. However, the amino acid 
analyzer was found not sensitive enough to quantify Phe and Tyr in cell lysates, especially in 
cells expressing mutant PAH with low activity. Mass spectrometry allows the use of stable 
isotopes for amino acid quantification with increased specificity. In addition, we intended the 
validation of this analytical method. Validated PAH assays have not been thoroughly 
reported and comparison of mutant PAH activity between various assay methods is difficult. 
With tandem mass spectrometry, we aimed at using new technology for amino acid 
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quantification with a broad concentration range allowing the accurate determination of PAH 
activity.  
Furthermore, several particular mutations found in Turkish PKU patients were selected 
for detailed molecular analysis illustrated in Chapter 4. It is generally underestimated, how 
many missense mutations influence splicing mechanism and lead to aberrant splicing. 
Mutations in exonic splicing enhancers and silencers, as well as exon splice sites greatly 
contribute to efficiency of exon recognition by the spliceosome. The impact of such 
mutations may be more severe than the effect predicted from a missense change on enzyme 
function. In case of aberrant splicing, residual activity does not correlate with phenotype and 
this may be causing frequent inconsistent genotype-phenotype correlations. Mutations that 
disrupt splicing are unlikely to facilitate response to BH4 and if not recognized, their effect 
on splicing may lead to further inconsistent genotype-phenotype correlations. 
Moreover, the most prevalent PKU mutation, c.1066-11G>A is an intronic mutation 
causing aberrant PAH splicing. Our intent was to investigate the association of a mutation in 
PAH intron 10 with BH4 responsiveness and two mutations in PAH exon 11. Discordant PAH 
activity results were found for these mutations, as well as their location in important splicing 
regulatory elements pointed to an implication on PAH exon 11 mRNA processing. The 
establishment and analysis of PAH minigene constructs and EBV-transformed PKU patient 
cell lines were planned for investigation of these mutations in the 3’ splice site and in exon 
11.  
The final section, Chapter 5, presents the setup and validation of a mammalian cell test 
system with engineered plasmid vectors. The previous studies have shown that the 
combination of the two mutant PAH alleles determines BH4 responsiveness in vivo, and the 
individual mutations of a patient should not be viewed by themselves. Transient co-
expression of wild type or mutant PAH variants of previously selected genotypes and 
measurement of PAH activity and expression levels, in presence or absence of exogenous 
BH4 will be tested. A robust method for assessing responsiveness in cell culture and 
prediction of BH4-response of a specific genotype is fast, cheap and prevents some patients to 
undergo the burden of BH4 loading test. In addition, we expect to establish dominant 
influences of some mutations on the enzyme function. The analysis of numerous mutation 
combinations by the same system will enable the establishment of algorithms for the 
calculation of genotype-based BH4 responsiveness. 
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Abstract 
Background: The prevalence of phenylalanine hydroxylase (PAH)-deficient phenylketonuria 
(PKU) in Turkey is high (1 in 6500 births), but data concerning the genotype distribution and 
impact of the genotype on tetrahydrobiopterin (BH4) therapy are scarce.  
Objective: To characterize the phenotypic and genotypic variability in the Turkish PKU 
population and to correlate it with physiological response to BH4 challenge. 
Methods: We genotyped 588 hyperphenylalaninemic patients and performed a BH4 loading 
test (20 mg/kg body weight) in 462 patients. Residual PAH activity of mutant proteins was 
calculated from available in vitro expression data. Data were tabulated in the BIOPKU 
database (www.biopku.org). 
Results: Eighty-eight mutations were observed, the most common missense mutations being 
the splice variant c.1066-11G>A (24.6%). Twenty novel mutations were detected (11 
missense, 4 splice site, and 5 deletion/insertions). Two mutations were observed in 540/588 
patients (91.8%) but in 9 patients atypical genotypes with > 2 mutations were found 8 with 
p.R155H in cis with another variant) and in 19 patients mutations were found in BH4-
metabolizing genes. The most common genotype was c.1066-11G>A/c.1066-11G>A 
(15.5%). Approximately 22% of patients responded to BH4 challenge. A substantial in vitro 
residual activity (average > 25% of the wild type enzyme) was associated with response to 
BH4. In homozygous genotypes (n = 206), both severity of the phenotype (r = 0.83) and 
residual PAH activity (r = 0.85) correlate with BH4 responsiveness. 
Conclusion: Together with the BH4 challenge, these data enable the genotype-based 
classification of BH4 responsiveness and document importance of residual PAH activity. This 
first report of a large-scale genotype assessment in a population of Turkish PKU patients also 
documents a high prevalence (47%) of the severe classic phenotype. 
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Introduction 
Phenylketonuria (PKU; OMIM# 261600) is an autosomal recessive disorder associated 
with deﬁcient hepatic phenylalanine hydroxylase (PAH) activity [1]. PAH converts 
phenylalanine (Phe) to tyrosine in the presence of the essential cofactor tetrahydrobiopterin 
(BH4), molecular oxygen, and Fe
2+
. BH4 is synthesized from guanosine triphosphate (GTP) 
in a biosynthetic pathway including the enzymes GTP cyclohydrolase I (GTPCH; gene 
GCH1), 6-pyruvoyl-tetrahydropterin synthase (PTPS; gene PTS), and sepiapterin reductase 
(SR; gene SPR). The oxidized cofactor is regenerated in two enzymatic steps involving 
pterin-4a-carbinolamine dehydratase (PCD; gene PCBD1) and dihydropteridine reductase 
(DHPR; gene QDPR) [2]. Mutations in genes coding for PAH and BH4-metabolizing 
enzymes result in hyperphenylalaninemia (HPA) [3]. SPR deﬁciency and autosomal 
dominant GCH1 deﬁciency present without HPA [4]. BH4 deﬁciencies are more severe than 
PKU, and in addition to HPA present with catecholamines and serotonin deﬁciency [5].  
The overall prevalence of PKU in Europe and the United States is about 1 in 10,000 live 
births. Higher disease incidence is observed in cultures where consanguinity is practiced 
(e.g., Turkey, Saudi Arabia, or Gaza; ca. 1 in 3500 - 6500); however, in regions such as 
Finland the incidence is low (1 in > 100,000). Prevalence of BH4 deﬁciencies is about 1 - 2% 
of all HPAs [6].  
Late-diagnosed, untreated PKU leads to severe neurological impairment including mental 
retardation, microcephaly, autistic behavior, eczema, and seizures [7], particularly in the 
most severe forms of PAH deﬁciency, “classic PKU” (blood Phe concentrations > 1200 
µmol/L). Less severe forms include mild PKU (blood Phe concentrations 600 - 1200 µmol/L) 
and mild HPA without any clinical ﬁndings (blood Phe concentrations < 600 µmol/L). 
Hyperphenylalaninemic patients are identiﬁed through prospective newborn screening and 
follow-on diagnostic procedures will identify the defective gene, enabling early initiation of 
appropriate therapy [8]. Not every HPA patient is routinely tested for DNA mutations.  
The observation that serum Phe concentration may be controlled in a subset of PKU 
patients through oral administration of synthetic 6R-BH4 [9] and reports of a relatively high 
incidence (20 - 30%) of BH4 responsiveness [10, 11] provided an alternative to the traditional 
low Phe diet [14]. A number of studies documented that PAH-deﬁcient patients with mild to 
moderate phenotypes are more likely to beneﬁt from BH4 therapy [10 - 14]. In some patients 
Phe concentration may be controlled with BH4 monotherapy; however, others require a 
combination of BH4 and dietary restrictions to maintain blood Phe in the therapeutic range 
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while increasing daily Phe tolerance [15 - 18]. Mechanisms of BH4 responsiveness are 
multifactorial [19]. Current data suggest the most common mechanism by which BH4 rescues 
PAH function is by acting as a pharmacological chaperone promoting proper enzyme folding, 
which in turn reduces enzyme degradation and inactivation [20, 21].  
The PAHdb (www.pahdb.mcgill.ca/) has cataloged over 500 mutations in the PAH gene 
[22], while the BIOPKU database (www.bh4.org/BH4DatabasesBiopku.asp) describes an 
approximately equal number of PAH genotypes and their association with BH4 response [23]. 
A systematic review of PKU in Europe identiﬁed 29 mutations that may be regarded as 
prevalent in European populations [24], but there are very few reports on the molecular basis 
of PKU in Turkey [25, 26].  
Herein are presented PAH genotypes of 588 Turkish PKU patients where 88 mutations 
were identiﬁed; among these are 20 novel mutations. Data from oral BH4 challenge in 462 
patients are reported. Comparisons are made relating BH4 response with the genotype, 
residual in vitro PAH activity, and disease phenotype. The results extend the knowledge of 
the genotypic PKU variation in the Turkish PKU population and document a high prevalence 
of classical PKU (47%), a relatively high proportion (22%) of potential candidates for the 
BH4 therapy, and the common occurrence of BH4 deﬁciencies (2.4%) within this study.  
Patients and methods 
Patients and samples 
A total of 588 hyperphenylalaninemic patients were investigated. At the time of 
diagnosis, 165 patients presented with mild HPA (blood Phe < 600 µmol/L), 130 with mild 
PKU (blood Phe 600 - 1200 µmol/L), and 274 patients presented with classic PKU (blood 
Phe > 1200 µmol/L). Nineteen patients with BH4 deﬁciencies presented with a variable range 
of blood Phe (9 mild HPA, 7 mild PKU, 3 classic PKU). Forty-six percent of patients were 
the offspring of consanguineous mating (Table 1.1); however, an even higher percentage 
(48.7%) displayed mutation homozygosity, suggesting inbreeding (Suppl. Table 1).  
Nine pedigrees, where > 2 mutations were identiﬁed, are included in this study. The 
majority of patients (~75%) were identiﬁed through prospective newborn screening, while 
the remainders were identiﬁed by selective screening. Blood specimens were collected on 
ﬁlter paper cards by ﬁnger or heel prick, and all tests were performed within routine clinical 
and biochemical investigation and in accordance with local regulations. Blood phenylalanine 
was measured using a ﬂuorometric method until 2003, and tandem mass spectrometry was 
used afterwards. The ﬁrst conﬁrmatory quantitative phenylalanine was performed during 
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clinical assessment when the child was provided a normal diet. Informed consent for 
genotype assessment was obtained from all subjects. The University of Utah Institutional 
Review Board approved the plan to receive de-identiﬁed specimens for assessment of the 
PAH gene and genes of the BH4 synthesis/recycling pathways.  
Table 1.1: Consanguinity in Turkish PKU patients investigated in this study. 
 
Loading test with BH4  
A single-dose BH4 challenge (20 mg/kg body weight) was performed on 462 PKU 
patients (81%) (Schircks Laboratories, Switzerland). Three different protocols were used: A) 
Prior to 1999, a partially active formulation of BH4, containing a mixture of the active R 
enantiomer and inactive S enantiomer (66.6% 6R-BH4 and 33.3% 6S-BH4), was used to 
challenge 166 patients. Thus a 20 mg tablet contained 13.3 mg of biologically active BH4. In 
this subset, serum Phe was monitored over 8 h. B) A fully active formulation of BH4 (6R-
BH4) was utilized post-1999. Among the 296 patients challenged, Phe was monitored over an 
8-h period (0, 4, and 8 h) in 104 patients and C) over a 24-h period (0, 4, 8, and 24 h) in 192 
patients. Data from patients whose plasma Phe concentration was monitored over 24 h were 
used for genotype-phenotype correlation and determination of residual PAH activity. In all 
BH4 challenge protocols, response was deﬁned as a sustained reduction of blood Phe 
concentration by ≥ 30% from the pre-challenge baseline [27].  
Assessment of the PAH, PTS, and QDPR genes  
DNA was prepared from dried blood on ﬁlter paper as previously described [28]. The 
PAH gene was assessed utilizing a previously described system involving high-resolution 
melt proﬁling and follow-on DNA sequencing of regions displaying aberrant melting proﬁles 
[29, 30]. DNA sequence data were analyzed using Mutation Surveyor software (Softgenetics, 
State College, PA, USA). The protocols utilized in assessment of PTS and QDPR also 
involved high-resolution melt proﬁling and follow-on DNA sequencing of regions displaying 
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aberrant melting proﬁles. The speciﬁcs of these assessments will be included in a separate 
study.  
In several instances, PAH-deﬁcient patients were identiﬁed with > 2 mutations in the 
PAH gene. When family participation could be recruited in such cases, blood samples were 
obtained from parents and other ﬁrst-degree relatives for performance of pedigree studies to 
determine the cis/trans relationship between the mutations.  
Relative residual PAH activity  
Relative residual PAH activity (‘PAH activity’) was calculated from data provided from 
in vitro experiments using recombinantly expressed mutant proteins in eukaryotic cells. PAH 
activity is the average of the sum of activities of both alleles, and expressed as the percentage 
of the wild type enzyme. Expression data were compiled from the PAHdb 
(www.pahdb.mcgill.ca/). Calculated in vitro ‘PAH activity’ is most probably different from 
in vivo enzyme activity. A splice site mutation is estimated as having no ‘PAH activity’ if it 
is associated with classic phenotype in > 95% of patients and is not recognized to facilitate a 
response to BH4. Some splice site mutations may, however, produce wild type protein (albeit 
at a reduced level) and are thus associated with milder phenotypes.  
 Phenotype scoring  
Phenotype scoring was utilized for patients with homozygous mutations. Phenotype 
severity was scored according to blood Phe levels assigning a score of 1 for the mildest HPA 
(lowest blood Phe levels) and a score of 10 for the severe classic PKU (highest blood Phe 
levels).  
Statistical analysis  
Statistical analysis was performed using WinSTAT 2007.1 for Excel (R. Fitch Software, 
Germany). Passing-Bablok regression analysis was used to compare the relative residual 
‘PAH activity’ and phenotypes with BH4 responsiveness. 
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Results  
PAH genotypes  
Among the patients genotyped two mutations were observed in 540/569 (94.9%) patients 
(Suppl. Table 1). A single mutation was observed in 29 patients (data not shown) and in no 
instances was there a PAH-deﬁcient patient in which no mutation was observed. A total of 88 
mutations were observed and Table 1.2 provides those mutations that were observed with ≥ 
3% allele frequency.  
Table 1.2: Most common mutations (AF>3%) found in Turkish patients with PKU. 
 
The most frequently encountered PAH genotypes and their association with BH4 
responsiveness are shown in Table 1.3.  
Table 1.3: Most common genotypes and association with BH4 responsiveness. 
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Consanguinity and inbreeding are apparent in that 8 of the 12 most frequently observed 
genotypes involve homozygosity and furthermore the c.1066-11G>A mutation is represented 
in 5 of the most common genotypes. Twenty novel mutations were identiﬁed, with p.Y204X 
occurring in 15 alleles (Table 1.4).  
Table 1.4: Novel mutations detected in Turkish PKU patients. 
 
Table 1.5 shows that a high number of deletions (n = 54) and insertions (n = 5) were 
observed. 
Table 1.5: Deletions and insertions found in Turkish PKU patients. 
 
Within the same group of genotypes, BH4 responsiveness is equally distributed and 
frequently associated with mild HPA or mild PKU. In several instances, patients with 3 or 
even 4 mutations were identiﬁed (Table 1.6). Frequently the missense mutations p.R115H 
and p.A300S were observed together. To determine the inheritance phase of sequence 
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variants when > 2 mutations are observed, specimens from parents and other ﬁrst-degree 
relatives were recruited. Pedigree studies demonstrate a relatively common compound 
mutation in Turkish PKU patients where p.R155H and p.A300S are present on a common 
chromosome. Although not all parents were tested for hyperphenylalaninemia, two mothers 
presented with mild HPA (blood Phe levels 170 - 255 µmol/L).  
Table 1.6: Turkish PKU genotypes with additional mutations in cis. 
 
Loading test with BH4  
Prior to 1999, a formulation of BH4 containing 66.6% 6R-BH4 and 33.3% 6S-BH4 was 
utilized in challenge studies; thus, a 20 mg dose contained 13.3 mg of active drug. One 
hundred sixty-six patients (19% mild HPA, 19% mild PKU, 62% classic PKU) were 
challenged with 20 mg/kg (that in actuality provided 13.3 mg/kg), and Phe was monitored 
over 8 h. Among this group 6 patients (3.5%) responded with blood Phe reduction of ≥ 30% 
(Figure 1.1A). The residual ‘PAH activity’ of BH4-responsive genotypes (4 mild HPA and 2 
mild PKU) was between 25 and 72.5%. Additionally, three classic PKU patients responded 
to BH4; however, their genotypes indicated that they had < 1% ‘PAH activity’ and as such 
were classiﬁed as BH4 non-responders.  
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Two hundred ninety-six patients were challenged with the fully active BH4 formulation; 
thus a dose of 20 mg/kg was achieved. One hundred four patients were monitored for 8 h 
post-challenge; among these, 19 patients were responsive including 11 mild HPA (31 - 73% 
‘PAH activity’), 4 mild PKU (38 - 39% ‘PAH activity’), and 4 classic PKU (< 1% ‘PAH 
activity’) (Figure 1.1B). One hundred ninety-two patients, challenged with the fully active 
BH4 formulation, were assessed for 24 h post challenge. Responsive patients included 45 
mild HPA (16 - 56% PAH activity), 18 mild PKU (14 - 39% ‘PAH activity’), and 4 classic 
PKU (< 1% ‘PAH activity’) (Figure 1.1C). Because the 8-h test may not identify some 
responsive patients, only data from the 24-h test were used for genotype–phenotype 
correlation.  
 
Figure 1.1: Number of patients loaded with (A) 13.3 mg BH4 (old product) over 8 h; (B) 20 
mg BH4 over 8 h; and (C) 20 mg BH4 over 24 h and numbers of responsive patients (blood Phe 
reduction by > 29.9%) defined by both the BH4 challenge and genotype; resp. = BH4-responder 
BH4 deﬁciency 
Nineteen patients (8 female, 11 male) were diagnosed with BH4 deﬁciency (11 with 
QDPR deﬁciency, 8 with PTS deﬁciency), all of them responding to BH4 administration by 
lowering blood phenylalanine levels by more than 80% after 24 h (data not shown). These 
patients require a unique treatment regimen that includes neurotransmitter precursors and will 
be described in a separate study. 
Phenotype, genotype, PAH activity, and BH4 responsiveness  
For the comparison between the genotype, phenotype, BH4 responsiveness, and residual 
‘PAH activity,’ the 10 most common homozygous genotypes (total n = 206) with a frequency 
of > 5 patients were compared, utilizing the severity of the phenotype and the residual ‘PAH 
activity’ calculated from in vitro experiments (Table 1.7).  
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Table 1.7: Ten most common homozygous genotypes occurring in more than 5 Turkish 
PKU patients with different phenotypes, residual in vitro ‘PAH activity’, percentage of 
responders, and calculated phenotype score. Phenotype score was calculated for 
genotypes presented with different phenotypes.  
 
For most homozygous genotypes distribution of the phenotype was clear (e.g., 
p.R408W/p.R408W with no ‘PAH activity,’ classic phenotype, and 100% non-responsive-
ness). However, some genotypes (e.g., p.L48S/p.L48S) show a high inconsistency with 
regard to both phenotype (42% mild HPA, 33% mild PKU, 25% classic PKU) and BH4 
responsiveness (44.4% responder) (Suppl. Table 1).  
Phenotype severity was scored according to highest blood Phe levels assigning a score of 
1 for the mildest HPA and a score of 10 for the severe classic PKU. A good correlation 
(r = 0.83) was observed for BH4 responsiveness and ‘PAH activity’ (Figure 1.2A) and with 
r = 0.85 for BH4 responsiveness and phenotype (Figure 1.2B). Similar calculations with 
compound heterozygous genotypes yielded low correlation coefﬁcients (data not shown). 
 
 
 
 
 
 
Figure 1.2: Correlation between (A) BH4 responsiveness and residual ‘PAH activity’, and 
(B) BH4 responsiveness and phenotype in patients with 10 most common (n ≥ 6) homozygous 
mutations. Phenotype was scored according to the number of mild HPA, mild PKU or classic 
PKU patients within the same genotype and with the lowest score (1) for mild HPA and highest 
score (10) for classic PKU. For details see Table 1.7. 
 76 Chapter 1 
 
 
Discussion  
The observed frequency of PAH-deﬁcient PKU is higher in the Turkish population than 
in either Europe or the United States. Consanguinity, as a social norm in some communities 
within Turkish culture, has led to an increased frequency of PKU; furthermore, inbreeding 
within ethnic groups has also contributed to an increased disease frequency. An additional 
problem is delayed diagnosis and the quality of dietary management, both issues are a 
consequence of a paucity of PKU centers and the long distance patients must often travel to 
obtain care. The need for effective newborn screening and follow-on diagnostic procedures to 
categorize prospectively identiﬁed HPA newborns in the Turkish population is evident. We 
report a large-scale assessment of Turkish PKU patients and critically examine both PAH 
genotypes and response to challenge with BH4.  
Genotypes observed among the patient cohort showed homozygosity at a rate of ~ 48%. 
A high rate of homozygosity is not unique to Turkish PKU patients as we previously reported 
a high rate of homozygosity for the p.R408W mutation (43%) along with a limited spectrum 
of mutations among patients in western Poland [29]. As this study identiﬁed 88 different 
PAH mutations, including 20 novel mutations, the spectrum of PAH mutations in the Turkish 
population is relatively diverse. A unique genotypic feature of Turkish PKU patients is the 
number of in cis compound mutations (see Table 1.6). The p.R155H mutation was identiﬁed 
in cis with p.A300S in several patients. Upon reevaluation of a previously reported patient, 
we found p.R115H to be in cis with p.D143G (data not shown) [31]. Previously we 
determined that p.R155H is a mild mutation with minimal impact upon characteristics of the 
PAH enzyme; however, the combined inﬂuence of two missense changes in the same 
polypeptide chain could impact the enzyme more so than either mutation individually [31].  
The mutation spectrum in Turkish PKU patients reveals c.1066-11G>A (24.6%), 
p.R261Q (8.7%) and p.P281L (8.4%) to be frequently associated with mild to classic PKU. 
This ﬁnding is in accordance with previous reports from small studies involving 44 Turkish 
PKU patients [25, 26] and patients of Turkish origin in Germany [32]. Four of the 10 most 
common mutations (p.R261Q, p.L48S, p.A300S, and p.E390G) present with substantial 
residual activity (31 - 72.5% of the wild type PAH) when expressed in eukaryotic cell 
systems, and are associated with mild HPA or mild PKU. It has been suggested that p.E390G 
has only a modestly deleterious impact on the PAH enzyme [26] and the same may apply to 
the p.A300S. In contrast, p.L48S with 39% residual ‘PAH activity’ may be associated with 
both mild and classic PKU [23, 33]; thus, the mutation should be classiﬁed as equivocal in 
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regard to being BH4-responsive. However, classifying alleles as BH4-responsive or non-
responsive has limited utility, particularly when compound heterozygosity is involved. 
Interallelic complementation between unique PAH missense enzymes may exert a dominant 
negative effect in regard to BH4 response. Also, in vitro expressed activity may not 
necessarily represent the PAH activity in hepatocytes. Bartholomé et al. [34] showed that 
patients with classic PKU had no PAH activity in liver needle biopsies, patients with mild to 
moderate PKU showed up to 6% residual activity, and patients with mild HPA showed 8 -
 35% of the normal activity. This and other studies [35, 36] have shown that HPA occurs at 
in vivo PAH activities below 10 - 15% and that residual activity is essential for maintaining 
normal hepatic phenylalanine homeostasis. Thus, in vitro data should be interpreted 
cautiously, particularly with regard to BH4 responsiveness. As liver needle biopsy is no 
longer justiﬁed in PKU patients, in vitro assessment of mutant PAH proteins is the primary 
source of information concerning residual enzyme activity, which may be applied to patient 
phenotypes.  
Our study documents, in contrast to a previous report [23], that some mutations (e.g., 
p.R158Q) with < 20% ‘PAH activity’ should not be classiﬁed as BH4-responsive. 
Alternatively, some splice site variants (e.g., c.1066-3C>T) are clearly associated with 
response to BH4. It is possible that a BH4-responsive splicing mutation may not be fully 
penetrant and the gene may produce multiple mRNAs, including some wild type PAH-
mRNA message. This hypothesis would explain a mild phenotype and BH4 responsiveness in 
one patient from our cohort who is homozygous for c.1066-3C>T (Suppl. Table 1).  
There is a single report on BH4 response among 20 Turkish PKU patients (4 mild HPA, 
16 mild to moderate PKU, no classic PKU) that estimates the prevalence of responsive 
patients to be 45%. The authors conclude that predicting BH4 response based solely on the 
genotype is difﬁcult owing to a small sample size and compound heterozygous genotypes 
[37]. In our study, we compared genotypes in which the residual ‘PAH activity’ of the 
mutated proteins was previously investigated with the outcome of the BH4 test. As expected 
and reported in previous studies [11, 14], mild HPA and mild to moderate PKU patients are 
most likely to elicit a physiological response to BH4.  
For the ﬁrst time, we are able to compare a large number of homozygous genotypes with 
the outcome of the BH4 loading test and with the residual ‘PAH activity.’ Genotypes that lack 
residual ‘PAH activity’ (e.g., p.R408W/p.R408W or IVS4+5G>T/IVS4+5G>T) can be 
considered non-responsive to BH4, eliminating the need for a clinical BH4 challenge. 
Calculating the residual ‘PAH activity’ from the information available from in vitro 
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experiments may be useful for the prediction and/or exclusion of potential candidates for BH4 
therapy. This method is demonstrably more powerful than calculations based on a single 
mutation only.  
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Abstract 
Specific mutations in the gene encoding phenylalanine hydroxylase (PAH), located on 
chromosome 12q22 - 24.1, are linked to tetrahydrobiopterin (BH4; sapropterin)-responsive 
phenylketonuria (PKU). Diagnosis is usually done through the newborn screening for PKU, 
followed by a BH4 loading test. So far, more than 60 mutant alleles, presenting with a 
substantial residual PAH activity (average ~ 47%), were identified in more than 500 patients 
worldwide. We investigated the predictive value of BH4-responsive PAH mutations in 
Croatian population. From a group of 127 PKU patients, 62 were selected (based on the 
genotype) as potentially BH4-responsive and 39 loaded with BH4 (20 mg/kg). The overall 
frequency of BH4 responsiveness (> 30% blood phenylalanine reduction within 24 h) was 
36% (14 out of 39 patients with 23 different genotypes), significantly less than expected. The 
best responders were patients with mild hyperphenylalaninemia (4/4; 100%), followed by 
mild PKU (8/9; 89%), and classical PKU (2/26; 8%). The most common BH4-responsive 
genotypes were p.E390G/p.R408W and p.P281L/p.E390G. These genotypes correspond for 
approximately > 30% residual PAH activity. The p.E390G mutation was 100% associated 
with BH4 responsiveness, regardless of the second allele (p.R408W, p.P281L, p.F55Lfs, 
p.L249P). With regard to the predicted relative PAH activity of recombinantly expressed 
mutant alleles, there was a significant (p < 0.002) difference between BH4-responders and 
non-responders. In a general Croatian PKU population, disease-causing mutations were 
identified on 226 alleles (99%). There were 35 different mutations: 21 missense, 8 splice site, 
3 nonsense, 2 single nucleotide deletions, and 1 in-frame deletion. Four mutations are 
reported for the first time: p.E76D, p.L333P, p.G346E, and IVS8-2A>G. Five mutations 
accounted for over two-thirds of investigated alleles: p.L48S, p.R261Q, p.P281L, p.E390G, 
and p.R408W. Thus, the Croatian PKU population seems to be more homogenous than some 
other Mediterranean or Central European populations. This study reveals the importance of a 
full genotype for the prediction of BH4 responsiveness. In contrast to previous assumption 
and with exception of the p.E390G mutation, single allele mutations are not reliable for the 
selection of potential PKU candidates for pharmacological therapy with BH4. 
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Introduction 
Phenylketonuria (PKU; OMIM #261600) is an autosomal recessive metabolic disease 
caused by hepatic phenylalanine hydroxylase (PAH; EC 1.14.16.1) deﬁciency [1]. Over 500 
different mutations, identiﬁed on PAH gene, are responsible for a large spectrum of clinical 
phenotypes [2], from mild hyperphenylalaninemia (MHP), a variant that does not require 
treatment, to classical PKU that leads to severe neurological impairment when untreated. 
Although phenylalanine restriction has been the mainstay of successful dietary treatment 
since 1953 when ﬁrst initiated [3], it imposes a substantial burden on individuals with PKU 
and the family. This synthetic, highly restrictive diet is associated with a risk of nutritional 
deﬁciencies and phenylalanine control, despite good compliance, is sometimes difﬁcult to 
achieve. However, compliance is often poor, particularly as individuals reach adolescence 
[4]. Moreover, there is information on poor phenylalanine control before and during 
pregnancy in women with PKU, which can adversely inﬂuence fetal health [5]. Hence there 
is a need for an alternative treatment of PKU.  
BH4, a catalytic cofactor for PAH, has been shown to activate residual PAH activity and 
partially restore oxidative Phe metabolism in a substantial number of PKU patients. Although 
this ﬁnding was suggested many years ago [6, 7], not much attention has been paid to this 
issue until 1999 when Kure et al. [8] reported patients with PAH deﬁciency who had 
responded to oral BH4 intake by lowering their blood Phe levels. Since then, an increasing 
number of BH4-responsive PAH-deﬁcient patients has been reported [9 - 22]. Continued 
treatment with BH4 in responding patients has been shown to increase Phe tolerance, reduce 
or eliminate the need for Phe-free protein supplements or even to completely replace the diet 
[23 - 29]. One of the greatest issues still remains how to identify BH4-responsive individuals 
in a large and heterogeneous pool of PAH-deﬁcient patients.  
BH4 loading test result depends on many methodological factors such as preload plasma 
Phe level, the patient’s age at test (newborn vs. older) [12, 18, 30 - 32], Phe intake during the 
test, amount of administered BH4 and dosage scheme, cut-off levels of Phe reduction and 
duration of BH4 test. An optimized 48-h BH4 loading protocol, with two BH4 administrations 
(20 mg/kg/d) on two consecutive days and with four blood samplings (T0, T8, T16, and T24) 
after BH4 administration has been proposed for this reason [33]. Nevertheless, one study 
reported a signiﬁcant number (> 50%) of initially positive BH4 responders (Phe reduction > 
30% in short-term loading test lasting up to 24 h) who did not respond to long-term BH4 
treatment [27]. Also, there are several reports on patients with no signiﬁcant response to 
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single-dose loading test, but with a marked decrease in plasma Phe after several days of BH4 
administration [12, 34]. These inconsistencies stress the need for an additional approach to 
evaluation of BH4 responsiveness.  
Speciﬁc mutations in the PAH gene, many of them characterized by substantial residual 
activity when recombinantly expressed in different cell systems, are repeatedly found to be 
associated with BH4 responsiveness [10, 35, 36]. This is in accordance with data from BH4 
loading tests indicating an incidence of BH4 responsiveness of > 80% in mild variants of 
PKU patients with an overall incidence of > 40% in general PKU population [37]. Up to 10% 
of classical PKU patients respond in BH4 loading test (with a usual 30% cut-off in blood Phe 
reduction) and they are a more difﬁcult target to properly evaluate BH4 responsiveness. This 
is because some severe PKU patients had responded to BH4 by lowering Phe levels for 20%, 
which was deﬁned as a signiﬁcant response for this phenotype. Thus, Fiege and Blau [30] 
propose to modify the cut-off level for BH4 responsiveness accordingly to the patient’s 
clinical phenotype. However, there is no accurate correlation between genotype and BH4 
responsiveness, still with many reported responding inconsistencies within the same 
genotype [36]. So far, mutational analysis provides useful information on potential non-
responders comprising two null mutations but the prediction of BH4 responders remains 
incomplete [37].  
The aim of our study was to provide more information on predictive value of genotype 
for BH4 responsiveness and to summarize the mutation spectrum of the PAH gene in 
Croatian PKU population. We initially suggested that the presence of a mutation with in vitro 
substantial residual activity, compared with the wild type enzyme, on at least one PAH gene 
copy would be sufﬁcient for BH4 responsiveness. 
Patients and Methods 
Patients 
From a group of 127 patients diagnosed with hyperphenylalaninemia (HPA) (the highest 
blood phenylalanine 300 - 3630 µmol/L) from Croatia in whom PAH gene mutation analysis 
had been done, 39 patients were included in BH4 loading test. Although we selected 62 
patients, only 39 individuals accepted to perform the BH4 loading test. In four families two 
sibs were included. Selection criteria were only based on genotype. Inclusion criteria were: 
(a) presence of at least one BH4-responsive mutation; or (b) presence of at least one mutation 
termed as unclear in correlation to BH4 responsiveness; or (c) presence of at least one 
mutation with so far unknown response to BH4. A mutation was classiﬁed as BH4-responsive 
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if it was present either in homozygous or functional heterozygous form in BH4 responders 
from data in different publications (for further explanation on deﬁnition of BH4-responsive or 
unclear mutations see Zurﬂüh et al. [37]). Patients with two null mutations (with no residual 
activity) were excluded from the study. For mutation classiﬁcation in relation to BH4 
responsiveness and for additional information on PAH gene mutations we used data from 
BIOPKU database (www.bh4.org/BH4DatabasesBiopku.asp) and a locus-speciﬁc 
knowledgebase PAHdb (www.pahdb.mcgill.ca). There was an almost equal distribution 
between females (19/39) and males (20/39) (age ranged 1 - 24 years; mean 11 years) entering 
BH4 trial. BH4 deﬁciency was excluded in all patients by measuring urinary pterins and dried 
blood dihydropteridine reductase activity. Patients were assigned to one of the three 
phenotype categories according to the highest plasma Phe concentration before introducing 
the diet or after protein loading test (180 mg/kg/d of Phe intake over 5 days): 4/39 patients 
(10%) were classiﬁed as MHP (phenylalanine levels ≤ 600 µmol/L), 9/39 patients (23%) 
were assigned to mild PKU (Phe levels 600 - 1200 µmol/L) and 26/39 patients (67%) to 
classical PKU (Phe levels > 1200 µmol/L).  
BH4 loading test  
BH4 loading was performed at Department of Pediatrics, University Hospital Center 
Zagreb, after obtaining an informed consent from all participants or their parents including 
the approval of the institutional ethics committee. Three or four days before BH4 loading 
(classical PKU vs. milder forms) and during the entire testing period patients had no dietary 
restrictions, moreover, they were encouraged to consume Phe-rich food. BH4 (6R-BH4 
dihydrochloride; Schircks Laboratories, Jona, Switzerland) was administered orally to all 
patients as a single dose of 20 mg/kg body weight. Blood was collected just before BH4 
administration (T0), and 8 (T8), 24 (T24), and 48 h (T48) after the loading. We simpliﬁed the 
criteria suggested by Fiege et al. [17] to deﬁne BH4-responders as follows: ‘‘responder”, 
reduction of blood Phe by ≥ 30% within 24 h and ‘‘slow responder”, reduction of blood Phe 
by < 20% at T8, and ≥ 20% but < 30% at T24. One patient was classiﬁed as ‘‘not clear” with 
the reduction of blood Phe by ≥ 30% at T8, and < 20% at T24. No side effects were observed 
during the BH4 loading test. Phe and BH4 were measured from dried blood spots; Phe was 
analyzed using tandem-mass spectrometry and BH4 was measured according to the method 
previously published [38].  
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Mutational analysis  
One hundred and fourteen families with HPA (127 patients), all but four patients detected 
by Guthrie test within neonatal screening program, were enrolled in a comprehensive 
analysis of PAH gene mutations in Croatia in the last 17 years. According to the previously 
mentioned criteria, 78% of patients suffer from classical PKU, 14% from mild PKU whilst 
MHP phenotype is present in only 8%. Analyzed patients comprise 78% of total Croatian 
PKU population. Patients and/or parents signed informed consent for mutational analysis. 
Genotyping was performed as follows: DNA was isolated from dried blood spots using the 
QIAamp DNA Micro Kit (Qiagen). PCR was performed using Hot FirePol DNA Polymerase 
(Solis Biodyne) and standard thermal cycling, i.e., 15 min denaturation at 95°C followed by 
37 cycles of 30 s at 95°C, 45 s at 56°C, 45 s at 72°C, and ﬁnal incubation for 10 min at 72 °C 
(on a Gene-Amp PCR System 9700 (Applied Biosystems)). Primers ﬂanking all exons are 
listed in Table 2.1. The same primers were used to directly sequence the ampliﬁed products 
with the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). Sequencing 
reactions were puriﬁed by gel ﬁltration (using MultiScreen HV 96-well ﬁlter plates from 
Millipore with Sephadex G-50 (GE Healthcare)) and analyzed on a 3130xl Genetic Analyzer 
(Applied Biosystems). Sequencing results were compared with the wild type sequence of the 
PAH gene (Accession numbers NM_000277.1 and NG_008690.1) using the Mutation 
Surveyor (Demo) Software v3.20 (SoftGenetics). Gene analysis of 39 PKU families 
(included in this study) was done elsewhere as described in two previous publications on 
PKU mutations in Croatia [39, 40].  
The relative PAH activity of mutant alleles was calculated from the data published in the 
BIOPKUdb (www.biopku.org). It was calculated as a sum of activities for alleles 1 and 2, 
when expressed recombinantly in different cell systems, divided by two. For alleles 
expressed in more than one cell system, an average PAH activity was used. 
Statistical analysis  
Statistical analysis was performed using WinSTAT 2007.1 for Excel (R. Fitch Software, 
Germany). Wilcoxon test was used to compare the predicted relative PAH activity between 
BH4-responders and non-responders.  
 
 
 
Chapter 2 97 
 
 
97 
Table 2.1: Primers used for PCR-amplification and sequencing of all 13 exons plus 
flanking intronic regions of the human PAH gene (see also ‘Patients and methods’). 
 
a F, forward; R, reverse.  
b 
Without GC clamp.  
c Personal communication Pia Hougaard and Lisbeth Birk Møller, Kennedy Institute, Denmark.  
 
Results 
Mutational spectrum in Croatian PKU population  
In our mutation frequency assessment we included 114 PKU families. In one family there 
were three independent mutant alleles (affected child and uncle) what was the reason for 
investigating the total of 229 independent alleles. Disease-causing mutation was identiﬁed on 
226 alleles, corresponding to a diagnostic efﬁciency of approximately 99%. There were 35 
different mutations, including 21 missense mutations, 8 splice site, 3 nonsense, 2 single 
nucleotide deletions, and one in-frame deletion. The commonest PKU mutation p.R408W 
accounted for 36% of mutant alleles. Following mutations p.L48S, p.P281L, p.E390G, 
p.R261Q, and p.R158Q accounted for 10%, 8%, 7%, 6%, and 5.5% of mutant alleles, 
respectively. Five mutations accounted for over two-thirds of investigated alleles (Table 2.2). 
Four mutations have not been previously reported: p.E76D, p.G346E, p.L333P, and IVS8-
2A>G. 
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Table 2.2: The most frequent mutations in Croatian PKU population, which account for 
over two-thirds of the investigated population (229 independent chromosomes)  
 
Croatian PKU population is more homogenous than some Mediterranean or Central 
European populations as Zschocke et al. [40] already described. We found homozygosity in 
24% of genotypes (for following mutations: p.R408W, p.P281L, p.E390G, p.L249P, p.L48S, 
and p.R158Q) and only 10 allelic combinations accounted for over 50% of investigated 
families in Croatia (Table 2.3). Thus, the investigation of these allelic combinations in 
accordance to BH4 response was of great interest for our population. 
Table 2.3: The most frequent allelic combinations in Croatia that account for over half 
of the investigated PKU population (114 families) 
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Responsiveness to BH4  
The outcome of the loading test with BH4 in 39 PKU patients with 23 different genotypes 
is summarized in Table 2.4 (according to biochemical and genetic phenotype and its‘ mean 
predicted residual PAH activity [41]). The prevalence of BH4 responsiveness (at least 30% 
cut-off of phenylalanine reduction within 24 h) was only 36% (14 of 39 patients). 
Additionally, there were two slow responders who decreased Phe for 26.4% and 24% within 
24 h post loading (patient 1 and 25). The prevalence of BH4-responders in different 
phenotype groups was as follows: 100% (4/4 patients) in MHP group, 89% (8/9 patients) in 
mild PKU group, and 8% (2/26 patients) in classical PKU group. All MHP patients and 5/8 
responding mild PKU patients (patients 2, 3, 4, 5, and 39) showed signiﬁcant Phe reduction 
(> 50%) already 8 h post loading. In severe phenotypes that responded (two patients plus one 
slow responder) phenylalanine reduction was signiﬁcantly (over 20%) expressed 24 h post 
loading. Interestingly, patient 6 with the same genotype (p.E390G/p.R408W) (and disease 
severity, accordingly) as patients 2, 3, 4, and 5 showed signiﬁcantly slower and less effective 
response to BH4. We could not explain this by differences in test performance or BH4 
pharmacokinetics, and to our knowledge such poor response of this genotype has never been 
described before. It is, however, possible that in this patient Phe intake during the test was 
lower than in other patients with the same genotype. In all patients blood BH4 levels 
increased from initial 1.25 ± 1.11 nmol/g Hb (mean ± SD) to 6.06 ± 4.79 nmol/g Hb 8 h after 
BH4 administration and decreased to 2.07 ± 1.16 nmol/g Hb after 24 h and 1.64 ± 1.47 
nmol/g Hb after 48 h.  
Thirty-ﬁve patients from this study (see Table 2.4) had at least one mutation with known 
in vitro residual activity of 10% or more (compared with the wild type enzyme), and we 
assumed that each patient from this group would respond to BH4. However, only 14/35 
(40%) of these patients responded and one patient was labeled “not clear” (patient 19) as he 
responded just at T8, and then elevated Phe signiﬁcantly at T24. This was not estimated as 
reliable response to BH4. Additionally, we loaded with BH4 four patients with p.L249P, 
mutation with unknown response to BH4 (and with no in vitro studies on residual enzyme 
activity). To our knowledge, this mutation was only described in Croatian PKU population. 
p.L249P was ﬁrst described by Zschocke et al. [40]. It accounts for 3.5% of mutant alleles 
and, according to the results of BH4 loading test, it does not have any substantial residual 
enzyme activity. Namely, this mutation was associated with BH4 responsiveness only when 
in allelic combination with p.E390G (so far 100% responsive mutation), but did not show 
any response in homozygous or functional heterozygous condition.  
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Analysis of predicted relative PAH activities revealed a signiﬁcant difference (p < 0.002) 
between BH4-responders and non-responders (Figure 2.1). The median relative PAH activity 
was 37.2% in BH4-responder (5th - 95th percentile: 20.0 - 39.0%) and 20.0% in BH4 non-
responder group (5th - 95th percentile: 0.5 - 24.3%). 
 
Figure 2.1: Comparison of the predicted relative PAH activity in patients with the BH4-
responsive PKU (n = 14) and in non-responders (n = 20). For deﬁnition of the predicted relative 
PAH activity, see ‘‘Patients and methods” and Table 4. Three patients (two slow-responder and 
one not clear) were not included in the comparison. In four non-responder patients the relative 
PAH activity was calculated from only one allele, as well as for one responder. In two patients 
no data were available for the relative PAH activity. 
Discussion  
This is the ﬁrst study on BH4 responsiveness in a cohort of HPA patients where selection 
criteria for BH4 loading test were only based on genotype information. We predicted BH4 
responsiveness in individuals with at least one mutation expressing in vitro substantial 
residual activity (> 10%). This prediction was based on a current knowledge that speciﬁc 
mutation with some residual activity would be considered as the major determinant of BH4-
responding phenotype. Mutation-predicted prevalence of BH4 responsiveness was, however, 
almost threefold higher than prevalence data obtained after our BH4 loading test. This ﬁnding 
reveals the importance of the complete PAH genotype instead of just a single responsive 
mutation in predicting the BH4 responsiveness.  
Croatia has relatively homogenous PKU population with around 75% of families 
comprising classical PKU. Mutational background conﬁrms this ﬁnding as the most common 
mutation p.R408W accounts for 36% of mutant alleles, with p.R408W homozygosity rate of 
13%. Total homozygosity rate (24%) is higher than in majority of other European 
102 Chapter 2 
 
 
populations (according to data summarized in Guldberg et al. [42]). However, we believed 
there could be a significant number of BH4-responsive patients in this population, not just 
among 22% of milder forms, but also in severe phenotypes. This prediction was based on the 
fact that ‘‘milder” mutations such as p.L48S, p.E390G, p.R261Q, and p.R158Q were 
following p.R408W with allelic frequency of 10%, 7%, 6%, and 5.5%, respectively, in 
Croatian PKU population.  
Our results reveal, however, negative impact of the most frequent mutation, p.R408W, on 
the second allele with BH4-responsive mutation (p.L48S, p.R261Q, or p.R158Q). These three 
mutations have been repeatedly reported as inconsistent in BH4 responsiveness [10, 13, 16, 
18, 36], and they cannot be regarded as dominant in compound heterozygous patients as their 
behavior highly depends on the other mutation. Moreover, we observed to some extent 
consistent pattern in BH4 responsiveness for speciﬁc combinations of “inconsistent” 
mutations p.L48S and p.R261Q. They are non-responders (except patient 19 regarded as “not 
clear”) in functional hemizygous form, but found as BH4-responders in homozygous form 
(including one slow responder), in compound heterozygosity with MHP mutation as well as 
in in trans combination of this two mutations (p.L48S/p.R261Q). Although similar results 
were reported in many publications, there are several exceptions such as a report of BH4-
responsive p.R261Q/p.R243X genotype by Spaapen and Estela Rubio-Gozalbo [43] as well 
as reported non-responder with p.L48S homozygosity by Fiori et al. [16]. Both p.L48S 
homozygotes (patient 24 and 25) belong to milder form of classical PKU as they increase Phe 
much slower than typical classical PKU patients when not on diet, but however they can 
eventually reach high Phe levels (see their pretreatment Phe concentrations from Table 2.4). 
As reported by Leuzzi et al. [18] and conﬁrmed in our study, p.L48S homozygotes 
sometimes show slow response to BH4 (at T24 Phe reduction of 24%). Thus, in a case of this 
genotype a 30% cut-off in Phe reduction would not be always reliable to estimate BH4 
responsiveness. Trefz et al. [36] found p.R158Q mutation as the most inconsistent of all 
mutations (500 alleles investigated) in responding to BH4. Our results conﬁrm this 
observation, especially in case of compound heterozygosity with p.L48S (patient 27 and 28). 
Functional hemizygous patients for p.R158Q result in BH4 non-responsiveness. Our study 
conﬁrms the deﬁnition of p.E390G mutation as 100% responsive allele. To our knowledge, 
this mutation has never so far been described as BH4 non-responsive, regardless of the 
second allele. The similar was observed for much less frequent p.I306V mutation (full 
responsiveness in two patients and “slow” responsiveness in the third loaded patient), 
although the response of the latter needs to be evaluated on more patients.  
Chapter 2 103 
 
 
103 
Our ﬁndings reveal following features: one mutation is sufﬁcient to estimate response to 
BH4 just in case of MHP mutations (e.g., p.E390G). In all other cases mutational 
combination (i.e., complete genotype) should be used to indicate and adjust, still not 
standardized, BH4 loading test. On the basis of allelic mutational combination we were able 
to predict BH4-response for the majority of patients. The exceptions were genotypes with 
mutations with unknown response to BH4 and so far unmeasured in vitro residual activity 
(p.L249P), with in cis mutations (p.V245A+p.R241C), and highly inconsistent genotype 
(p.L48S/p.R158Q). Genotype information is also useful for the selection of a target 
population among patients with classical PKU (i.e., by excluding patients with two null 
mutations), as well as to point to patients who are probable slow-responders not to be missed 
by too rigorous loading protocol (e.g., some p.L48S homozygotes).  
The predicted relative PAH activities (Table 2.4 and Figure 2.1) were signiﬁcantly higher 
in BH4-responders, compared with the non-responder group. It seems that a substantial 
residual PAH activity resulting from a combination of both alleles is needed to predict 100% 
responsiveness in PKU patients.  
Acknowledgments  
This work was supported by Grant No. 108-1081870-1885 of the Ministry of Science, 
Education and Sport of Republic of Croatia, by the Swiss National Science Foundation Grant 
No. 3100A0-1199852/1, and in part by a grant from BioMarin Pharmaceuticals Inc., Novato, 
CA (to N.B.). We thank our nurses from The Division of Genetics and Metabolism, 
Department of Pediatrics in University Hospital Center Zagreb for technical assistance, 
Thomas Polanski for measurement of pterins, and Rita Denz for measurement of amino 
acids.  
 
© 2009 ELSEVIER Inc. All rights reserved. 
 
104 Chapter 2 
 
 
References  
[1]  C.R. Scriver, S. Kaufman, Hyperphenylalaninemia: phenylalanine hydroxylase 
deﬁciency, in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, B. 
Vogelstein (Eds.), The Metabolic and Molecular Bases of Inherited Disease, 
McGraw-Hill, New York, 2001, pp. 1667–1724.  
[2]  C.R. Scriver, The PAH gene, phenylketonuria, and a paradigm shift, Hum. Mutat. 28 
(2007) 831–845.  
[3]  H. Bickel, J.W. Gerrard, E.M. Hickmans, Inﬂuence of phenylalanine intake on 
phenylketonuria, Lancet (1953) 812–819.  
[4]  J.H. Walter, F.J. White, S.K. Hall, A. MacDonald, G. Rylance, A. Boneh, D.E. 
Francis, G.J. Shortland, M. Schmidt, A. Vail, How practical are recommendations for 
dietary control in phenylketonuria?, Lancet 360 (2002) 55–57.  
[5]  A.S. Brown, P.M. Fernhoff, S.E. Waisbren, D.M. Frazier, R. Singh, F. Rohr, J.M. 
Morris, A. Kenneson, P. MacDonald, M. Gwinn, M. Honein, S.A. Rasmussen, 
Barriers to successful dietary control among pregnant women with phenylketonuria, 
Genet. Med.4 (2002) 84–89.  
[6]  S. Milstien, S. Kaufman, Studies on the phenylalanine hydroxylase system in liver 
slices, J. Biol. Chem. 250 (1975) 4777–4781.  
[7]  A. Niederwieser, H.C. Curtius, Tetrahydrobiopterin deﬁciencies in 
hyperphenylalaninemia, in: H. Bickel, U. Wachtel (Eds.), Inherited Diseases of 
Amino Acid Metabolism, Georg Thieme, Stuttgart, 1985, pp. 104–121.  
[8]  S. Kure, D.C. Hou, T. Ohura, H. Iwamoto, S. Suzuki, N. Sugiyama, O. Sakamoto, K. 
Fujii, Y. Matsubara, K. Narisawa, Tetrahydrobiopterin-responsive phenylalanine 
hydroxylase deﬁciency, J. Pediatr. 135 (1999) 375–378.  
[9]  C. Bernegger, N. Blau, High frequency of tetrahydrobiopterin-responsiveness among 
hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002, Mol. 
Genet. Metab. 77 (2002) 304–313.  
[10]  A.C. Muntau, W. Röschinger, M. Habich, H. Demmelmair, B. Hoffmann, C.P. 
Sommerhoff, A.A. Roscher, Tetrahydrobiopterin as an alternative treatment for mild 
phenylketonuria, N. Engl. J. Med. 347 (2002) 2122–2132.  
[11]  M. Lindner, R. Steinfeld, P. Burgard, A. Schulze, E. Mayatepek, J. Zschocke, 
Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine 
hydroxylase deﬁciency, Hum. Mutat. 21 (2003) 400.  
[12]  H. Shintaku, S. Kure, T. Ohura, Y. Okano, M. Ohwada, N. Sugiyama, N. Sakura, I. 
Yoshida, M. Yoshino, Y. Matsubara, K. Suzuki, K. Aoki, T. Kitagawa, Long-term 
treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia 
with a mutant phenylalanine hydroxylase gene, Pediatr. Res. 55 (2004) 425–430.  
[13]  B. Perez-Duenas, M.A. Vilaseca, A. Mas, N. Lambruschini, R. Artuch, L. Gomez, J. 
Pineda, A. Gutierrez, M. Mila, J. Campistol, Tetrahydrobiopterin responsiveness in 
patients with phenylketonuria, Clin. Biochem. 37 (2004) 1083–1090.  
[14]  L.R. Desviat, B. Pérez, A. Bèlanger-Quintana, M. Castro, C. Aguado, A. Sánchez, 
M.J. García, M. Martínez-Pardo, M. Ugarte, Tetrahydrobiopterin responsiveness: 
results of the BH4 loading test in 31 Spanish PKU patients and correlation with their 
genotype, Mol. Genet. Metab. 82 (2004) 157–162.  
Chapter 2 105 
 
 
105 
[15]  J.J. Mitchell, B. Wilcken, I. Alexander, C. Ellaway, H. O’Grady, V. Wiley, J. Earl, J. 
Christodoulou, Tetrahydrobiopterin-responsive phenylketonuria: the New South 
Wales experience, Mol. Genet. Metab. 86 (2005) 81–85.  
[16]  L. Fiori, B. Fiege, E. Riva, M. Giovannini, Incidence of BH4-responsiveness in 
phenylalanine-hydroxylase-deﬁcient Italian patients, Mol. Genet. Metab. 86 (2005) 
67–74.  
[17]  B. Fiege, L. Bonafé, D. Ballhausen, M. Baumgartner, B. Thöny, D. Meili, L. Fiori, M. 
Giovannini, N. Blau, Extended tetrahydrobiopterin loading test in the diagnosis of 
cofactor-responsive phenylketonuria: a pilot study, Mol. Genet. Metab. 86 (2005) 91–
95.  
[18]  V. Leuzzi, C. Carducci, C. Carducci, F. Chiarotti, C. Artiola, T. Giovanniello, I. 
Antonozzi, The spectrum of phenylalanine variations under tetrahydrobiopterin load 
in subjects affected by phenylalanine hydroxylase deﬁciency, J. Inherit. Metab. Dis. 
29 (2006) 38–46.  
[19]  S. Yildirim, A. Tokatli, E. Yilmaz, T. Coskun, Assessment of tetrahydrobiopterin 
responsiveness in Turkish hyperphenylalaninemic patients, Turk. J. Pediatr. 49 (2007) 
1–6.  
[20]  L. Wang, S. Surendran, K. Michals-Matalon, G. Bhatia, S. Tanskley, R. Koch, J. 
Grady, S.K. Tyring, R.C. Stevens, F. Guttler, R. Matalon, Mutations in the regulatory 
domain of phenylalanine hydroxylase and response to tetrahydrobiopterin, Genet. 
Test. 11 (2007) 174–178.  
[21]  M.D. Boveda, M.L. Couce, D.E. Castineiras, J.A. Cocho, B. Perez, M. Ugarte, J.M. 
Fraga, The tetrahydrobiopterin loading test in 36 patients with 
hyperphenylalaninaemia: evaluation of response and subsequent treatment, J. Inherit. 
Metab. Dis. 30 (2007) 812.  
[22]  B.K. Burton, D.K. Grange, A. Milanowski, G. Vockley, F. Feillet, E.A. Crombez, V. 
Abadie, C.O. Harding, S. Cederbaum, D. Dobbelaere, A. Smith, A. Dorenbaum, The 
response of patients with phenylketonuria and elevated serum phenylalanine to 
treatment with oral sapropterin dihydrochloride (6Rtetrahydrobiopterin): a phase II, 
multicentre, open-label, screening study, J. Inherit. Metab. Dis. 30 (2007) 700–707.  
[23]  R. Cerone, M.C. Schiafﬁno, A.R. Fantasia, M. Perfumo, L. Birk Moller, N. Blau, 
Long-term follow-up of a patient with mild tetrahydrobiopterin-responsive 
phenylketonuria, Mol. Genet. Metab. 81 (2004) 137–139.  
[24]  J.B. Hennermann, C. Bührer, N. Blau, B. Vetter, E. Mönch, Long-term treatment with 
tetrahydrobiopterin increases phenylalanine tolerance in children with severe 
phenotype of phenylketonuria, Mol. Genet. Metab. 86 (2005) 86–90.  
[25]  N. Lambruschini, B. Perez-Duenas, M.A. Vilaseca, A. Mas, R. Artuch, R. Gassio, L. 
Gomez, A. Gutierrez, J. Campistol, Clinical and nutritional evaluation of 
phenylketonuric patients on tetrahydrobiopterin monotherapy, Mol. Genet. Metab. 86 
(2005) 54–60.  
[26]  F.K. Trefz, D. Scheible, G. Frauendienst-Egger, H. Korall, N. Blau, Long-term 
treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin, 
Mol. Genet. Metab. 86 (2005) 75–80.  
[27]  H. Levy, A. Milanowski, A. Chakrapani, M. Cleary, P. Lee, F.K. Trefz, C.B. Whitley, 
F. Feillet, A.S. Feigenbaum, J.D. Bebchuk, H. Christ-Schmidt, A. Dorenbaum, 
Efﬁcacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of 
phenylalanine concentration in patients with phenylketonuria: a phase III randomized 
placebo-controlled study, Lancet 370 (2007) 504–510.  
106 Chapter 2 
 
 
[28]  P. Lee, E.P. Treacy, E. Crombez, M. Wasserstein, L. Waber, J. Wolff, U. Wendel, A. 
Dorenbaum, J. Bebchuk, H. Christ-Schmidt, M. Seashore, M. Giovannini, B.K. 
Burton, A.A. Morris, Safety and efﬁcacy of 22 weeks of treatment with sapropterin 
dihydrochloride in patients with phenylketonuria, Am. J. Med. Genet.A 146A (2008) 
2851–2859.  
[29]  A. Burlina, N. Blau, Effect of BH4 supplementation on phenylalanine tolerance, J. 
Inherit. Metab. Dis. 32 (2009) 40–54.  
[30]  B. Fiege, N. Blau, Assessment of tetrahydrobiopterin (BH4)-responsiveness in 
phenylketonuria, J. Pediatr. 150 (2007) 627–630.  
[31]  H. Levy, B. Burton, S. Cederbaum, C. Scriver, Recommendations for evaluation of 
responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in 
treatment, Mol. Genet. Metab. 92 (2007) 287–291.  
[32]  N. Blau, Deﬁning tetrahydrobiopterin (BH4)-responsiveness in PKU, J. Inherit. Metab. 
Dis. 31 (2008) 2–3.  
[33]  N. Blau, A. Belanger-Quintana, M. Demirkol, F. Feillet, M. Giovannini, A. 
MacDonald, F.K. Trefz, F.J. van Spronsen, Optimizing the use of sapropterin (BH4) n 
the management of phenylketonuria, Mol. Genet. Metab. 96 (2009) 158–163.  
[34] U. Lässker, J. Zschocke, N. Blau, R. Santer, Tetrahydrobiopterin responsiveness in 
phenylketonuria. Two new cases and a review of molecular genetic ﬁndings, J. 
Inherit. Metab. Dis. 25 (2002) 65–70.  
[35]  N. Blau, H. Erlandsen, The metabolic and molecular bases of tetrahydrobiopterin-
responsive phenylalanine hydroxylase deﬁciency, Mol. Genet. Metab. 82 (2004) 101–
111.  
[36] F.K. Trefz, D. Scheible, H. Gotz, G. Frauendienst-Egger, Signiﬁcance of genotype in 
tetrahydrobiopterin-responsive phenylketonuria, J. Inherit. Metab. Dis. 32 (2009) 22–
26.  
[37]  M.R. Zurﬂüh, J. Zschocke, M. Lindner, F. Feillet, C. Chery, A. Burlina, R. Stevens, 
B. Thöny, N. Blau, Molecular genetics of tetrahydrobiopterin responsive 
phenylalanine hydroxylase deﬁciency, Hum. Mutat. (2008) 167–175.  
[38]  M. Zurﬂüh, M. Giovannini, L. Fiori, B. Fiege, Y. Gokdemir, T. Baykal, L. Kierat, 
K.H. Gärtner, B. Thöny, N. Blau, Screening for tetrahydrobiopterin deﬁciencies using 
dried blood spots on ﬁlter paper, Mol. Genet. Metab. 86 (2005) 96–103.  
[39]  I. Baric, D. Mardesic, G. Gjuric, V. Sarnavka, B. Gobel-Schreiner, U. Lichter-
Konecki, D.S. Konecki, F.K. Trefz, Haplotype distribution and mutations at the PAH 
locus in Croatia, Hum. Genet. 90 (1992) 155–157.  
[40]  J. Zschocke, A. Preusse, V. Sarnavka, K. Fumic, D. Mardesic, G.F. Hoffmann, I. 
Baric, The molecular basis of phenylalanine hydroxylase deﬁciency in Croatia, Hum. 
Mutat. 21 (2003) 399.  
[41]  M. Bik-Multanowski, J.J. Pietrzyk, B. Didycz, A. Szymczakiewicz-Multanowska, 
Development of a model for assessment of phenylalanine hydroxylase activity in 
newborns with phenylketonuria receiving tetrahydrobiopterin: a potential for practical 
implementation, Mol. Genet. Metab. 94 (2008) 389–390.  
[42]  P. Guldberg, F. Rey, J. Zschocke, V. Romano, B. Francois, L. Michiels, K. Ullrich, 
Hoffmann, P. Burgard, H. Schmidt, C. Meli, E. Riva, I. Dianzani, A. Ponzone, Rey, F. 
Güttler, A European multicenter study of phenylalanine hydroxylase deﬁciency: 
classiﬁcation of 105 mutations and a general system for genotype-based prediction of 
metabolic phenotype, Am. J. Hum. Genet. 63 (1998) 71–79.  
Chapter 2 107 
 
 
107 
[43] L.J. Spaapen, M. Estela Rubio-Gozalbo, Tetrahydrobiopterin-responsive 
phenylalanine hydroxylase deﬁciency, state of the art, Mol. Genet. Metab. 78 (2003) 
93–99.  
[44]  P. Guldberg, V. Romano, N. Ceratto, P. Bosco, M. Ciuna, A. Indelicato, F. Mollica, 
C. Meli, M. Giovannini, E. Riva, et al., Mutational spectrum of phenylalanine 
hydroxylase deﬁciency in Sicily: implications for diagnosis of hyperphenylalaninemia 
in southern Europe, Hum. Mol. Genet 2 (1993) 1703–1707.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 Chapter 2 
 
 
 
 109 
 
 
 
 
 
 
 
 
Chapter 3 
 
Quantification of Phenylalanine Hydroxylase Activity by 
Isotope-Dilution Liquid Chromatography-Electrospray 
Ionization Tandem Mass Spectrometry 
 
Caroline Heintza, Heinz Troxlera, Aurora Martinezb, Beat Thönya,c,d, Nenad Blaua,c,d,e,⁎ 
a Division of Clinical Chemistry and Biochemistry, University Children's Hospital, Zürich, Switzerland 
b Department of Biomedicine, University of Bergen, Bergen, Norway  
c Zürich Center for Integrative Human Physiology (ZIHP), Zürich, Switzerland  
d Research Center for Children (RCC), Zürich, Switzerland 
e Division of Metabolism, University Children's Hospital, Heidelberg, Germany 
 
Published in Molecular Genetics and Metabolism 2012, 105(4): 559-65. 
 
 
110 Chapter 3 
 
 
Abstract 
Background: Residual phenylalanine hydroxylase (PAH) activity is the key determinant for 
the phenotype severity in phenylketonuria (PKU) patients and correlates with the patient's 
genotype. Activity of in vitro expressed mutant PAH may predict the patient's phenotype and 
response to tetrahydrobiopterin (BH4), the cofactor of PAH. 
Methods: A robust LC-ESI-MSMS PAH assay for the quantification of phenylalanine and 
tyrosine was developed. We measured PAH activity a) of the PAH mutations p.Y417C, 
p.I65T, p.R261Q, p.E280A, p.R158Q, p.R408W, and p.E390G expressed in eukaryotic COS-
1 cells; b) in different cell lines (e.g. Huh-7, Hep3B); and c) in liver, brain, and kidney tissue 
from wild type and PKU mice. 
Results: The PAH assay was linear for phenylalanine and tyrosine (r2 ≥ 0.99), with a 
detection limit of 105 nmol/L for Phe and 398 nmol/L for Tyr. Intra-assay and inter-assay 
coefficients of variation were < 5.3% and < 6.2%, respectively, for the p.R158Q variant in 
lower tyrosine range. Recovery of tyrosine was 100%. Compared to the wild type enzyme, 
the highest PAH activity at standard conditions (1 mmol/L Phe; 200 µmol/L BH4) was found 
for the mutant p.Y417C (76%), followed by p.E390G (54%), p.R261Q (43%), p.I65T (33%), 
p.E280A (15%), p.R158Q (5%), and p.R408W (2%). A relative high PAH activity was found 
in kidney (33% of the liver activity), but none in brain. 
Conclusions: This novel method is highly sensitive, specific, reproducible, and efficient, 
allowing the quantification of PAH activity in different cells or tissue extracts using 
minimum amounts of samples under standardized conditions. 
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Introduction 
Deficiency of phenylalanine hydroxylase (PAH, EC 1.14.16.1) is causing 
phenylketonuria (PKU, OMIM 261600), an autosomal recessively inherited disease 
presenting with elevated blood phenylalanine (Phe) levels [1, 2]. The phenotypic severity of 
PKU is characterized by the type of mutation, and thus by residual PAH enzyme activity. The 
fully functional homotetrameric PAH catalyzes hydroxylation of Phe to tyrosine (Tyr) in the 
presence of cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and molecular oxygen 
[3, 4]. According to the Locus Knowledgebase (PAHdb, www.pahdb.mcgill.ca), about 60% 
of mutations in the PAH gene are missense mutations, which may lead to a misfolding of the 
protein [5, 6], disturbing the complex enzyme regulation and changes in kinetics, due to 
altered affinities for the Phe substrate and the BH4 cofactor. 
The incidence of PKU is about 1 in 10,000 newborns in Caucasian populations [2]. For 
most patients, therapy consists in a life-long dietary restriction of Phe to prevent neurological 
impairment. Recently, it has been reported that a subgroup of PKU patients (mild to 
moderate phenotype) can benefit from a pharmacological therapy with BH4 (sapropterin 
dihydrochloride; Kuvan®) [7,8]. Newborn screening program for PKU, initially based on the 
Guthrie test [9], has been established for the early detection of PKU patients. Today, 
electrospray ionization tandem mass spectrometry (ESI-MSMS or TMS) is the method of 
choice for fast screening and monitoring of Phe and Tyr levels in dried blood spots (DBS) 
[10]. Of the over 550 disease-causing mutations listed in the PAHdb [11], 88 were expressed 
in different in vitro cell systems to estimate the residual PAH activity. Expression systems 
like Escherichia coli, eukaryotic cell lines, or cell-free systems were most commonly used 
systems [12 - 14]. In addition to cell systems, PAH activity was studied in rat liver biopsy 
samples [15]. Expression of recombinant PAH in bacteria was applied for characterization of 
physical and chemical properties of the enzyme [16]. 
Previous methods for PAH activity measurement were based on the determination of 14C-
labeled Tyr produced [3] or release of 3H [17]. Other methods are based on detection of Tyr 
by fluorescence coupled to HPLC [18], colorimetric assays [19], or fluorescence monitoring 
[20]. Recently described method by Gersting et al. [20] was developed for characterization of 
purified mutant PAH proteins at different Phe and BH4 concentrations. 
In our novel assay, we applied liquid chromatography (LC) with ESI-MSMS for the 
quantification of Tyr produced from Phe. Prior to analysis, the amino acids are derivatized to 
propyl chloroformate derivatives, using the commercially available Phenomenex EZ:faastTM 
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kit. Our method allows for short analysis times and lower limit of detection and is optimized 
for determination of PAH enzyme activity of recombinantly expressed mutant proteins in 
COS-1 and other cell lines, as well as in mice liver, kidney, and brain. Thus, it allows 
comparison between different mutant proteins at standard conditions. 
Materials and methods 
Materials 
The Phenomenex EZ:faastTM kit for LC with ESI-MSMS amino acid analysis was 
purchased from Phenomenex (Torrance, CA, USA). L-phenylalanine-d5 and L-tyrosine-d4 
standard reagents were purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA, 
USA) whereas L-phenylalanine-d8 was obtained from C/D/N Isotopes Inc. (Pointe Claire, 
Quebec, Canada). L-Phenylalanine and L-Tyrosine, as well as the DMEM cell culture 
medium were purchased from Sigma Aldrich (St. Louis, MO, USA). RPMI 1640 medium 
was from Invitrogen (San Diego, CA, USA). BH4 dihydrochloride was obtained from 
Schircks Laboratories (Jona, Switzerland). Mouse tissues were extracted from C57Bl/6 (wild 
type) or C57Bl/6-Pahenu2 (PKU) [21] mice strains. 
Expression plasmid preparation 
The expression plasmid pCMV-FLAG-PAH (Promoter-N-Fusion-PAH) was received as 
courtesy gift from L. R. Desviat [22]. Mutations in the human PAH-cDNA sequence were 
introduced by site-directed mutagenesis, using QuikChange XL kit from Agilent 
Technologies (Santa Clara, CA, USA) and confirmed by sequencing analysis using BigDye 
Terminator Cycle sequencing v1.1 (Applied Biosystems) on an ABI Prism 3100 Sequencer. 
Transfection of cells and preparation of mouse tissue 
Cell lines (COS-1, Hep3B, Huh-7) were cultured either in DMEM or RPMI1640 (HaCat, 
lymphoblasts) medium, with appropriate additives, at 37°C under 5% CO2. One day prior to 
transfection, COS-1 cells were seeded at 2 ×  105 cells/mL in 10-cm dishes. Transfection 
experiments were performed using Fugene 6 (Roche Diagnostics, Mannheim, Germany) 
according to manufacturer's recommendations. Hereby, 13 µg of the pCMV-FLAG-PAH 
plasmid (either wild type or mutant) were co-transfected with 2 µg of pSV-βgal reporter 
plasmid (Promega, Madison, USA). Transfected cells were harvested after 48 h for 
determination of PAH activity or flash-frozen in liquid N2 for storage at -80°C.  
Transfection efficiency was verified by determining β-galactosidase activity in 5 µl lysate in 
PAH assay cell lysis buffer (1× PBS pH 7.4, 0.25 M sucrose, complete protease inhibitors 
Chapter 3 113 
 
 
113 
cocktail (Roche)) using in-situ β -galactosidase enzyme assay system (Promega, Madison, 
USA). PAH activities of wild type and mutants were normalized according to transfection 
efficiency. 
Frozen mouse tissues were lysed in homogenization buffer (10 µl/mg tissue), as described 
in [23], and homogenized using Qiagen TissueLyser II at 4°C. After centrifugation at 13,000 
g and 4°C for 30 min, supernatants were kept frozen at -80°C. 
PAH activity assay 
Cell lysates were prepared and enzyme activity was determined using previously 
described methods [24]. Briefly, assay conditions included pre-incubation at 25°C with Phe 
(1 mmol/L) for 4 min, then Fe(NH4)2(SO4)2 (100 µmol/L) was added, and incubation was 
continued for one more minute. After 5 min total pre-incubation time, BH4 (200 µmol/L for 
cell extracts or 75 µmol/L for mouse tissue) was added to start the reaction. Between 2.5 and 
20 µl (2 - 165 µg) of total protein lysate extracted from cells or mouse tissue was used for 
activity measurements. The applied total protein amount depended on lysate type, 
transfected, non-transfected, or mouse tissue samples. It was generally higher for sample 
types with low activity where only little amounts of Tyr were produced. Initially, this was 
determined empirically by measuring a series of increasing total protein amounts for each 
sample type to determine the measurable linear range. Reaction time was 2 min for mouse 
tissue lysates and 15 min for cell lysates. Short incubation time reduces any possible 
chaperone-like effect of BH4. The amount of Tyr produced was determined by LC with ESI-
MSMS (see below). 
Protein concentrations of all sample types were determined using Pyrogallol Red protein 
dye binding assay [25] after completion of PAH assay due to low stability of protein lysates. 
Specific PAH activities are expressed in mU per mg total protein to account for differences in 
total protein amount and with mU equal to nmol L-Tyr produced per minute. 
Stock solution preparation and calibration 
Labeled internal standard stock solutions (10 mmol/L Phe-d5 and 10 mmol/L Tyr-d4) 
were prepared in 50 mmol/L HCl, stored at -20°C, and freshly diluted to working 
concentrations (see sample preparation). Stock solutions of non-labeled Phe (50 mmol/L) and 
Tyr (8 mmol/L) were prepared for calibration curves in 50 mmol/L HCl and stored at  
-20°C. 
Working solutions for calibration curves were freshly prepared from the non-labeled 
stock solutions in H2O from 100 to 700 µmol/L Phe and 4 to 350 µmol/L Tyr (Table 3.1).  
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In order to include the matrix effect to the calibration curves, 20 µl of COS-1 non-transfected 
cell lysate was added to the calibration samples. 
Table 3.1: Standards used for the calibration curve of L-Tyr and L-Phe. 
 
Sample preparation and derivatization 
Samples were prepared according to the Phenomenex EZ:faastTM kit's manual [26], with 
the following modifications: prior to amino acid extraction and derivatization, 20 µL of each 
internal standard solution containing 100 µmol/L Phe-d5 and 20 µmol/L Tyr-d4 (in 50 
mmol/L HCl) were added to 20 µL of sample lysate. Using the kit's reagents, the amino acids 
are derivatized with propyl chloroformate resulting in the addition of a propyl formate at the 
amine moiety and a propyl group at the carboxylic end of the amino acids, respectively. The 
hydroxy group of Tyr is also derivatized by the addition of a propyl formate group. 
Instrumentation 
For RP (reversed phase)-HPLC separation of amino acids, a 250 ×  2 mm C18 column 
(Phenomenex EZ:faastTM) was used. The derivatized amino acids were separated using the 
following program: (i) isocratic flow 75% solvent B for 6 min; (ii) linear gradient from 75% 
to 95% solvent B (v/v) in 9 min; (iii) linear gradient from 95% to 100% solvent B in 0.1 min; 
(iv) isocratic flow 100% solvent B for 3 min; (v) linear gradient from 100% to 75% solvent B 
in 0.1 min; (vi) isocratic flow 75% solvent B for 2 min. Solvents A and B were 10 mmol/L 
ammonium formate in H2O and 10 nmol/L ammonium formate in methanol, respectively. 
Flow rate was 150 µL/min, and the injection volume was 10 µL. 
A PerkinElmer SCIEX API 2000 LC-ESI-MSMS system equipped with a PerkinElmer 
Series 200 autosampler and two PerkinElmer Series 200 micro pumps were used for LC–
ESI-MSMS analysis. Amino acids were acquired using the multiple reaction mode (MRM) 
positive ion mode with the following transitions: 294 → 206 (Phe), 299 → 211 (Phe-d5), 302 
→ 214 (Phe-d8), 396 →  308 (Tyr), and 400 →  312 (Tyr-d4). The dwell time was 500 ms. 
Mass spectra were acquired in the time range of 6 to 20 min. 
Immunoquantification by Western blot 
Five to 50 µg of lysate from activity assay was used for verifying PAH expression in the 
various cell lines or mouse tissue samples by Western blotting, using commercially available 
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anti-PAH antibody PH8 (Abcam, Cambridge, UK) and donkey anti-goat IgG-HRP (Santa 
Cruz Biotechnology, CA, USA). Antibody binding was detected by enhanced 
chemiluminescence (Amersham ECLTM) as described by the manufacturer's instructions (GE 
Healthcare, CT, USA). 
Limit of detection 
The limit of detection (LOD) was determined by measuring six blank samples of non-
transfected COS-1 cell lysate with very low amounts of Phe and Tyr using the following 
formula: 
LOD = ((mean + 3.3)Ûstandard deviation) / slope. 
The limit of quantification (LOQ) for Phe and Tyr was calculated as follows:  
LOQ = ((mean + 10)Ûstandard deviation) / slope. 
 
Results 
Linearity and limit of detection 
Figure 3.1 depicts linear regression of calibration standards for Phe and Tyr. Both 
calibration curves were linear with correlation coefficients of r2 ≥ 0.99. The LOD was 105 
nmol/L for Phe and 398 nmol/L for Tyr and LOQ 147 nmol/L for Phe and 574 nmol/L for 
Tyr. 
 
Figure 3.1: Calibration curves (linear regression) for Phe and Tyr using Phe-d5 and Tyr-d4 
as internal standards for quantification. The ratio of analyte peak area and corresponding 
internal standards is plotted as a function of analyte concentration. 
Imprecision and recovery 
Inter- and intra-assay analyses were performed with the wild type enzyme, with medium 
activity (p.R261Q), and low activity (p.R158Q) PAH variants, transfected into COS-1 cells. 
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Six samples were each prepared either on the same day (intra-assay) or during the period of 
two weeks (inter-assay). Table 3.2 summarizes the intra- and inter-assay imprecision 
measurements of the method. 
The intra-assay coefficient of variation (CV) varied between 2.4% and 10.8% and 
between 2.7% and 8.9% for Tyr and Phe, respectively (Table 3.2). The inter-assay 
imprecision data for Tyr and Phe ranges from 5.3% to 14.3% (Table 3.2). Comparable CVs 
in the intra- and inter-assays show that the PAH assay samples are stable over more than 2 
weeks at -20°C. 
The recovery of 100 µmol/L exogenous Tyr added to the variant PAH p.R261Q after 
PAH assay was 100% (data not shown). 
Analytical performance 
Three characteristic parameters, retention time, mother ion mass, and daughter ion mass 
were measured in the LC-ESI-MSMS method for each analyte, e.g. 12.59 min, m/z 396 Da 
and m/z 308 for Tyr. Figure 3.2A shows a representative chromatogram of a wild type PAH 
assay sample with the peak-pairs at 11.0 min representing Phe (294 →  206) and IS-Phe 
(299→ 211) and at 12.6 min assigned to Tyr (396 →  308) and IS-Tyr (400 →  312). The 
peaks at 9.0 and 12.2 min correspond to d3-methionine and homophenylalanine and are the 
internal standards included in the Phenomenex EZ:faastTM kit. 
Table 3.2: Imprecision data of Phe and Tyr quantification determined with wild type, 
p.R261Q and p.R158Q PAH samples. The intra- and inter-assays were performed with 
individual cell lysates (n = 6). All PAH activities are normalized by co-transfection with 
pSV-ßgal. 
 
PAH activity assay 
The linearity of the PAH enzyme assay was investigated using transfected COS-1 cells 
with human wild type PAH. The reaction time was optimized to 15 min. As demonstrated in 
Figure 3.2B, Tyr production increased linearly with the amount of protein. However, the 
(A) 
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linear range of assay is rather small (< 250 µmol/L) and PAH activity decreases with 
increasing Tyr production, due to reagent availability in the reaction mixture and possible 
product inhibition. 
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Figure 3.2: (A) Mass spectrum of wild type PAH expressed in COS-1 cells, prepared with 
EZ:faast kit and measured by LC ESI-MSMS. Preparation by the kit includes 3 additional 
internal standards to correct for sample preparation variability. These are d3-methionine, 
homophenylalanine and homoarginine (not shown in the spectrum above); (B) Linearity of Tyr 
production from PAH wild type expressed in COS-1 cells transfected with increasing amounts 
of plasmid. 
All mutants produced lower amounts of Tyr at similar reaction times, compared with the 
wild type enzyme. Stability of PAH during the reaction is critical and short reaction time 
should be used at low protein concentrations (< 30 µg for the wild type PAH and < 165 µg 
for low-activity mutants). The mean wild type PAH activity in COS-1 cells was 43.9 ± 14.5 
mU/mg protein under standard reaction conditions (15 min reaction time and 5 µl cell lysate). 
(B) 
 
(A) 
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PAH intra-assay variation determined in triplicate was 7.3%, 6.4%, and 7.5% for the wild 
type, p.R261Q and p.I65T in COS-1 cells, respectively. Comparative analyses of activity for 
wild type PAH activity in transfected COS-1 cells using a HPLC-based assay with 
fluorimetric detection [27] provided similar values of activity for wild type (38 ± 2 mU/mg) 
and p.R261Q mutant (16 ± 1 mU/mg). However, this HPLC based analysis requires > 30 µg 
of protein in each assay, i.e. 1.5–6 fold higher than in the LC-ESI-MSMS assay at the 
selected conditions. 
PAH mutations found in PKU patients 
In order to further evaluate the LC-ESI-MSMS method, we determined PAH activity of 
several known PAH mutations, in addition to p.R261Q and p.R158Q used in the method 
characterization and development (see above). Figure 3.3A shows the percent of PAH mutant 
activities compared to the wild type activity for the p.I65T (33%), p.R261Q (43%), p.R158Q 
(5%), p.R408W (2%) and p.E390G (54%) proteins. 
These mutations have previously been tested in different in vitro systems, but we also 
analyzed two novel PAH mutations p.E280A and p.Y417C, recently reported in Turkish 
PKU patients [28] (Figure 3.3A). While a severe p.E280A mutation exhibits only 15% of the 
wild type PAH activity, a mild p.Y417C mutation was almost as active as the wild type 
enzyme (76%). All mutant PAH activities were normalized for β -galactosidase, which was 
co-transfected into COS-1 cells. Figure 3.3B illustrates the different PAH mutant proteins by 
Western blot analysis.  
All of the PAH mutant proteins with rather low activity also present with reduced 
amounts of PAH protein, when compared to the wild type (Figure 3.3C). The only exception 
is p.R158Q with a very low activity and substantial amount of protein. PAH expression was 
normalized for β-actin expression in these COS-1 cells and quantified by densitometry. 
PAH activity in mouse tissue 
The quantification of PAH activity with the novel LC–ESI-MSMS method is not only 
restricted to cell extracts, but can also be used for animal tissues. For this purpose, we 
measured PAH activity in liver, kidney, and brain tissue from wild type (C57Bl/6) or PKU 
mice (C57Bl/6-Pahenu2). Figure 3.4A shows PAH activity in liver, kidney and brain extracts 
from the wild type and PKU mice. As expected, the highest activity was found in liver of the 
wild type mouse. A relatively high PAH activity (33% of the liver) was found in the kidney, 
whereas in tissues from the PKU mice no PAH activity was detectable. No PAH activity was 
observed in brain extracts from the wild type and PKU animals. 
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Figure 3.3: (A) PAH activities of various common PAH mutant proteins expressed in COS-1 
cells and quantified by LC-ESI-MSMS. Activities are displayed as % wt activity. All PAH 
activities are normalized with β -galactosidase activity for correction of transfection efficiency. 
(B) Western blot analysis of wild type PAH and mutations tested for PAH activity. The same 
amount of total protein (25 µg) was analyzed per lane. (C) PAH expression in all samples was 
normalized with β -actin expression and expressed as % wild type PAH expression. Non-
transfected COS-1 cells do not show PAH protein. 
The Western blot analysis shows high amounts of PAH protein in the wild type mice 
extracts from liver and kidney, while in the same organs of the PKU mice bands of the PAH 
protein were detected despite no activity (Figure 3.4B). These results correlate well with the 
enzyme activity measurements for the wild type mouse (Figure 3.4A).  
 
Figure 3.4: (A) Comparison of absolute PAH activity in mouse tissues of wild type (C57Bl/6) 
and PKU (C57Bl/6-Pahenu2) mice (n = 3). Standard deviation results for PKU liver and brain are 
not displayed due to very small values. (B) Western blot analysis of PAH expression in liver (L), 
kidney (K) and brain (B) tissue from wild type and PKU mice. As shown by β -actin loading 
control, increased protein amounts of brain tissue were loaded.  
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The PAH expression seems to appear as two signals in Western blot analysis. This double 
band of PAH has previously been observed for PAH in tissues and when expressed in 
eukaryote systems, and was found to be the result of an apparent electrophoretic shift of the 
Ser-16 phosphorylated enzyme [4]. 
PAH activity in different cell lines 
For in vitro PAH expression studies, liver, or kidney mammalian cells (organs with 
highest PAH activity) exhibit the most similar physiological environment. However, these 
cell lines might exhibit endogenous PAH activity that interfere with activity from transfected 
PAH. Therefore, we investigated PAH expression and PAH activity in several common 
hepatic cell lines (e.g. HepG2, Hep3B and HuH-7) (Figure 3.5A). No PAH activity or protein 
was detected in HepG2 cells, and only low endogenous activity was found in Hep3B and 
HuH-7 cells (Figures 3.5A and B).  
 
 
Figure 3.5: (A) PAH activity in various cell lines, eventually for use as cell host in in vitro 
studies or previously analyzed in PAH metabolism. (B) Western blot analysis of protein lysates 
from various cell lines transfected with wild type PAH probed for PAH expression. 20µg of total 
protein analyzed (5 µg of COS-1 wild type due to high expression), NT = non-transfected 
Using the labeled Phe-d8 isotope in the PAH assay, which is consequently oxidized to 
Tyr-d7, we were able to distinguish the assay product Tyr-d7 from Tyr from the cell extracts. 
We found that PAH activities using Phe-d8 are lower than using non-labeled Phe (32.5 
mU/mg versus 43.7 mU/mg protein) due to a possible isotope effect, but high enough to 
discriminate between different PAH mutants. The same reduction accounts for the p.R261Q 
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mutant, but the activity of this mutant is consistently measured to be 40% of wild type PAH 
activity both with Phe or Phe-d8 as substrates. 
Figure 3.5B shows wild type PAH protein expression in Hep3B, HuH-7, and COS-1 cells, 
compared to non-transfected cells. No wild type PAH protein could be detected from non-
transfected Hep3B, HuH-7, and COS-1 cell lines with 20 µg of total protein analyzed. 
Furthermore, no PAH activity or protein was detected in EBV-transformed lymphocytes, 
even though PAH transcript can be amplified from their RNA [29]. Also, no PAH activity 
and transcript could be detected in the HaCaT cell line (human adult low calcium high 
temperature keratinocytes).  
Discussion 
Molecular mechanisms of PKU and other hyperphenylalaninemias were established over 
several decades through investigations of mutations within the PAH gene [30]. Based on 
genotype findings and description of BH4-responsive forms of PKU [31], functional assays of 
mutation effects in vitro have proven to be very fruitful for the characterization of PAH 
mutations, building a bridge between patient and pure protein. Although, these data sets tend 
to overestimate PAH activities in vivo. Residual in vitro PAH activity was shown to correlate 
with the patient's phenotype [32]. Thus, knowing patient's residual PAH activity can be 
relevant for selecting therapeutic options, the likely Phe tolerance, and the expected response 
to BH4 [28]. 
In this study, we have developed a new method for the quantification of the amino acids 
Phe and Tyr by LC-ESI-MSMS, as a basis for the measurement of PAH activity. The 
EZ:faastTM sample preparation (amino acid extraction, washing and derivatization steps are 
included in the procedure) was originally developed for the rapid processing and measuring 
of biological fluids in clinical analyses. We optimized this procedure to the quantitative 
determination of PAH activity in an in vitro expression system and in various mouse tissues. 
Using the EZ:faastTM kit, sample preparation is fast and time consuming steps, such as 
protein precipitation, removal of interfering substances (e.g. salts and other buffer 
components), or elaborating derivatization procedures, can be omitted. Furthermore, since 
our mass spectrometric analysis technique enables the application of isotopically labeled 
internal standards (Phe-d5 and Phe-d8, Tyr-d4), our method is highly specific and reliable. It is 
suitable for the quantification of Phe and Tyr even in very complex biological matrices. Its 
fast and simple sample preparation procedure allows for the analysis of a big sample series in 
a short amount of time. 
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The calibration range of Phe and Tyr is variable and can be selected according to the type 
of in vitro expression system and predicted enzyme activity. Low coefficients of variation in 
intra- and inter-assay confirm that the method can be applied in the nanomolar range. 
The PAH assay method used for the quantification by MS is a discontinuous assay 
commonly used in PAH mutation studies. The time between extraction of total protein from 
cultured cells and enzymatic reaction is critical and should be kept short. Our expression 
system in COS-1 cells shows a high transfection efficiency and protein expression, therefore 
only little amounts of total protein are required for assessing activity. We verified this 
method to determine activities in the linear range and diluted the proteins accordingly. Thus, 
other systems with lower protein expression can be easily quantified by this new method. 
Every PAH mutant was assessed in at least three different transfection systems and 
quantification experiments. The results of each mutant, expressed as percent of wild type 
PAH, are well in accordance with previously published data for the same mutations [33]. The 
slight differences found were due to the fact that previously reported PAH activity 
measurements were performed under different assay conditions and using several substrates 
with different affinities (e.g. BH4, 6-methyl-tetrahydropterin or 6,7-dimethyl-
tetrahydropterin) [3, 12]. In previous reports, in vitro activities for some mutations (e.g. 
p.R261Q) ranged between 24 and 100%, depending on the expression system and assay used 
[34, 35]. 
Two new PKU mutations, p.E280A and p.Y417C, are described in our study, which were 
detected among a larger Turkish patients cohort and were not previously expressed in vitro. 
The activities determined for p.E280A and p.Y417C mutants (15% and 76% of the wild type 
PAH) correlate with the severity of hyperphenylalaninemia in the corresponding patients. 
The quantification of Phe and Tyr is not only limited to cell extracts, but can also be used 
on various mouse tissues. The advantages of using Phenomenex EZ:faastTM kit also apply to 
these complex biological samples, omitting interferences from the mixtures. Thus, the liver is 
not the only site of PAH expression in humans and animals. Up to 40% PAH activity has 
been reported in the kidneys, as compared to the liver in human tissue [36]. In this study, we 
report 33% of kidney PAH activity in wild type mouse tissue in relation to PAH activity in 
liver, in accordance with previous data in rodents [37]. In addition to liver and kidneys, 
significant PAH activity and expression were also reported in pancreas tissue [36, 38]. 
Keratinocytes were suggested as potential target for PKU gene therapy [39] and claimed to 
contain intact PAH metabolism [40], however with our assay no PAH activity or protein was 
detected in these cells. 
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In contrast to the method published by Gersting et al. [20], our method measures PAH 
activity at standardized Phe and BH4 concentrations and may be a good screening method for 
selection of mutations of interest for the kinetic studies at different Phe and BH4 
concentrations [41]. Thus, the main application of this new method will be the quantification 
of the relative in vitro PAH activity in patients with PKU by expressing mutant proteins in 
COS-1 cells. A recent study with a large cohort of Turkish PKU patients suggested that both 
the phenotype and BH4 responsiveness are genotype-dependent and that the residual PAH 
activity is a good predictor for the severity of the disease [28]. Finally, this method can easily 
be extended to other amino acids since labeled compounds are available as internal standards 
for quantification. 
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Abstract 
In about 20 - 30% of phenylketonuria (PKU) patients, phenylalanine (Phe) levels can be 
controlled by cofactor 6R-tetrahydrobiopterin (BH4) administration. The phenylalanine 
hydroxylase (PAH) genotype has predictive value concerning BH4-response and therefore a 
correct assessment of the mutation molecular pathology is important. Mutations that disturb 
the splicing of exons (e.g. interplay between splice site strength and regulatory sequences like 
exon splicing enhancers (ESEs)/exon splicing silencers (ESSs) may cause different severity 
of PKU. In this study, we identified PAH exon 11 as a vulnerable exon and used patient 
derived lymphoblast cell lines and PAH minigenes to study the molecular defect that 
impacted pre-mRNA processing. We showed that the c.1144T>C and c.1066-3C>T 
mutations cause exon 11 skipping, while the c.1139C>T mutation is neutral or slightly 
beneficial. The c.1144T>C mutation resides in a putative splicing enhancer motif and binding 
by splicing factors SF2/ASF, SRp20 and SRp40 is disturbed. Additional mutations in 
potential splicing factor binding sites contributed to elucidate the pathogenesis of mutations 
in PAH exon 11.  
We suggest that PAH exon 11 is vulnerable due to a weak 3’ splice site and that this 
makes exon 11 inclusion dependent on an ESE spanning position c.1144. Importantly, this 
implies that other mutations in exon 11 may affect splicing, since splicing is often determined 
by a fine balance between several positive and negative splicing regulatory elements 
distributed throughout the exon. 
Exonic mutations that disrupt splicing are unlikely to facilitate response to BH4 and may 
lead to inconsistent genotype-phenotype correlations. Therefore, recognizing such mutations 
enhances our ability to predict the BH4-response.  
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 Introduction  
Hyperphenylalaninemia (HPA) is the result of a defect in hydroxylation of phenylalanine 
(Phe) to tyrosine (Tyr) [1]. The reaction is catalyzed by phenylalanine hydroxylase (PAH, EC 
1.14.16.1) requiring the essential cofactor tetrahydrobiopterin (BH4) [2]. In the majority of 
cases hyperphenylalaninemia (HPA) is caused by mutations in the PAH gene, resulting in 
different phenotypes classified according to Phe levels in the blood ranging from mild HPA, 
mild PKU to classic PKU. PKU is a very heterogeneous disease and belongs to the most 
common inherited diseases in amino acid metabolism [3]. As elevated Phe levels cause 
severe brain damage, it is compulsory to start treatment as early as possible. 
Over 500 mutations have been reported in the coding sequence as well as in the 
intervening sequence of the PAH gene (Online database, http://www.pahdb.mcgill.ca/) [4]. 
More than half of these are classified as missense changes. Several PKU mutations have been 
shown to affect protein folding, thereby causing accelerated degradation and/or aggregation 
[5]. The measurement of enzymatic activities in vitro of mutant proteins can generally be 
useful in predicting HPA’s, but it has also been suggested that up to 50% of exonic mutations 
may perturb pre-mRNA splicing, thereby leading to more deleterious effects on protein 
function, irrespective of the predicted amino acid change [6].  
In ~ 30% of PKU patients (all phenotypes), Phe levels may be controlled through BH4 
(sapropterin dihydrochloride [7]) therapy [8]. Only the patient’s full genotype determines 
BH4 responsiveness [9, 10], but genotype-phenotype correlations are not always reliable as 
discordant results have been observed between patients with common genotypes [11]. Exonic 
mutations that disrupt splicing are unlikely to facilitate BH4-response and recognizing such 
mutations enhances our ability to predict BH4 responsiveness. It is therefore important to 
correctly assess the molecular pathology of PAH mutations. 
Cis-acting elements such as exon splicing enhancers (ESE) or exon splicing silencers 
(ESS) participate in exon recognition in a finely balanced interplay with splice site strengths 
and this fine balance can be disturbed through deleterious effects of mutations in these 
elements. When bound to ESEs serine/arginine-rich proteins (SR proteins) promote exon 
definition by directly recruiting the splicing machinery through their RS domain and/or by 
antagonizing the action of nearby silencer elements [12]. 
Relatively few studies have investigated mRNA processing defects owing to exonic 
sequence variation in the PAH gene. The mutation c.611A>G, putatively p.Y204C, was 
investigated for a role in mRNA processing when in vitro assessment of the mutant enzyme 
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did not demonstrate significantly reduced activity and correspond to the phenotype in the 
PKU patients [13]. Analysis of the PAH mRNA in a patient lymphoblast cell line showed 
that the c.611A>G mutation masquerades as a missense mutation, but actually creates a new 
5’ splice site resulting in a 96nt deletion at the 3’ end of PAH exon 6. This study, together, 
with the finding that a synonymous mutation, c.1197A>T, causes exon 11 skipping instead of 
being neutral [14] and our recent study of a c.30C>G synonymous mutation, which creates an 
ESS [15] with unexpected effects on mRNA splicing, show that more detailed analysis of 
PAH pre-mRNA processing may be required to determine a mutation’s molecular pathology 
which ultimately may relate to both the patient’s phenotype and the possibility of BH4-
response. Herein, we established and validated a PAH exon 11 minigene, which allows 
testing the impact of PAH exon 11 missense and splice site mutations on mRNA splicing. 
Both natural mutations and several artificial mutations were investigated to gain insight into 
the splicing mechanism of PAH exon 11. The pathology of the two exonic mutations, 
c.1139C>T and c.1144T>C, was analyzed by transfection of the minigene reporter, by RNA 
affinity purification and results were confirmed by analysis of patient cell lines. 
Materials and Methods 
Patient specimens 
Patient samples analyzed in this work were previously reported among a large cohort of 
Turkish PKU patients [10]. Table 4.1 summarizes the genotypes and phenotypes of the 4 
patients analyzed in this study. Patients 1 and 2 have been identified as BH4-responsive by 
the oral loading test. 
Table 4.1: Summary of genotype and phenotype of PKU patients analyzed in this work. 
 
Generation of patient cell lines and cell culture 
Peripheral blood lymphocytes from PAH deficient patients were transformed with 
Epstein-Barr virus [16] to generate lymphoblast cell lines. Lymphoblast cell lines and Chang 
human liver epithelial cells were cultured in RPMI 1640 (Sigma Aldrich, St. Louis, MO, 
USA) and 5% fetal calf serum. COS-1 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Sigma) with 10% fetal calf serum.  
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To perform nonsense-mediated mRNA decay analysis, lymphoblast cells were cultured 
overnight in presence of 10 µg cycloheximide (Sigma) prior to mRNA extraction. 
Minigene construction 
Initially, a 1946-bp fragment of human PAH including exon 10, intron 10, exon 11, intron 
11 reduced to 988bp and exon 12 was synthesized by GenScript (NJ, USA). A start codon 
was added to exon 10 and a KpnI site was removed from intron 10 to facilitate cloning. In 
addition, intron 11 was extended by inserting at an EcoRI site a PCR amplified 963 bp 
fragment amplified using AccuPrime Pfx SuperMix (Invitrogen). Five unique minigene 
constructs were prepared: WT, c.1139C>T, c.1144T>C, c.1066-3C>T and c.1197A>T. The 
minigenes were cloned into the polylinker of pcDNA3.1+ vector (Invitrogen) by using KpnI 
and XhoI restriction enzymes. The correct insertion was verified by sequencing with BigDye 
Terminator Cycle sequencing v1.1 (Applied Biosystems) on an ABI Prism 3100 Sequencer. 
Other mutations used for the characterization of eventual splicing regulatory elements 
caused by the mutations of interest were either introduced by site-directed mutagenesis with 
QuikChange XL II kit (Agilent Technologies, CA, USA) or ordered from GenScript. These 
nucleotide changes include: c.1139C>A, c.1139C>G, c.1144T>A, c.1144T>G, c.1169A>G, 
c.1146C>A, c.1144C+1146A, c.1139T+1144C, c.1144_1146delTTC and the insertion of a 
known wild type and mutant ESE sequence from the ACADM gene [17].   
Transient transfection experiments  
Transient transfection experiments were conducted with Fugene 6 Transfection reagent 
(Roche Applied Biosciences) as described [17]. Chang or COS-1 cells were seeded at 2x105 
(resp. 3x105) cells per 35 mm well and transfected with 0.8 µg of minigene construct DNA. 
Co-transfections with the vectors for SF2/ASF, SRp40 (generous gifts from Adrian Krainer, 
Cold Spring Harbor, NY), hnRNPH (generous gift from Mark McNally, University of 
Wisconsin) and hnRNPA1 (generous gift from Benoit Chabot, University of Sherbrooke, 
Canada) were performed as described [17]. After 48 hours, cells were harvested in 300 µl 
RLT buffer and either stored at -80°C for later processing or RNA extraction was continued 
according to the manufacturer’s protocol of Qiagen RNA blood mini kit.  
Analysis of RNA processing 
Analyses of illegitimate PAH transcripts from patient lymphoblasts were performed 
according to previously described methods [18]. After harvesting, total RNA was extracted 
from patient lymphoblast cell lines using Qiagen RNA blood mini kit. One microgram of 
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isolated RNA was reverse-transcribed with iScriptTM cDNA Synthesis kit (BioRad, CA, 
USA) containing a mix of Oligo (dT) and random hexamer primers. The cDNA from patient 
lymphoblasts covering exons 9 - 13 was PCR-amplified using primers PAHX9fwd (5’-
TGGCCTTGCCTCTCTGGGTGC-3’) and PAHDrev (5’-GACCACATTCTGTCCATGGCT 
TTA-3’).  
Amplification of PAH from the minigenes was performed with a minigene-specific 
primer pair to exclude detection of endogenous PAH: forward primer 11s2 (5’-
GGTAACGGAGCCAACATGGTTTTACTG-3’) and reverse 11as (5’-AGACTCGAGG 
GTAGTCTATTATCTGTT-3’). The amplification products were analyzed by 1% agarose 
gel electrophoresis. PCR products were gel extracted, purified, and sequenced using the 
BigDye Terminator Cycle sequencing v1.1 (Applied Biosystems) on an ABI Prism 3130xL 
Sequencer. 
RNA oligonucleotide affinity purification 
The affinity purification of RNA binding proteins utilized 3’-biotin-labeled RNA 
oligonucleotides as described, (DNA Technology Denmark) [15]. For each purification 100 
pmol of RNA oligonucleotide was coupled to 100µl of streptavidin-coupled magnetic beads 
(Invitrogen) and incubated with HeLa nuclear extract (Cilbiotech S.A., Belgium) [17]. After 
washing, bound proteins were investigated by western blotting using a monoclonal mouse 
antibody SF2/ASF (AK96 from Zymed Laboratories (Invitrogen)), SRp40, SRp20, hnRNPH 
or hnRNPA1 (sc-33418, sc-13510, sc-10042 and sc-10029, Santa Cruz Biotechnology, Santa 
Cruz, CA).  
Expression of PAH proteins and activity assay 
PAH activities were determined using a novel mass spectrometry method for 
quantification of Phe and Tyr in cell lysates [19]. Mutations in the human PAH cDNA 
sequence in pCMV-FLAG-PAH were introduced by site-directed mutagenesis using 
QuikChange XL kit from Agilent Technologies (Santa Clara, CA, USA) and confirmed by 
DNA sequence analysis. Expression plasmids were transfected into COS-1 cells using 
Fugene 6 (Roche Applied Biosciences) and harvested after 48h.  
Cell lysates were prepared and enzyme activity determined using previously described 
methods. The amount of Tyr produced was determined by LC ESI-MSMS. 
Protein concentrations of all sample types were determined using Pyrogallol Red protein 
dye binding assay [20]. Specific PAH activities are expressed in mU/mg total protein, with 
mU equal to nmol Tyr produced per min. 
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Results 
PAH exon 11 is flanked by a weak 3’ splice site 
We initially assessed the strength of all splice sites in the PAH gene to identify exons that 
are weakly defined and thus vulnerable to mutations affecting splicing regulatory  
elements [12]. Table 4.2A displays all splice sites of the 13 exons of the PAH gene and the 
calculated strengths using the maximum entropy (MaxEntScan 
http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) which showed exon 11 is 
vulnerable with a weak 3’ splice site.  
Table 4.2A: PAH Splice Site Strength 
 
The c.1066-3C>T mutation, which is located in the 3’ splice site has previously been 
demonstrated to result in exon 11 skipping [18], although this change only modestly weakens 
the score (3.16 to 2.11, Table 4.2B) and the mutant splice site retains within the splice site 
consensus. Moreover, c.1197A>T, an exonic mutation that only decreases the MaxEnt score 
of the 5’ splice site from 9.16 to 7.65 has also been reported to cause exon 11 skipping [14].  
Table 4.2B: Maximum entropy score variation for 3’splice site of PAH exon 11 upon 
c.1066-3C>T mutation 
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Together these data indicated that exon 11 is weakly defined and is likely to be dependent 
on exonic splicing enhancer sequences. We therefore hypothesized that mutations in exon 11 
might disrupt the fine balance between exonic splicing enhancers (ESE) and exonic splicing 
silencers (ESS) and thus result in exon 11 skipping. We decided to investigate some of the 
missense mutations reported to be BH4 responsive.    
Aberrant PAH splicing in patient lymphoblast cell lines 
PAH pre-mRNA processing was investigated using patient derived lymphoblast cell lines. 
RT-PCR was used to amplify a fragment from PAH exon 9 to the end of the coding region. In 
patients 1, 2 and 3 the expected 463 bp fragment was observed along with a 329 bp fragment 
(Figure 4.1A). This alternative product is most pronounced in patient 1 who is homozygous 
for the c.1066-3C>T mutation. DNA sequence analysis of the purified 329 bp band showed 
that exon 11 was missing. This analysis indicates that the c.1066-3C>T and c.1144T>C 
mutant alleles cause exon 11 skipping in patient cells. 
Skipping of exon 11 results in deletion of 134 bp from the PAH mRNA leading to a 
shifted reading frame and replacement of the 97 C-terminal codons with 21 missense codons 
followed by three in frame premature stop codons in exon 12, which is the penultimate exon 
of the PAH gene. The first premature stop codon in exon 11 skipped PAH mRNA is located 
53 nucleotides upstream of the last exon-exon junction. This corresponds to the required 
minimal distance (50-55 nt) upstream of the last exon, which typically triggers degradation of 
the premature stop codon containing mRNA by the Nonsense Mediated Decay (NMD) 
system [21]. There are, however, examples where NMD is triggered by premature stop 
codons located even closer to the last exon-exon junction [21]. To determine whether NMD 
is degrading the aberrantly spliced PAH mRNA, we treated patient cells overnight with 
cycloheximide (CHX), to block NMD. Assessment of PAH mRNA following CHX treatment 
showed a dramatic increase in the 329 bp cDNA product lacking exon 11 which 
demonstrates that the aberrantly spliced PAH mRNA is degraded by NMD (Figure 4.1B). 
The presence of the full length product confirms that the c.1139C>T mutant allele does not 
lead to exon 11 skipping. 
The minor DNA species migrating close to the wild type transcript is a heteroduplex 
formed between cDNA strands of the wild type and exon 11 deleted mutant. This was 
confirmed by sequencing.  
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Figure 4.1: PAH pre-mRNA splicing analysis in patient lymphoblast cells. Cells from control 
and patients were analyzed with and without blockage of NMD by CHX treatment. Genotypes: 
Patient 1: c.1066-3C>T/c.1066-3C>T, Patient 2: c.1066-3C>T/c.1208C>T, Patient 3: 
c.1144T>C/c.1144T>C, Patient 4: c.1139C>T/c.898G>T. (A) Comparison of PAH mRNA 
transcript from lymphoblast patient cells by amplification of exons 9 - 13. (B) Comparison of 
PAH transcript from lymphoblast patient cells treated with 10 µg cycloheximide (CHX). The 
cells were passaged the day before harvesting and supplemented with CHX.  
Minigene analysis confirms results from patients’ lymphoblasts 
To further elucidate the molecular mechanism of aberrant PAH exon 11 splicing and to 
enable testing of exon 11 mutations where cell lines are not available, a PAH minigene was 
constructed. The minigene harbors exons 10, 11 and 12, with intron 10 and a shortened intron 
11 (Figure 4.2A). We tested the exon 11 mutations c.1066-3C>T, c.1139C>T, c.1144T>C, in 
addition to c.1197A>T that was previously reported to cause exon 11 skipping [22, 14] and 
c.1169A>G which is a prevalent BH4 responsive allele in the Turkish population [10]. 
Analysis of COS-1 cells transfected with the minigenes shows that the mutations c.1197A>T, 
c.1144T>C and c.1066-3C>T lead to exon 11 skipping, whereas the c.1169A>G mutation is 
neutral and the c.1139C>T mutation seems to have a slightly positive effect on exon 11 
inclusion (Figure 4.2B). These results are consistent with our analysis of the patient cells and 
underlines that the splicing of PAH transcripts from our minigene mimics that of the 
endogenous PAH gene. In addition, the minigene analysis confirms that the c.1197A>T, 
c.1144T>C and c.1066-3C>T mutations compromise splicing and that the observed 
missplicing in patient cells does not result from a linked mutation located outside the 
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sequenced region of the gene or from the other mutant allele present in the compound 
heterozygous patients. The minigene analysis also indicates that splicing of wild type PAH 
exon 11 results in small amounts of exon 11 skipping, consistent with the fact that it is 
weakly defined and dependent on ESE’s [12]. 
As PAH is primarily expressed in the liver, we also transfected Chang cells with PAH 
minigene constructs. A higher degree of missplicing of the c.1144T>C minigene (Figure 
4.2C) was observed, but the degree of missplicing was inconsistent between separate 
transfection experiments. As such, COS-1 cells were used in subsequent experiments. The 
results from Chang cells indicated that the c.1144T>C mutation may result in different 
degrees of missplicing varying from complete skipping to the same degree of skipping as 
observed in the COS-1 cells.  
 
Figure 4.2: PAH pre-mRNA splicing in COS-1 and Chang cells transfected with PAH 
minigenes. (A) Schematic description of the PAH minigene harboring exons 10 to 12. Start and 
stop codons were added to complete the reading frame. (B) Analysis of COS-1 cells transfected 
with minigenes harboring WT, c.1139C>T, c.1144T>C, c.1066-3C>T, c.1169A>G and 
c.1197A>T mutations. (C) Analysis of two different transfections in Chang liver cells with 
minigenes harboring WT, c.1139C>T, c.1144T>C and c.1066-3C>T mutations. (D) Analysis of 
COS-1 cells transfected with minigenes harboring WT, c.1144T>C and c.1066-3C>T mutations 
with and without an optimized 3’ splice site. Amplification of PAH exons 10 – 12 was done with 
minigene-specific primers. Transfection experiments were performed as at least two 
independent transfections.  
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This also illustrates that the degree of missplicing may vary dependent on the cell type. 
Heteroduplex formation of wild type and exon 11 deleted mutant cDNAs was confirmed by 
sequencing in both cell lines. 
Correction of the 3’ splice site of exon 11 by mutagenesis 
To investigate the contribution of the weak 3’ splice site to exon skipping in PAH exon 
11, the 3’ splice site was optimized. The four guanosine nucleotides (c.1066-8 to c.1066-11) 
that interrupt the polypyrimidine tract were replaced with thymidines. This substitution 
increased the maximum entropy score from a weak 3.16 to a robust 9.58. In the wild type 
minigene construct, improved exon 11 inclusion was observed (Figure 4.2D). Moreover, 
when the optimized polypyrimidine tract is included in the c.1066-3C>T and c.1144T>C 
constructs, aberrant splicing is no longer observed. At position -3 upstream of the 3’ splice 
site, a thymidine base is considered to match the consensus motif. PAH exon 11 skipping 
owing to the c.1066-3C>T mutation is an indication to the weakness of the splice site owing 
to guanosine bases at -8 to -11. Amelioration of missplicing owing to c.1144T>C with the 
corrected polypyrimidine tract suggests that the c.1144T>C mutation disrupts the function of 
an ESE, which is required for recognition of the weak 3’ splice site.  
The c.1144T>C mutation disrupts an ESE, which is required for inclusion of PAH 
exon 11. 
The c.1144T>C mutation causes exon 11 skipping. To elucidate whether the mechanism 
underlying pre-mRNA missplicing is owing to disruption of an ESE or creation of an ESS in 
the minigene constructs, various proportions of the sequence surrounding position c.1144 
were deleted (Figure 4.3A). Minigenes with a 9 bp deletion (c.1141 to c.1149) showed 
complete exon 11 skipping, whereas the 6 bp deletion (c.1144 to c.1149) has a slightly less 
dramatic effect, and the 3 bp deletion (c.1144 to 1146) has a minor deleterious effect on exon 
11 inclusion (Figure 4.3B). This shows that an ESE element is located in this region of exon 
11, but it may also suggest that this ESE is complex and may bind more than one splicing 
factor, since 6 bp and 9 bp had to be deleted in order to completely abolish splicing. 
Alternatively, the 3 bp deletion recreates an ESE sequence (see below). To further 
characterize this putative ESE, we analyzed the wild type and mutant sequences with the 
Human Splicing Finder (HSF) program (http://www.umd.be/HSF/HSF.html) and made site-
specific mutations in the region. The HSF program suggested that the c.1144T>C mutation 
disrupts a TTCCAG(C) ESE, which could be a binding site for the splicing stimulatory factor 
SRp40 (SRSF5).  Moreover, the HSF program also suggested that a TTCCAG motif, which is 
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a putative ESE [23] is disrupted both by the c.1144T>C mutation and the c.1146C>A 
mutation, but that the c.1144T>C/c.1146C>A double mutation creates a new ESE AGCTAC. 
These predictions were consistent with our minigene analysis (Figure 4.3B) and suggest that 
the TTCCAG sequence functions as an ESE, perhaps by binding of SRp40 (SRSF5) and/or 
other factors. The HSF analysis also suggested that although the 3 bp deletion removes part 
of this TTCCAG motif it also recreates several potential ESE sequences, explaining the lack 
of a dramatic effect from this mutation. Consistent with our transfection results HSF analysis 
suggested a deleterious impact of both the 6 bp and the 9 bp deletions.  
 
Figure 4.3: PAH pre-mRNA splicing in COS-1 cells transfected with PAH minigenes. (A) 
Sequences showing the precise location of the deletions and the inserted MCAD ESE. (B) 
Analysis of COS-1 cells transfected with minigenes harboring WT, 3 bp, 6 bp and 9 bp deletions 
and analysis of COS-1 cells transfected with minigenes harboring WT, c.1144T>C, c.1146C>A 
and c.1144T>C + c.1146C>A mutations. (C) Analysis of COS-1 cells transfected with minigenes 
harboring WT and all possible nucleotide variations at positions c.1139 and c.1144. (D) Analysis 
of COS-1 cells transfected with minigenes harboring WT, c.1139C>T, c.1144T>C, c.1139C>T+ 
c.1144T>C mutations and analysis of COS-1 cells transfected with minigenes harboring WT 
and substitutions with wild type and mutant MCAD ESE sequences. Amplification of PAH 
exons 10 – 12 was done with minigene-specific primers. Transfection experiments were 
performed as at least two independent transfections. 
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Moreover we also mutated position c.1139 and c.1144 to all possible substitutions and 
also created a double mutation. Interestingly, this showed that c.1139C>G and c.1144T>G 
both cause skipping and that introduction of the c.1139C>T mutation together with the 
c.1144T>C mutation compensates for the splicing defect (Figure 4.3 C, D). These data were 
not consistent with the HSF analysis predictions and may contradict that the ESE functions 
by binding of SRp40 and they suggest that the c.1139C>T mutation has a positive effect on 
splicing. Finally, we substituted the PAH ESE region with a functional ESE from the 
ACADM gene [17], which has been demonstrated to function in several other genes [17, 23]. 
Surprisingly, the wild type MCAD ESE could only partly substitute the PAH ESE sequence. 
As expected the mutated MCAD ESE was also non-functional in the PAH context (Figure 4.3 
A, D). Taken together our data are consistent with a model where the c.1144T>C mutation 
causes exon 11 skipping by disrupting the function of an ESE, which is required for 
recognition of the weak 3’ splice site.  
Analysis of the PAH exon 11 ESE by RNA affinity purification  
 To identify proteins that bind the PAH exon 11 ESE, RNA affinity purification was 
performed. RNA oligonucleotides containing c.1139C>T and c.1144T>C mutant sequences 
were incubated in HeLa cell nuclear extracts (Figure 4.4). Western blot analysis showed 
strong binding of SF2/ASF (SRSF1) to the WT sequence, which was abolished by both the 
c.1139C>T and c.1144T>C mutant sequences. While factor binding was less robust for 
SRp20 (SRSF3) and SRp40 (SRSF5) the same pattern was observed. No difference was 
observed for binding of hnRNPA1. This may indicate that c.1144T>C causes exon 11 
skipping by disrupting binding of an SR protein to an ESE motif that includes c.1144. 
However, it is not clear, if all three SR proteins bind an identical sequence motif or if they 
bind overlapping motifs, which are all disrupted by the c.1144T>C mutation. Alternatively 
one SR protein may bind the RNA while the others are associated via protein-protein 
interaction through their RS-domains. Moreover, it is unclear why binding of SR proteins is 
disrupted by c.1139C>T, as this mutation is shown to improve splicing in our minigene 
studies (see Figures 4.2 and 4.3). This could, however, be due to steric hindrance by binding 
of another protein to the new ESE created by the c.1139C>T mutation.  
In support for this notion, we observed increased binding of hnRNPH to the c.1139C>T 
sequence and this would block binding of the SR proteins to the flanking ESE harboring 
position c.1144. The hnRNPH protein is, however, typically a negative regulator of splicing 
[15]. Further analysis is required in order to identify conclusively the involved splicing 
regulatory proteins that bind the exon 11 ESE.  
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Figure 4.4: RNA oligonucleotide affinity purification. RNA oligonucleotide affinity 
purification of HeLa nuclear extracts using oligonucleotides with WT, c.1139C>T and 
c.1144T>C sequences followed by Western blot analysis. 
Co-transfection with splicing factors leads to change in splicing pattern 
Because the RNA affinity studies had suggested a possible role for SF2/ASF (SRSF1) and 
SRp40 (SRSF5) in binding to the ESE, we performed co-transfection of the PAH minigenes 
with expression plasmids for SF2/AF (SRSF1) or SRp40 (SRSF5) human proteins to see if 
the mutant ESE could be compensated by increasing the amounts of these SR proteins. 
However, instead of correcting splicing, overexpression of SF2/ASF (SRSF1) resulted in 
strong activation of a previously unknown pseudoexon (exon 11a) comprising 287bp of 
intron 11 and severely reduced inclusion of exon 11 (Figure 5A, B and supplementary figures 
S1, S2). The c.1139C>T mutant minigene had slightly less pseudoexon inclusion, consistent 
with the fact that this mutation results in improved splicing, possibly because it creates a new 
ESE, which results in stronger definition of exon 11. In line with this, pseudoexon inclusion 
in response to SF2/ASF (SRSF1) overexpression was nearly abolished when the weak 3’ 
splice site is improved, showing that this pseudoexon activation is only possible because 
exon 11 is weakly defined (Figure 5C).   
Similar results as above were obtained from co-transfecting the different minigenes with 
SRp40 (SRSF5) (Supplementary Figure S1). Co-transfection of hnRNPA1 and hnRNPH, two 
negative regulators of splicing, did not result in changes in splicing pattern or splicing 
efficiencies (data not shown). When patient cells are treated with cycloheximide, the new 
exon 11a can be amplified from patient’s cDNA using an exon 11a specific primer 
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(Unpublished). This shows that the pseudoexon inclusion is not merely an artifact produced 
only from the minigenes, but that some level of pseudoexon inclusion is possible from the 
endogenous PAH gene, although the relevance of this is unclear. The pseudoexon could have 
deleterious effects if it is activated by mutations or by improved splicing conditions.  
 
Figure 4.5: SF2/ASF overexpression in COS-1 cells transfected with PAH minigenes leads to 
pseudoexon activation. (A) Schematic overview of PAH splicing showing inclusion of a 
pseudoexon sequence from intron 11. (B) Analysis of COS-1 cells transfected with minigenes 
harboring WT,  c.1139C>T, c.1144T>C, c.1066-3C>T and c.1169A>G mutations with and 
without co-transfection of a vector overexpressing SF2/ASF. (C) Analysis of COS-1 cells 
transfected with minigenes harboring WT, c.1144T>C and c.1066-3C>T mutations with and 
without and optimized 3’ splice site and co-transfection of a vector overexpressing SF2/ASF. 
Amplification of PAH exons 10 – 12 was done with minigene-specific primers. Transfection 
experiments were performed as at least two independent transfections.  
Enzyme activities of c.1139C>T and c.1144T>C are reduced compared to wild type 
PAH 
The expression of c.1139C>T (p.T380M) and c.1144T>C (p.F382L) mutant proteins 
showed reduced activities compared to wild type PAH protein (Supplementary Figure S3). 
Residual activity for mutant p.T380M was found to be 38% of wild type activity, whereas 
p.F382L activity was lower with 18%. Patients with these mutations exhibit a mild 
phenotype, which is in accordance with residual PAH activity of 25%. The p.F382L mutant 
has previously been expressed in a eukaryotic expression system with a residual activity of 
56%. But in this case, the amino acid change was caused by c.1146G [24].  
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Discussion 
Correlation between genotype and disease phenotype is fundamental to inform about 
treatment in inherited diseases. The utility of PAH genotyping is increasingly relevant as 
efficient newborn screening is a facilitator of patients having their first clinic visit often 
within the first week of life. As Phe levels in early identified patients will not have reached 
peak concentrations, discerning disease phenotype often relies on the PAH genotype. The 
PAH genotype may also inform on the utility of BH4 therapy. Furthermore in vitro 
biochemical characterization of missense mutations may provide clues as to efficacy of BH4. 
However, in recent years it has become increasingly clear that a so called “splicing code” is 
also in operation and mutations in the coding sequence may affect pre-mRNA processing and 
thus overrule what can be predicted based on assumed amino acid substitutions. The splicing 
code is poorly defined, but it is clear that not all exons are equally subject to aberrant splicing 
by mutations affecting cis-acting splicing regulatory elements. So-called “weak exons” may 
often be on the verge of not being recognized, whereas other well-defined exons are easily 
recognized by the splicing machinery. Since the primary determinants for exon definition is 
the strength of their flanking splice sites, we first evaluated the splice sites of all exons of the 
PAH gene. From this analysis exon 11 clearly stood out by having the weakest 3’ splice site 
of all exons of the PAH gene, and we therefore hypothesized that exon 11 could be a 
vulnerable exon to aberrant mRNA processing. This is further corroborated by the fact that 
mutations that only very modestly affected splice site strength had been reported to cause 
aberrant splicing of exon 11 [13,17]. Consequently, we investigated in more detail how 
exonic mutations may affect PAH exon 11 splicing.  
Analysis of patient cells showed that both c.1066-3C>T and a missense mutation, 
c.1144T>C cause exon 11 skipping. This corroborates our hypothesis that exon 11 is 
vulnerable and exemplifies that simple comparison of splice site strength may help to identify 
vulnerable exons. Moreover, we demonstrate that NMD may lead to an underestimation of 
the degree of exon 11 skipping when analyzing patient derived cell lines. Similar analyses of 
patient cells may therefore easily overlook exon 11 skipping if NMD is not blocked prior to 
analysis. In order to enable investigation of patient mutations without the need of obtaining 
cells and to enable analysis of exon 11 splicing in more detail we established a minigene, 
which closely mimics the endogenous PAH gene. Minigenes confirmed that the c.1144T>C 
mutation affects splicing; moreover our testing of other artificial mutations (like c.1139C>G, 
c.1144T>G and c.1146C>A) shows that other exonic variants lead to exon 11 skipping. 
Minigene assessment demonstrated that the patient mutations c.1139C>T and c.1169A>G do 
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not affect splicing. Our mutagenesis of the minigene showed very clearly, that it is the weak 
3’ splice site that is responsible for the vulnerability of exon 11, since increasing the splice 
site strength by optimization of the polypyrimidine tract neutralized the effect of all the 
splicing mutations. 
The c.1066-3C>T mutation has been first reported by Abadie et al. [18] The PAH 
amplification by RT-PCR from lymphoblast cells of their patient revealed two different 
transcripts, corresponding to normal spliced PAH and exon 11 skipped PAH transcripts. 
However, the patient was compound heterozygous for p.R261Q/c.1066-3C>T and the normal 
PAH transcript may exclusively result from p.R261Q allele. A BH4-responsive, homozygous 
c.1066-3C>T patient has been reported by Desviat et al. [26]. We were not able to detect 
normal spliced PAH transcript in our homozygous patient for c.1066-3C>T. In addition, our 
patient was not responding to BH4 in an 8 h test. To our knowledge, PAH gene transcript 
amplification from a homozygous patient was not reported before. Lymphoblasts are not the 
primary tissue for PAH protein expression, but we speculate that very small amounts of 
normal spliced PAH transcript could be present in liver. Faint bands observed in our 
transfected COS-1 and Chang cells indicate that low amounts of normally spliced PAH can 
be produced from the c.1066-3C>T. Even low amounts of PAH transcript would be stabilized 
by BH4 and result in lowered Phe levels upon BH4 treatment. 
Because testing mutations using minigenes and/or patient cells is cumbersome there is a 
growing need for computer-based predictions of possible deleterious effects on splicing. The 
Human Splicing Finder program simultaneously analyzes wild type and mutant sequences for 
changes in splicing regulatory sequences and theoretical binding motifs for splicing factors. 
Although, such programs may provide useful hints to potential regulatory sequence motifs, 
which are changed by a mutation, the present study demonstrates that predictions cannot be 
used uncritically and that the different algorithms may produce contradictory predictions. In 
the present study the c.1139C>T mutation is predicted to be deleterious, but instead it seems 
to improve splicing, which demonstrates why functional testing is still warranted. 
Alternatively, HSF predictions concerning the c.1144T>C mutation and in particular 
identifying TTCCAG (c.1144-c.1148) as an ESE may be correct. The importance of this 
sequence is further demonstrated by the fact that it is conserved in species ranging from 
elephants to mice (Figure 4.6). Moreover, comparison with our database of other exonic 
splicing mutations (unpublished observation) showed that a G>T SNP in exon 4 of the 
CYP2B6 gene (rs3745274) [27], which causes aberrant splicing, disrupts the same motif at a 
different position (TTCCAG), and is also predicted to be deleterious by HSF. 
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Figure 4.6: Alignment of PAH exon 11 sequences from different species. Alignment of 
sequences from different species shows that the TTCCAG (c.1144 - c.1148) sequence is 
conserved in different species and that mutation (underlined G) in this element causes aberrant 
splicing in the human CYP2B6 gene. 
 This indicates that cis-acting motifs are general and may be functional in other genes. On 
the other hand, the well-characterized ESE from the ACADM gene [17, 24] has been 
demonstrated to function in other genes, failed to replace the endogenous PAH ESE 
sequence. The failure of the ACADM ESE shows that motifs are not completely 
interchangeable, but that there are exon-specific requirements, possibly reflecting the need 
for recruitment of different splicing regulatory proteins. Our preliminary attempts to identify 
the factor(s) that binds to the PAH ESE spanning position c.1144 were not conclusive, 
although they very clearly showed that there were dramatic differences in the binding of 
important splicing regulatory proteins to wild type and mutant PAH sequences. 
We conclude that our study shows that exon 11 of the PAH gene is a vulnerable exon due 
to its weak 3’ splice site and that this makes exon 11 inclusion dependent on an ESE 
spanning position c.1144. Importantly, this implies that also a number of other mutations in 
exon 11 are likely to affect splicing, since splicing is often determined by a fine balance 
between several positive and negative splicing regulatory elements distributed throughout the 
exon. It is therefore important to assess the effect of all mutations in exon 11 on splicing by 
using our established minigene, since such mutations that disrupt splicing are unlikely to 
facilitate response to BH4 and if not recognized their effect on splicing may lead to 
inconsistent genotype-phenotype correlations.  
 
Chapter 4 145 
 
 
145 
Acknowledgments  
This work was supported by grants from The Danish Medical Research Council (FSS 
grants no. 271-07-342 and no.11-107174) to BSA and Swiss National Science Foundation 
grant no. 31003A-119982/2 to NB and National Institutes of Health grant no. R44HD075156 
and no. R44DK069106 to SFD. We thank Prof. D. Nadal from the Children’s Hospital 
Zurich for the help with the establishment of lymphoblast cell lines.   
 
© 2012 ELSEVIER Inc. All rights reserved. 
146 Chapter 4 
 
 
References 
[1] N. Blau, F.J. Van Spronsen, H.L. Levy, Phenylketonuria Lancet 376 (2010) 1417-
1427. 
[2] S. Kaufman, New tetrahydrobiopterin-dependent systems Annu Rev Nutr 13 (1993) 
261-286. 
[3] C.R. Scriver, S. Kaufman, Hyperphenylalaninemia: Phenylalanine hydroxylase 
deficiency, in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, B. 
Vogelstein (Eds.), The Metabolic and Molecular Bases of Inherited Disease, 
McGraw-Hill, New York, 2001, pp. 1667-1724. 
[4] C.R. Scriver, The PAH gene, phenylketonuria, and a paradigm shift Hum Mutat 28 
(2007) 831-845. 
[5] A.L. Pey, F. Stricher, L. Serrano, A. Martinez, Predicted effects of missense 
mutations on native-state stability account for phenotypic outcome in 
phenylketonuria, a paradigm of misfolding diseases Am J Hum Genet 81 (2007) 
1006-1024. 
[6] F. Pagani, F.E. Baralle, Genomic variants in exons and introns: identifying the 
splicing spoilers Nat Rev Genet 5 (2004) 389-396. 
[7] N. Blau, Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin 
deficiency Expert Rev Endocrinol Metab 5 (2010) 483-494. 
[8] A.C. Muntau, W. Röschinger, M. Habich, H. Demmelmair, B. Hoffmann, C.P. 
Sommerhoff, A.A. Roscher, Tetrahydrobiopterin as an alternative treatment for mild 
phenylketonuria N Engl J Med 347 (2002) 2122-2132. 
[9] I. Karacic, D. Meili, V. Sarnavka, C. Heintz, B. Thony, D.P. Ramadza, K. Fumic, D. 
Mardesic, I. Baric, N. Blau, Genotype-predicted tetrahydrobiopterin (BH4)-
responsiveness and molecular genetics in Croatian patients with phenylalanine 
hydroxylase (PAH) deficiency Mol Genet Metab 97 (2009) 165-171. 
[10] S.F. Dobrowolski, C. Heintz, T. Miller, C.R. Ellingson, C.C. Ellingson, I. Özer, G. 
Gökcay, T. Baykal, B. Thöny, M. Demirkol, N. Blau, Molecular genetics and impact 
of residual in vitro phenylalanine hydroxylase activity on tetrahydrobiopterin-
responsiveness in Turkish PKU population Mol Genet Metab 10 (2011) 116-121. 
[11] F.K. Trefz, D. Scheible, H. Gotz, G. Frauendienst-Egger, Significance of genotype in 
tetrahydrobiopterin-responsive phenylketonuria J Inherit Metab Dis 32 (2009) 22-26. 
[12] B.S. Andersen, A.R. Krainer, When the genetic code is not enough – How sequence 
variations can affect pre-mRNA splicing and cause (complex) disease, in: L. Almasy, 
A. Al-Chalabi (Eds.), Genetics of Complex Human Diseases, Cold Spring Harbor 
Laboratory Press, New York, 2009, pp. 165-182. 
[13] S. Ellingsen, P.M. Knappskog, H.G. Eiken, Phenylketonuria splice mutation 
(EXON6nt-96A-->g) masquerading as missense mutation (Y204C) Hum Mutat 9 
(1997) 88-90. 
[14] H.K. Chao, K.J. Hsiao, T.S. Su, A silent mutation induces exon skipping in the 
phenylalanine hydroxylase gene in phenylketonuria Hum Genet 108 (2001) 14-19. 
[15] S.F. Dobrowolski, H.S. Andersen, T.K. Doktor, B.S. Andresen, The phenylalanine 
hydroxylase c.30C>G synonymous variation (p.G10G) creates a common exonic 
splicing silencer Mol Genet Metab (2010). 
[16] P.M. Brickell, Immortalization of human B-lymphocytes by epstein-barr virus 
Methods Mol Biol 8 (1992) 213-218. 
Chapter 4 147 
 
 
147 
[17] K.B. Nielsen, S. Sorensen, L. Cartegni, T.J. Corydon, T.K. Doktor, L.D. Schroeder, 
L.S. Reinert, O. Elpeleg, A.R. Krainer, N. Gregersen, J. Kjems, B.S. Andresen, 
Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating 
mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious 
mutations in a flanking exonic splicing enhancer Am J Hum Genet 80 (2007) 416-
432. 
[18] V. Abadie, J. Jaruzelska, S. Lyonnet, P. Millasseau, M. Berthelon, F. Rey, A. 
Munnich, J. Rey, Illegitimate transcription of the phenylalanine hydroxylase gene in 
lymphocytes for identification of mutations in phenylketonuria Hum Mol Genet 2 
(1993) 31-34. 
[19] C. Heintz, H. Troxler, A. Martinez, B. Thöny, N. Blau, Quantification of 
phenylalanine hydroxylase activity by isotope-dilution liquid chromatography–
electrospray ionization tandem mass spectrometry Mol Genet Metab (2012) 
doi:10.1016/j.ymgme.2011.1012.1025. 
[20] N. Watanabe, S. Kamei, A. Ohkubo, M. Yamanaka, S. Ohsawa, K. Makino, K. 
Tokuda, Urinary protein as measured with a pyrogallol red-molybdate complex, 
manually and in a Hitachi 726 automated analyzer Clinical chemistry 32 (1986) 1551-
1554. 
[21] J. Hwang, L.E. Maquat, Nonsense-mediated mRNA decay (NMD) in animal 
embryogenesis: to die or not to die, that is the question Curr Opin Genet Dev 21 
(2011) 422-430. 
[22] J. Jaruzelska, V. Abadie, Y. d'Aubenton-Carafa, E. Brody, A. Munnich, J. Marie, In 
vitro splicing deficiency induced by a C to T mutation at position -3 in the intron 10 
acceptor site of the phenylalanine hydroxylase gene in a patient with phenylketonuria 
J Biol Chem 270 (1995) 20370-20375. 
[23] A. Goren, O. Ram, M. Amit, H. Keren, G. Lev-Maor, I. Vig, T. Pupko, G. Ast, 
Comparative analysis identifies exonic splicing regulatory sequences-The complex 
definition of enhancers and silencers Mol Cell 22 (2006) 769-781. 
[24] I. Tournier, M. Vezain, A. Martins, F. Charbonnier, S. Baert-Desurmont, S. 
Olschwang, Q. Wang, M.P. Buisine, J. Soret, J. Tazi, T. Frebourg, M. Tosi, A large 
fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is 
associated with splicing defects Hum Mutat 29 (2008) 1412-1424. 
[25] A. Daniele, G. Cardillo, C. Pennino, M.T. Carbone, D. Scognamiglio, L. Esposito, A. 
Correra, G. Castaldo, A. Zagari, F. Salvatore, Five human phenylalanine hydroxylase 
proteins identified in mild hyperphenylalaninemia patients are disease-causing 
variants Biochim Biophys Acta 1782 (2008) 378-384. 
[26] L.R. Desviat, B. Pérez, A. Bèlanger-Quintana, M. Castro, C. Aguado, A. Sánchez, 
M.J. García, M. Martínez-Pardo, M. Ugarte, Tetrahydrobiopterin responsiveness: 
results of the BH4 loading test in 31 Spanish PKU patients and correlation with their 
genotype, Mol. Genet. Metab. 82 (2004) 157–162.  
[27] M.H. Hofmann, J.K. Blievernicht, K. Klein, T. Saussele, E. Schaeffeler, M. Schwab, 
U.M. Zanger, Aberrant splicing caused by single nucleotide polymorphism c.516G>T 
[Q172H], a marker of CYP2B6*6, is responsible for decreased expression and 
activity of CYP2B6 in liver J Pharmacol Exp Ther 325 (2008) 284-292. 
 
 
 
148 Chapter 4 
 
 
Supplementary Figure S1: SRp40 and SF2/ASF overexpression in COS-1 cells 
transfected with PAH minigenes also leads to pseudoexon activation. 
 
(A) Analysis of COS-1 cells transfected with minigenes harboring WT and MCAD wild type 
and mutant ESE inserted and WT, c.1144T>C, c.1146C>A and c.1144T>C + c.1146C>A 
mutations. (B) Analysis of COS cells transfected with minigenes harboring WT, MCAD ESE 
substitutions or deletions of 3 bp, 6 bp or 9 bp. (C) Analysis of COS-1 cells transfected with 
minigenes harboring WT, c.1066-3C>T, c.1197A>T or c.1169A>G mutations. All 
transfections were carried out with or without co-transfection of a vector overexpressing 
SRp40 or SF2/ASF. Amplification of PAH exons 10 - 12 was done with minigene-specific 
primers. Transfection experiments were performed as at least two independent transfections. 
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Supplementary Figure S2: PAH intron 11 pseudoexon sequence. The pseudoexon 
corresponds to position 65379907 - 65380192 in NT_029419.12.  
 
 
Supplementary Figure S3: PAH activities of p.T380M (c.1139C>T) and p.F382L 
(c.1144T>C) transiently transfected into COS-1 cells.  
 
Mutations were introduced into intact PAH cDNA by site-directed mutagenesis in pCMV 
FLAG PAH overexpression plasmid. PAH activities are normalized for transfection 
efficiency by co-transfection with β-galactosidase expression vector. 
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Co-Expression of PAH Mutant Alleles in Eukaryotic Cells  
Biochemical Characterization and Genotype-Phenotype Correlations in BH4-
responsive PKU 
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Abstract 
The genotype-based classification of tetrahydrobiopterin (BH4) responsiveness and the 
importance of residual PAH activity have been documented in a cohort of Croatian and 
Turkish PKU patients. It has been shown that single allele mutations are not reliable for the 
selection of potential PKU candidates for pharmacological therapy with BH4. On the basis of 
these results, several mutations were characterized on protein level to elucidate BH4-response 
and explain inconsistent genotype/phenotype correlations. Our goal is to document and 
catalog all genotype-phenotype data for easier prediction of patient’s outcome. In the current 
project, mutations were characterized by transient expression and co-expression in eukaryotic 
cells and correlated with patients’ phenotype and available BH4 loading test data. With the 
co-expression system we aimed to elucidate interallelic interactions and mutation dominance 
effects in previously identified genotypes combined with in vitro BH4 responsiveness data. A 
new highly sensitive and specific PAH assay method by LC-ESI-MSMS was used for in vitro 
PAH activity measurement. Molecular, in vitro characterization of genotypes, i.e. the 
analysis of compound heterozygote mutations by co-expression, together with comparison to 
thoroughly cataloged patient data will provide a sophisticated tool for the true BH4 
responsiveness diagnosis in new PKU patients. 
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Introduction 
The investigation of the severity and impact of a mutation in a corresponding metabolic 
phenotype is one aim of in vitro expression of PAH mutations. The pathogenic effects of 
about 100 mutant PAH proteins have been investigated in detailed biochemical studies for a 
better understanding of relationships between mutant biochemistry and PKU disease 
presentation. Protein misfolding with increased aggregation and destabilized native 
conformation is a main cause of PKU and many of the PAH missense mutations, distributed 
all over the gene, influence folding and stability of the resulting enzyme. Thus, PKU disorder 
was found to be a good candidate for treatment by pharmacological chaperones and the 
natural cofactor BH4 emerged as first FDA- and EMEA-registered therapeutic agent for some 
PKU patients.  
The potential of BH4 reponsiveness among PKU patients with mild to moderate 
phenotypes is high and thus, the in vitro mechanisms and testing of BH4 responsiveness were 
assessed for many mutations (1, 2, 3, 4). Some mutations were associated with a response to 
BH4, but for many an unclear relation was reported (5, 6). PAH is naturally active as a 
homotetramer and the association of different monomers to a heterotetramer highly vary 
depending on the type of mutation and its impact on the 3D structure. PAH deficiency 
therefore most often results from complex interactions of mutant alleles or rapid intracellular 
dissociation of mutant enzyme subunits, making genotype-phenotype correlations, based on 
knowledge about individual mutations, challenging (7). Around 75% of PKU patients exhibit 
a compound heterozygote genotype, often including a mild mutation. These patients are main 
targets for BH4-loading tests, as they generally present with a significant residual PAH 
activity and PAH protein that can be potentially stabilized by BH4. Still, only a few studies 
have correlated the genotype with an effect of BH4 treatment and highlighted the importance 
of full genotype information (6, 8, 9). Although, it is now known that the genotype 
determines responsiveness, little is known on how a single mutation in the compound 
heterozygous situation affects the structure, stability, and kinetics of the heterotetrameric 
mutant PAH. The interaction of two mutated subunits may exhibit a different response to 
BH4 and different molecular behavior as the single homozygous mutation alone. Therefore, 
the characterization of subunit interactions is important as it leads to better understanding and 
prediction of the patient’s phenotype and BH4 responsiveness.  
Interallelic complementation describes the interaction between two mutant alleles at  
a given locus to form a multimeric protein. A particular combination of two alleles may 
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produce a more (negative complementation) or less (positive complementation) severe 
phenotype than expected from the homoallelic counterpart (10). It is possible, that 
complementation leads to correction of misfolding of one of the monomers (11). This 
phenomenon of positive or negative complementation contributes to the phenotypic severity 
in PKU and may explain for example the absence of BH4-response in patients carrying two 
responsive alleles (12). Several experimental setups have been reported and evaluated for the 
study of interactions between two PAH subunits. Two-hybrid analysis allows the 
measurement of protein-protein interactions occurring in living cells. PAH monomers were 
expressed as fusion proteins and results showed that misfolded mutant PAH subunits interact 
to some extent and that heteromeric enzymes are formed leading to interallelic effects (13, 
14).  
The co-expression of two distinct mutants in bacteria using a dual vector approach or a 
bicistronic expression system requires the purification of the heterotetrameric proteins (12, 
15). In these systems higher amounts of protein are produced that allow more detailed 
analysis on stability and kinetics of the heterotetrameric PAH forms in terms of residual 
activity, stability and affinity for BH4. The existence of negative interallelic complementation 
has been demonstrated for a few allele combinations (15). However, the prokaryotic 
expression system is limited in testing the effect of BH4 concentrations when the protein 
assembles in vivo. The assessment of BH4-treatment and possible effects of responsiveness 
induced by only one of the mutant alleles is not feasible in such a bacterial co-expression 
system. 
In this chapter, residual PAH activities are studied upon transient co-expression of two 
distinct PAH alleles in a mammalian system. The mammalian cell system provides a close 
approximation to the in vivo milieu for protein expression. PAH p.R261Q mutant is 
frequently reported with different phenotypes and inconsistent response to BH4 treatment 
(see also Table 1.7 in Chapter 1) (16), although the mutant shows substantial residual activity 
(43% of the wild type, Chapter 3). In a single expression study, p.R261Q protein was 
reported with reduced binding affinity for Phe and no increase in half-life by addition of BH4. 
Also, no activation and increase in specific affinity was found upon pre-incubation with Phe. 
The affinity for the cofactor was similar than in the wild type protein. (2, 3, 4). The p.R261Q 
allele was selected for expression in combination with several other alleles reported with 
inconsistent BH4 responsiveness and the impact on residual PAH activity and BH4 response 
was investigated. A dual eukaryotic vector system was used with the two mutant PAH 
proteins N-terminally fused to different epitope tags for discernible allele expression. The 
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expression combinations were chosen according to genotype data in the BIOPKU database 
(www.biopku.org), where identical genotypes are sometimes listed with diverging reports of 
BH4 responsiveness and with significant residual activity of the second allele. The response 
to BH4 of a given allele combination was analyzed by supplementation of the cell culture 
medium with BH4 or sepiapterin. Sepiapterin can be reduced to BH4 in the cell by 
dihydrofolate reductase (DHFR) (17). However, the response to BH4 does not only depend 
on the genotype and mechanisms are probably multifactorial (6). Genetic environment and 
differences in BH4 absorption or metabolism cannot be controlled, but it has been suggested 
by Pey et al. (18) and Staudigl et al. (19) that residual PAH activity and cofactor response 
depend also on the Phe level. Hence, residual activities and BH4-response of co-expressed 
PAH mutants were analyzed under normal and high Phe culturing conditions.  
The transient co-expression of two distinct PAH mutations in cell culture mimics most 
closely the patient situation and may allow testing the effect of various BH4 and Phe levels 
for better prediction of BH4 responsiveness. 
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Materials and Methods 
Construction of mammalian expression vectors and site-directed mutagenesis 
The expression plasmid pCMV-FLAG-PAH wild type (Promoter-N-Fusion-PAH) was 
received as courtesy gift from L. R. Desviat (20). PAH wild type cDNA had been cloned into 
pFLAG-CMV-2 vector (Sigma) using SalI and NotI restriction sites after amplification of 
cDNA from pMAL-PAH (21) (human PAH GenBank reference NM_000277.1). The 
pFLAG-CMV-2 vector is a high-copy plasmid with CMV promoter, leading to high levels of 
expression in mammalian cells. Mutations in the human PAH cDNA sequence were 
introduced by site-directed mutagenesis using QuikChange XL kit from Agilent 
Technologies (Santa Clara, CA, USA). The online primer design program offered by Agilent 
was used to design mutagenic primers (http://www.genomics.agilent.com/HomePage.aspx). 
The pCMV-FLAG-PAH wild type plasmid was the template for replacement of FLAG tag by 
c-Myc tag in two sequential rounds of mutagenesis to generate pCMV-Myc-PAH wild type 
(Plasmid maps in Figure 5.1). Lyophilized primer stocks were ordered from Microsynth AG 
(Switzerland).  
 
Figure 5.1: Plasmid maps of human PAH expression vectors.  
The following three primers were used to sequence complete PAH cDNA:  
Table 5.1: Primers used for sequencing of hPAH cDNA 
Name Sequence 
pCMV-hPAH: 5’-AATGTCGTAACAACTCCGCCCCATTGACGC-3’ 
hPAH_2: 5’-TCTCAGCTATGGAGCGGAAC-3’ 
hPAH_3: 5’-CATGTATACCCCCGAACCTG-3’ 
Correct insertion of mutations was confirmed by sequencing analysis using BigDye 
Terminator Cycle sequencing v1.1 (Applied Biosystems) on an ABI Prism 3130xl Sequencer.  
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The following mutation combinations were chosen for transient expression in COS-1 
cells: 
Table 5.2: Mutation combinations planned for co-expression in COS-1 cells with 
residual PAH activity of second allele.  
hPAH allele 1 hPAH allele 2 Residual activity allele 2 (% Wt) 
Predicted residual 
activity (% Wt) 
p.R261Q p.L48S 39 41 
p.R261Q p.I65T 33* 38 
p.R261Q p.R408W 2* 22.5 
p.R261Q p.R408Q 55 49 
p.R261Q p.E280K 1-3 23 
p.R261Q p.R158Q 5* 24 
p.R261Q p.E390G 54* 48.5 
p.R261Q p.Y414C  57 48 
All mutagenic primers are listed in the supplementary table. *-marked residual activities were 
determined as described in Chapter 3. The others were compiled from PAHdb Knowledgebase 
(22). The predicted residual activity was calculated as follows: (43% for allele p.R261Q + % 
allele 2)/2. 
Comparison and Optimization of Mammalian Cell Transfection Methods 
All cell lines (HepG2, HuH-7, Hep3B, COS-1) were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM, Sigma Aldrich, USA), supplemented with 10% fetal calf serum, 4 
mM L-Glutamine and 1% Penicillin/Streptomycin at 37 °C under 5% CO2. One day prior to 
transfection a confluent 10-cm HuH-7 or COS-1 dish was split into two 6-well plates, which 
resulted in 50% cell confluency on the day of transfection. For a transfection experiment in 
10-cm culture dishes, confluent HuH-7 or COS-1 dishes were split in a 1:6 ratio one day 
before transfection. Hep3B cells were transfected only in 10-cm dishes with a split ration of 
1:3 on the day before transfection. The following transfection reagents were compared in 6-
well cell culture plates for transfection efficiency and scaled up to 10-cm cell culture dishes. 
Manufacturer’s guidelines recommending plasmid DNA amounts and transfection reagent 
volumes were followed for Jetpei, Fugene 6 and Lipofectamine reagents. Pei200 
transfections were performed similar to the Jetpei protocol using N/P ratios (measure of ionic 
balance of complexes) (25, 26). DEAE/Dextran transfections were performed according to 
(27).  
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Table 5.3: Transfection reagents tested in HuH-7, Hep3B and COS-1 cell lines.  
MW = molecular weight 
Efficiencies were assessed by transfecting pGeneGrip-GFP plasmid (Genlantis, USA) 
with CMV promoter using fluorescence microscopy. Staining of the cell nuclei was achieved 
with Hoechst dye 33342. Different ratios for transfection reagent/DNA mixtures were tested. 
Variations in transfection conditions included change of serum concentration (0 or 10%) or 
the use of Opti-MEM reduced serum medium (Invitrogen) for preparation of transfection 
complexes and/or incubation of cells.  
Expression of PAH mutants in COS-1 cells 
One day prior to transfection, COS-1 cells were split in a 1:5 or 1:6 ratio (corresponding 
to ~ 2 ×  105 cells/mL) in 10-cm dishes. Transfection experiments were performed using 
Fugene 6 (Roche Applied Sciences) according to manufacturer's recommendations. Hereby, 
13 µg of the pCMV-FLAG-PAH plasmid (either wild type or mutant) were co-transfected 
with 2 µg of pSV-βgal reporter plasmid (Promega, Madison, USA) using 30 µL of Fugene 6 
reagent in serum-free medium. Transfection experiments always included expression of wild 
type PAH, several mutant PAH constructs and the comparison to non-transfected COS-1 
cells. In addition, one COS-1 10-cm cell plate was transfected with 15 µg pSV-βgal vector 
and stained using in-situ β-galactosidase staining kit (Agilent Technologies, USA) after 48 h. 
PAH-transfected cells were harvested after 48 h for immediate determination of PAH activity 
or flash-frozen in liquid N2 for storage at -80°C. 
Transfection efficiency in co-transfected cell pellets was verified by determining β -
galactosidase activity in 5-10 µL lysate in PAH assay cell lysis buffer (1× PBS pH 7.4, 0.25 
M sucrose, complete protease inhibitors cocktail (Roche)) using in-situ β -galactosidase 
enzyme assay system (Promega, Madison, USA). PAH activities of wild type and mutants 
were normalized using the absorbance results at 420 nm of o-nitrophenol (yellow color 
Chemical transfection method Properties 
Jetpei (Polyplus, France) Linear polyethylenimine (Pei), 25kDa MW  
Pei200 (23, 24) Linear deacylated Pei, 87kDa MW 
Fugene 6  
(Roche Applied Sciences, Germany) 
Multi-component nonliposomal reagent 
DEAE/Dextran (Sigma Aldrich, USA) Cationic polymer 
Lipofectamine 2000/LTX 
(Invitrogen Life Technologies, USA) 
Cationic and neutral lipids, forming liposomes 
(LTX = advanced formulation) 
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development at 37°C with a linear range between OD420 0.1 and 0.9) as measure of 
transfection efficiency.  
PAH activity assay 
The PAH activity assay was performed according to (28, 29). In brief, cell pellets were 
lysed after harvest by 6 freeze-thaw cycles in lysis buffer (2 M KH2PO4/K2HPO4, 1.5 M KCl, 
protease inhibitors). For every PAH assay, cell homogenate containing 50 - 100 µg of total 
protein were used. The appropriate amount of homogenate was adjusted to a final volume of 
77.5 µL with H2O, followed by adding 22.5 µL of master mix containing 0.6 mM Phe, 3.6 U 
of catalase (Sigma), and 0.15 M KCl in a 0.2 M potassium phosphate buffer, pH 6.8. After 
pre-incubation at room temperature for 5 min, the reaction was started by adding 2 µL of 0.1 
M dithiothreitol and 2 µL of 4.5 mM 6-methyltetrahydropterin (Schircks Laboratories, 
Switzerland) to the samples and incubated for 60 min at 25 rech°C. The reaction was stopped 
by incubation for 5 min in a 96°C heating block and centrifuged for 5 min at 13’000 x g. The 
blank samples without PAH enzyme were adjusted as well with the appropriate amount of 
cell homogenate to a final volume of 104 µL with H2O and incubated for 5 min in a 96°C 
heating block. 
The supernatant was filtrated in a centrifugal filter device (Amicon Ultra-0.5, 
UFC501096, Millipore, USA) and centrifuged at 5’000 ×  g for 15 min. Phe and Tyr were 
quantified with a standard amino acid analyzer (Biochrom 20 Plus, Amersham Biosciences). 
Treatment of cells with BH4, sepiapterin, and phenylalanine 
BH4 dihydrochloride (no. 11.212) and sepiapterin (no. 11.225) were obtained from 
Schircks Laboratories (Jona, Switzerland). BH4 solution was prepared in 5 mM HCl and 50 
mM DTT for increased stability, as BH4 solution is sensitive to oxygen and basic pH. In cell 
culture, BH4 was further stabilized with the addition of ascorbic acid (Vitamin C, Fluka, 
Switzerland) solution in a 1:1 weight ratio (30). BH4 was added to a final concentration of 75 
µM to the cell culture medium five hours after addition of the DNA/Fugene 6 mixture. Cell 
culture medium with BH4 was renewed after 24 hours. 
Sepiapterin solution was prepared in degased double-distilled H2O (ddH2O) in the dark 
and stored under N2 atmosphere at -80°C in single aliquots to ensure stability. The 
sepiapterin solution was diluted to 75 µM in the cell culture medium, five hours after 
transfection. 
Phe was added at a concentration of 1200 µM to the cell culture medium, three hours after 
transfection. Phe solution was prepared in ddH2O and stored at -20°C. 
160 Chapter 5 
 
 
Oxidation of cell lysates and culture medium for pterin measurement 
Because BH4 is unstable and prone to oxidation, especially at alkaline conditions, it is 
difficult to directly determine BH4 concentrations analytically. This problem is circumvented 
by differential oxidation of the biological sample (31, 32). One hundred µL of cell medium 
from the medium bottle supplemented with BH4/Vitamin C or from the cell culture plate 24 
hours after addition of BH4/Vitamin C, were added to 150 µL of 0.2 M HCl and oxidized for 
one hour in the dark with the addition of 1% oxidation solution (1% iodine in H2O and 2% 
KI). After the addition of a 2% ascorbic acid solution, the samples were measured by 
reversed-phase HPLC and fluorimetric detection.  
We measured biopterin and neopterin concentration in the cell lysates to confirm that 
sepiapterin is metabolized. The cells were lysed using PAH assay protocol (Chapter 3) and 
lysates were oxidized according to the protocol described by Elzaouk et al. (33). At acidic 
conditions, iodine solution (0.5%) was therefore added to the lysates, followed by incubation 
for one hour in the dark. The oxidation was continued by adding 2% ascorbic acid, 1 M 
NaOH and alkaline phosphatase and incubation for 1 hour at 37°C in the dark. The sample 
was acidified by 2 M HCl and filtrated in a centrifugal filter device (Millipore) at 4’000 x g 
for 20 minutes. The concentrations of biopterin and neopterin were determined reversed-
phase HPLC and fluorimetric detection. 
Immunoquantification by Western blot 
A small portion of protein lysate from PAH assay was immediately flash-frozen after 
protein extraction and stored at -80°C until immunoblotting. Between 5 and 50 µg of lysate 
from PAH activity assay were used for verifying PAH expression in the various cell lines by 
Western blotting, using commercially available anti-PAH antibody PH8 (sc-58398, 1:300 
dilution, Santa Cruz Biotechnology, USA or ab21170, 1:5000 dilution, Abcam, UK). In order 
to detect FLAG- or Myc-tagged PAH proteins, monoclonal anti-FLAG M2 antibody (F1804, 
1:1000, Sigma) and c-Myc antibody (sc-40, Santa Cruz Biotechnology) were used. 
Secondary antibodies used were ECL mouse and rabbit IgG, HRP-linked (1:10000 dilution, 
NA931V, NA934V, GE Healthcare, CT, USA). The antibody used for β-actin detection (AC-
74, Sigma) was applied in a 1:10000 dilution.  
 Antibody binding was detected by enhanced chemiluminescence (Amersham ECLTM, GE 
Healthcare) as described by the manufacturer's instructions. 
Stability of PAH proteins after cell lysis 
The stability of PAH proteins after cell lysis was assessed by immunoblotting. A small 
portion of total protein lysate from PAH activity assay was frozen in liquid N2 immediately 
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after cell lysis and protein extraction. Subsequently, another portion of protein was frozen 1, 
2, and 3 hours after cell lysis and storage on ice. These frozen protein lysates were stored at  
-80°C until immunoblotting.  
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Results and discussion 
Selection of the transfection method and cell system 
Hepatic and renal cell lines manifest a close approximation to the human in vivo 
environment of PAH expression, for which highest PAH activity is found in the liver and in 
the kidneys. Three human liver cell lines (HepG2, Hep3B and HuH-7) and one kidney cell 
line (COS-1, monkey origin) were tested and optimized for high transfection efficiency and 
PAH expression. This was a requirement on the cell system for specific measurements of 
PAH activity in each mutant and distinguishing between the mutants. However, the cell lines 
should not exhibit high endogenous PAH activity in order not to be confound with expressed 
PAH form the pCMV-FLAG-PAH vector. HepG2 cells were difficult to transfect due to 
clustering cell growth behavior. Before reaching confluency on the cell culture dish, cells 
rather grow in multilayers, less accessible for uptake of exogenous DNA. For this reason, the 
HepG2 cell line was excluded from the study. HuH-7 cells are fast growing, monolayer cells. 
The comparison of GFP-transfected HuH-7 cells with Jetpei, Pei200 and Fugene 6 reagents 
showed higher amounts of green-fluorescing cells with Pei200 up to 10 µg plasmid DNA 
compared to Jetpei reagent. However, cytotoxicity was high after 48 hours even though 
Pei200/DNA complexes were removed after 3 hours. Cytotoxicity was markedly reduced 
upon transfection of 10 µg DNA with Fugene 6, although with reduced efficiency compared 
to Pei200 reagent (Figure 5.3 Panel A). 
Hep3B cells have been included in this study as they were already used in PAH 
expression studies by Aguado et al. (20) with the same PAH expression vector and Jetpei 
transfection reagent. They showed lower transfection efficiencies than found in HuH-7 cells 
upon GFP expression and slower cell growth. These results lead to the conclusion that HuH-7 
is a more favorable cell system than Hep3B cells for the study of co-expression of PAH 
mutations.  
In parallel to the optimization of the transfection protocol, PAH activities were measured 
in the various cell lines transfected with Jetpei, Pei200 and Fugene 6. The transfection 
protocols were therefore adapted from 6-well plates to 10-cm sized culture plates for higher 
protein expression. Figure 5.2 shows the comparison between PAH activities measured in 
Hep3B, HuH-7 and COS-1 cells. PAH activities detected in the hepatic cell lines were less 
than 0.1 mU/mg protein. As COS-1 cells have also been used in various PAH expression 
studies (3, 21), we decided to include this cell line in our study. DEAE/Dextran and 
Lipofectamine transfection protocols were already established and successfully used in the 
laboratory and were therefore tested with the COS-1 cell line. DEAE transfection 
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experiments showed almost no GFP expression. However, Lipofectamine transfections 
showed high GFP expression and higher PAH activity than found in HuH-7 cells (Figure 5.2, 
Figure 5.3).  
 
Figure 5.2: Comparison of PAH activities measured in three transfected mammalian cell 
lines and using different transfection methods. Lipo = Lipofectamine 
PAH protein expression was also compared by immunoblotting and similar results were 
found than in PAH activity assays. Transfecting a higher DNA amount (20 µg) with Jetpei 
reagent led to slightly higher PAH protein expression. However, in this comparative analysis, 
transfecting 10 µg of plasmid vector with Pei200 led to highest PAH expression.  
 
Figure 5.3: Comparison of PAH expression using anti-PAH PH8 antibody. (A) HuH-7 cells 
transfected with 10 or 20 µg pCMV-FLAG-PAH with Fugene 6, Pei200 or Jetpei transfection 
reagent. (B) COS-1 cells transfected with 12 µg pCMV-FLAG-PAH with Lipofectamine 2000 
and LTX reagent. No PAH expression was detected in non-transfected HuH-7 or COS-1 cells.  
High protein expression was found in transfected COS-1 cells with Lipofectamine 2000 
and Lipofectamine LTX reagents. In addition, PAH wild type expression was found much 
higher in COS-1 cells than in liver cell lines. Figure 3.5 panel B in Chapter 3 of this thesis 
shows a protein expression comparison of wild type PAH transfected with the same protocol 
using Fugene 6 reagent in COS-1, Hep3B and HuH-7 cells. Even though less protein lysate 
from COS-1 cells was analyzed by immunoblotting, transfected PAH expression was visibly 
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higher in COS-1 cells than in the two hepatic cell lines. Fugene 6 transfection was found 
more efficient with serum-containing medium than with Opti-MEM reduced serum medium, 
and no medium change was necessary for 48 hours.  
Fugene 6 is a transfection reagent with straightforward transfection protocol, leading to 
high PAH expression and little cell toxicity. In addition, a high measurable range of PAH 
activities is required for detection of significant differences between the various PAH 
mutants to be tested. COS-1 cells were concluded to be a suitable cell system for culturing 
and transfection with Fugene 6 reagent and fulfilled the requirements set for this co-
expression study.   
Stability of PAH protein lysates 
We assessed the stability of PAH protein lysates extracted from transfected COS-1 cells 
upon storage on ice until the completion of PAH activity assay. As can be seen from Figure 
5.4, PAH protein amounts remained comparable over a time course of at least 3 hours. This 
time is sufficient to complete a batch of PAH activity measurements. However, during the 
immunoblotting procedure, the transfer of the proteins to the membrane was sub-optimal, 
resulting in disturbed β-actin signals. Nonetheless, the signals do not show noticeable 
differences in protein amounts loaded.  
 
Figure 5.4: PAH wild type protein turnover transiently expressed in COS-1 cells after cell 
lysis for PAH activity assay. Anti-PAH PH 8 (Santa Cruz) antibody was used.  
Optimization of PAH assay protocol 
The expression plasmid containing CMV promoter in this study is used for constitutive 
high levels of gene expression. The cell line and transfection method were optimized with the 
same purpose of obtaining high PAH expression. However, the PAH activity range detected 
was still rather small and amino acids quantified were in the low micromolar range and 
signals of the amino acid analyzer were rather unspecific. This made the efficient separation 
of various PAH mutant activities cumbersome and unspecific. The PAH assay protocol might 
not be optimal and sensitive enough for PAH expression in mammalian cells, which contain 
lower protein amounts compared to mouse liver samples previously measured with this 
assay.  
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Tandem mass spectrometry displays lower limits of detection than the amino acid 
analyzer and is more specific for quantification of amino acids because of the use of internal 
isotope standards. The quantification of PAH activity was therefore transferred to a liquid 
chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MSMS) 
machine. The PAH activity assay protocol was simultaneously adapted to the assay 
procedure described by Pey at al. (34). The successful optimization of the PAH assay 
protocol was described in detail in Chapter 3 of this thesis. All further PAH transfection 
experiments were performed in COS-1 cells using Fugene 6 transfection reagent with the 
optimized PAH assay protocol and resulted in 100 times higher PAH wild type activities 
(Chapter 3). This robust, highly specific and accurate method for the determination of PAH 
activities was used in all following experiments.  
The LC-ESI-MSMS method was setup using only FLAG-tagged PAH proteins. Before 
co-expression of two variants in cells, PAH activity of identical mutations with either FLAG- 
or Myc-tagged proteins were compared. No significant differences in activity due to a 
different epitope tag could be detected.  
Co-expression of PAH p.R261Q with p.R158Q 
The single expression of several common PAH mutations has been performed for the 
validation of the LC-MSMS method to compare activity assay results with other methods for 
validation. With single expression results known, the co-expression of two distinct PAH 
alleles in COS-1 cells was initiated in a 1:1 ratio of identical amounts of each DNA vector. 
No differences in PAH activity were found between FLAG-p.R261Q and Myc-p.R261Q, as 
well as between FLAG-p.R158Q and Myc-p.R158Q in single expression. The co-transfection 
of p.R158Q with PAH wild type showed no reduction of activity (Figure 5.5). 
 
Figure 5.5: Residual activity expressed in percent (%) PAH wild type (Wt) of p.R158Q with 
PAH wild type and with p.R261Q. Residual activities were normalized for transfection 
efficiency. 
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The p.R158Q mutation is a severe mutation with low residual PAH activity (5% of the 
wild type activity), but high amounts of mutant protein were detected (see Figure 3.3 panel 
C). The co-expression of p.R158Q with PAH wild type did not result in a residual activity of 
54%, as calculated by averaging the activity of wild type and p.R158Q. The measured 
residual activity does not seem markedly influenced by the severe p.R158Q mutation. 
However, the co-expression of p.R261Q/p.R158Q showed 30% of residual PAH activity and 
was slightly higher than predicted 24% from averaging single expressed PAH activity for 
each mutant. This genotype was reported in mild and classic PKU patients and responsive to 
supplementation of BH4 (9, 35). The response to BH4 in cell culture remains to be tested. 
However, these results showed that it is possible to assess residual PAH activity of two 
distinct, co-transfected PAH mutants.   
Treatment of transfected COS-1 cells with BH4 
BH4 supplementation to transfected cells was used to study BH4 responsiveness, resulting 
in increased residual PAH activity for some of the mutants investigated. Figure 5.6 shows the 
results of PAH activity and pterin measurements in COS-1 cells transfected with PAH 
p.R261Q. The p.R261Q mutation is frequently reported with inconsistent BH4 
responsiveness. The effect of BH4, ascorbic acid (Vitamin C) or the combination of 
BH4/Vitamin C on residual PAH activity was assessed. Panel A depicts PAH activities 
normalized to PAH wild type using β-gal assay results for transfection efficiencies.  
Vitamin C is a stabilizing agent of BH4 and should not have an effect on PAH activity. As 
can be seen in panel A, PAH p.R261Q displays the same activity (40% PAH wild type) with 
and without Vitamin C treatment. However, PAH activity after treatment of the cells with 
BH4 or BH4/Vitamin C is markedly reduced. In panel B, the absolute PAH activities, which 
are not normalized for transfection efficiency, are displayed for the various treatment 
conditions. 
 It was noted, that absorbance reads from β-gal assay in BH4-treated lysates were only 
10% of non-treated cells or cells treated with Vitamin C only and were below the linear 
range. The treatment by BH4 apparently delays β-gal assay reaction as absorbance reads only 
reach comparable values to non-treated cells after longer incubation times. The results 
displayed in panel A were therefore correlated with time of incubation in the β-gal assay at 
37°C. However, they are not conclusive for the effect of BH4 on β-gal assay and therefore we 
compared normalized PAH activities with absolute activities in panel B. The absolute 
activities are similar in all samples whether treated with BH4, Vitamin C or a combination of 
both. Under assumption that transfection efficiencies are similar in all cell dishes, BH4 and 
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Vitamin C treatment does not result in increased PAH activities under conditions used, but 
shows rather lower PAH p.R261Q activity.  
After 24 hours of treatment with BH4 a small sample of cell culture medium was removed 
for measurement of pterin concentrations to analyze whether Vitamin C stabilizes BH4 in cell 
culture and whether BH4 is consumed rapidly. Fresh culture medium samples supplemented 
with the initial concentration of 75 µM BH4 was included for comparison. In medium 
without Vitamin C and BH4, no pterin was detected and little amounts of biopterin (6.2 
nmol/L). In all other samples, biopterin concentrations were below 600 nmol/L but high 
pterin concentrations were detected (24’000 - 29’000 nmol/L). However, these samples were 
not processed by differential oxidation, and it cannot be concluded on total BH4 amounts. 
 
Figure 5.6: Treatment of p.R261Q transfected COS-1 cells with BH4 and ascorbic acid and 
analysis of the stability of BH4 in cell culture. (A) Normalized PAH activities (B) Non-
normalized absolute PAH activities (C) Comparison of BH4 in fresh cell culture medium or 
after 24 hours incubated on cells at 37°C, with or without stabilization with ascorbic acid 
(Vitamin C, VitC). These are results from a single experiment and measurements in duplicate. 
Medium: DMEM without supplementation of BH4 
BH4 is stable in acidic solution, but at basic pH, BH4 is readily oxidized to pterin (2-
amino-4-hydroxy-pteridine, removal of BH4 side chain) (31). The pH of DMEM cell culture 
medium is neutral to slightly basic. It could be speculated that the basic pH of medium and 
culturing at 37°C are sufficient to degrade BH4 to pterin, but a conclusion on the effect of 
Vitamin C on BH4 cannot be drawn from these results.  
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Treatment of responsive PAH p.E390G with BH4 
The PAH p.E390G mutation has been reported as BH4-responsive, independent of the 
second allele (36). In the following experiment the activity of p.E390G with FLAG-tag and 
with Myc-tag was compared. All the FLAG-tagged cell lysates were stopped at the same time 
point during the β-gal assay to avoid incoherence with β-gal assay results. Both Myc-tagged 
samples were gathered at an earlier time point because of increased β-gal activity in the 
samples. Figure 5.7 shows the effect of BH4 on PAH p.E390G activity with an increase in 
activity of 30%.   
 
Figure 5.7: Effect of treatment of FLAG-PAH p.E390G with BH4 on residual PAH activity. 
The FLAG-tagged constructs were normalized to FLAG-wild type (Wt) for transfection 
efficiency and Myc-tagged p.E390G construct to Myc-Wt. Results are from a single experiment 
with duplicates measurement.  
However, PAH wild type transfected cells were not treated with BH4 and the effect of 
BH4 and p.E390G cannot be readily compared.  
Comparison of the effect of BH4 and sepiapterin treatment on PAH p.R261Q  
Sepiapterin has been used to assess BH4 responsiveness in cell culture (20). After entering 
the cell, sepiapterin is reduced to 7,8-dihydropterin (BH2) via the salvage pathway by SR. 
BH2 is a substrate for DHFR, which catalyzes the subsequent reduction to BH4. Figure 5.8 
panel A shows a 50% increase in PAH p.R261Q activity with BH4, as well as with BH4 
stabilized by Vitamin C and by sepiapterin supplementation. The cells transfected with wild 
type plasmid were not treated with BH4 or sepiapterin. A 70% increase in PAH activity upon 
sepiapterin treatment of non-transfected hepatoma cells has been reported by Aguado et al. 
(20), as well as 10% increase in PAH protein expression in transfected hepatoma cells.  
The effect of BH4, Vitamin C and sepiapterin on wild type PAH activity was not assessed 
in this experiment. Under the assumption that wild type PAH activity increases upon BH4 
treatment in transfected COS-1 cells, as described in (20) for hepatoma cells, the activity of 
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PAH p.R261Q in response to BH4 or sepiapterin would not exceed wild type PAH activity. 
The β-gal assay results were lower in sepiapterin-treated cells compared to non-treated cells, 
although the decrease was not as dramatic as with BH4 treatment. Therefore β-gal assay 
samples could still be harvested at the same time point without being out of the linear range 
of β-gal activity.  
However, the absolute PAH activity results in panel B of Figure 5.8 confirm the data 
from Figure 5.6, showing that BH4/Vitamin C treatment does not lead to increased residual 
activity. 
 
Figure 5.8: Comparison of PAH p.R261Q response to treatment with BH4 and with 
sepiapterin. (A) Mutant activities were normalized for transfection efficiency and expressed as 
% wild type. (B) Absolute PAH activities are depicted, not normalized for transfection 
efficiency. All PAH p.R261Q constructs were gathered at the same time point in β-gal assay and 
the time factor was included for normalization to PAH wild type (Wt). Results are from a single 
experiment with duplicates measurement.  
However, the absolute PAH activity results in panel B of Figure 5.8 confirm the data 
from Figure 5.6, showing that BH4/Vitamin C treatment does not lead to increased residual 
activity. In order to verify whether BH4 and sepiapterin are influencing the in vitro β-gal 
assay leading to lower absorbances and not influencing transfection efficiency, we 
transfected COS-1 cells with only pSV-βgal plasmid and treated one cell plate each with 
BH4, sepiapterin, and BH4/Vitamin C. After 48 hours, cells were stained using X-gal solution 
from in-situ staining kit. No differences in transfection efficiencies were observed from the 
stained COS-1 cells. BH4 and sepiapterin are oxidizing agents and may indeed influence β-
galactosidase enzyme or assay components.  
Stability of sepiapterin in cell culture  
Sepiapterin is less sensitive to oxygen than BH4, but it is more sensitive to light. It is 
known that exogenously administered sepiapterin is efficiently incorporated into cells where 
170 Chapter 5 
 
 
it is reduced to BH4 via the salvage pathway (37, 38). From a previous work (39), we know 
that sepiapterin solution is stable at 37°C in the dark, which is comparable to the condition in 
a cell culture CO2 incubator (Figure 5.9). 
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Figure 5.9: Decomposition of 1.25 mM sepiapterin stock solution when left at daylight and 
room temperature: n  sepiapterin solution stored in the dark at 37°C; ¡  sepiapterin solution 
kept at daylight and room temperature. [SP] measured in 1:20 dilution at 420 nm,  
ελ = 10400 M-1 cm-1. (Figure from (39)). 
To investigate the intracellular conversion of sepiapterin to BH4, we have measured pterin 
concentrations in COS-1 cell lysates that were transfected or not transfected with PAH wild 
type or p.E390G (Figure 5.10). Biopterin concentrations were compared between non-treated 
and sepiapterin-treated cells. The cell lysates used for PAH activity assay were oxidized by 
iodine under acidic and alkaline conditions to differentiate between BH4 and biopterin and 
measured by HPLC. No biopterin could be detected in non-treated cells. Biopterin 
concentration was highest in the p.E390G transfected cells, a known BH4-responsive 
mutation. Pterin concentrations were only slightly increased after sepiapterin treatment.  
 
Figure 5.10: Pterin and biopterin concentrations in cell lysates before and after treatment 
with sepiapterin, processed by differential oxidation. 
The biopterin concentration determined in this experiment is the total concentration after 
acidic and alkaline oxidation of the cell lysates. BH4, qBH2, and BH2 are oxidized to 
biopterin in the first step of the differential oxidation process under acidic pH, which 
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suggests that the cells take up sepiapterin and metabolize it. Pterin results from BH4 
oxidation after alkaline oxidation. As the increase in pterin after treatment is only minor, it 
can be concluded that only a small amount of BH4 was present in these cell lysates. However, 
no conclusions can be drawn from this experiment regarding the amount of sepiapterin used 
by PAH wild type and p.E390G and whether one of the constructs would use more BH4 than 
the other constructs. 
Further measurements in an identical experiment would be necessary to determine the 
amount of sepiapterin in cell medium at the moment of addition and after 43 hours of cell 
culture at 37°C. The stability of sepiapterin should also be tested at lower concentration than 
shown in Figure 5.9. These results would have to be deducted from the sepiapterin 
concentration in cell medium.  
Effect of sepiapterin on PAH wild type 
In the report by Aguado et al. (20) a 10% increase in PAH wild type protein was 
demonstrated after treatment of transfected Hep3B cells with 100 µM sepiapterin. The PAH 
activity after the treatment was not determined, which is difficult to distinguish from 
endogenous PAH activity. However, they reported no increase in mRNA expression levels in 
the hepatoma cells, and a 70% higher PAH activity in the non-transfected cells. The amount 
of PAH protein increased by 270% after treatment with increased half-life and increased 
biopterin levels were found.  
We measured the PAH wild type activity expressed in COS-1 cells and supplemented 
with 75 µM sepiapterin for 43 hours. PAH activity was increased by 80% after normalization 
to β-gal activity, as shown in Figure 5.11. 
 
Figure 5.11: Effect of sepiapterin treatment on transfected COS-1 cells with PAH wild type 
(Wt). Results are from a single experiment with duplicates.   
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Effect of sepiapterin and phenylalanine on PAH p.R261Q 
The phenotype associated with p.R261Q/p.R261Q is mostly a mild PKU phenotype. 
However, also some classic PKU patients were reported with this genotype (16, 40). As PAH 
is tightly regulated by BH4 and Phe, the effect of both compounds on the PAH p.R261Q 
residual activity was assessed. The cells were treated with 75 µM sepiapterin or 1200 µM 
Phe, mimicking a classic PKU environment.  
 
Figure 5.12: Comparison of PAH p.R261Q treated with 75 µM sepiapterin or 1200 µM Phe. 
The residual activity has been normalized to the PAH wild type (Wt) treated identically. Results 
are from a single experiment with duplicates measurement.  
Sepiapterin and Phe treatment of p.R261Q resulted in slight PAH activity increases. β-gal 
activity results were found again decreased upon sepiapterin treatment for both constructs. It 
is therefore recommended to normalize PAH mutant proteins only to identically-treated PAH 
wild type.  
Co-expression of p.R261Q/p.R408Q and effect of BH4 and phenylalanine treatment 
Initially, the PAH activities of p.R261Q and p.R408Q were compared after single and co-
expression in COS-1 cells. p.R408Q has been reported as mild mutation with high residual 
activity  (55%), but found in a mild or classical PKU phenotype, which was explained by an 
influence on splicing regulation on mRNA level of this mutation (35, 41, 42). We found a 
residual activity of 22% for p.R408Q, which may vary depending on the cell type used for in 
vitro expression and amount of wild type transcript expressed.  
The co-expression of p.R261Q/p.R408Q showed residual activity of 28% (predicted 
residual activity from the single expression: 31%). The treatment with sepiapterin showed an 
increase of 55% activity for this genotype. 
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Figure 5.13: Comparison of single and co-expression of PAH p.R261Q and p.R408Q in 
COS-1 cells and treatment with sepiapterin. Results are from a single experiment with 
duplicates measurement. 
PAH wild type has not been treated with sepiapterin in this experiment. If we speculate 
that wild type activity always increases by 70% after treatment and re-normalize the results, 
the increase in activity for p.R261Q/p.R408Q would only be 5%. In addition, the increase of 
PAH protein amount after treatment should be considered for a final conclusion on BH4 
responsiveness with this genotype. Previously, high p.R408Q protein expression was 
reported (21, 42). Therefore, sepiapterin treatment may favor the stabilization of p.R408Q 
full mRNA transcript and therefore lead to an increase in protein expression and activity.  
The treatment of the transfected cells with Phe led to a 15% increase of residual 
p.R261Q/p.R408Q activity and the combined sepiapterin/Phe treatment to an increase of 
13%. The results were normalized to the non-treated PAH wild type. PAH expression 
analysis by Western blot (still pending) will show whether an increase in protein expression 
led to the increase in residual activity. However, sepiapterin treatment does not seem to be 
effective at high Phe levels, which corresponds to the classic phenotype. Further experiments 
are needed to conclude on BH4-sensitivity of this genotype. 
In the literature, the p.R408Q mutant was reported with higher affinity for the substrate 
than wild type PAH (4). In addition, p.R408Q expression was found increased in a co-
overexpression with chaperonin GroESL, pointing to a susceptibility for response to BH4. 
Only one patient has been documented in the BIOPKU database carrying this genotype 
corresponding to a mild phenotype and non-responsive to BH4. 
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Figure 5.14: Comparison of co-expression of PAH p.R261Q and p.R408Q upon 
supplementation with sepiapterin or Phe or a combination of both reagents. Results are from a 
single experiment with duplicates measurement. 
Co-expression of p.R261Q/p.I65T and effect of sepiapterin supplementation 
The co-expression of p.R261Q and p.I65T is an example of negative interaction of two 
distinct PAH subunits. The predicted residual activity for this genotype combination is 38% 
(measurements with this system). The co-expression in COS-1 cells revealed 19% PAH 
activity, similar to the results reported by Leandro et al. (15) in a bacterial co-expression 
system of recombinant hPAH subunits. The supplementation of sepiapterin led to a 20% 
increase in residual activity.  
Three patients with this genotype have been reported in the BIOPKU database with Phe-
levels at diagnosis above 850 µM. Only one responder was found, who had normal Phe-
levels at the time of BH4-loading test. The other two patients responded slowly or were non-
responder in a combined Phe/BH4-loading test.  
 
Figure 5.15: Co-expression of PAH p.I65T and p.R261Q and effect of sepiapterin treatment 
in COS-1 cells. Results are from a single experiment with duplicates measurement. 
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Both mutations lie at the dimer interface. The p.I65T mutation is predicted to result in a 
significant structural perturbation of the regulatory core domain (43). In vitro residual 
activity was found increased in a Phe-activated assay setup for PAH compared to non-
activated PAH, and with reduced affinity for the cofactor (2). p.R261Q lies in a cofactor 
binding region and increased concentrations of cofactor restore PAH activity. Therefore, we 
predicted that in a phenotype with high Phe levels, the combination of conformational 
correction by the substrate and p.R261Q response to the cofactor results in higher PAH 
activity. However, the interplay of high Phe and BH4 treatment remains to be tested in this 
mammalian co-expression cell system.  
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Conclusions 
The frequent inconsistencies in genotype-phenotype correlations and inconsistent reports 
of response to BH4 for several mutations constitute disadvantages in the fast and efficient 
genotype-based diagnosis and adjusting of tailored treatment in PKU patients. Although the 
genotype is the main determinant of the phenotype and as is now generally accepted as a 
valuable determinant for BH4 responsiveness, genotyping does not always provide conclusive 
prediction. In 1975, Kaufman reported on the phenomenon of negative interallelic 
complementation in PKU patients for illustrating protein-protein interactions between the 
subunits of multimeric human PAH enzymes (44). It was often assumed from patient 
investigations that mild alleles with high activity dominate over alleles with low activity (42, 
45), but direct evidence was difficult to obtain. Two-hybrid systems for example 
demonstrated that two PAH subunits interact with each other and form heteromeric proteins. 
However, available in vitro expression systems generally did not allow the study of the 
impact of a particular mutation on PAH activity in the heteromeric enzyme and assessment of 
BH4 responsiveness of the investigated genotype.  
A number of PAH mutations listed in the BIOPKU database were associated with BH4 
responsiveness, but the influence of the other allele in the in vivo situation can be crucial. In 
the present chapter, various experiments were described aiming at establishing and validating 
a co-expression system of PAH mutants in mammalian cells. The evaluation of BH4 
sensitivity and effect of various Phe levels were analyzed by the co-expression of different 
PAH allele combinations. The combination of site-directed mutagenesis, co-expression in 
mammalian cells and relation to the influence of mutations on the three-dimensional structure 
represent a powerful tool for examining mutant protein residual activity. For time reasons, 
the variety of experiments was increased in order to evaluate the system but repetitions for 
strengthening conclusions on the obtained results and establishing statistical significances 
were postponed. The two expression vectors differ only in a few base pairs and are therefore 
expected to transfect and express PAH cDNA in similar efficiencies. However, protein 
quantification needs to be performed for every expression experiment and if divergent for 
both mutants, it should be correlated with residual activity. Especially if BH4 
supplementation to a particular mutant leads to increased protein expression, the analysis of 
protein expression hints to stabilization by BH4.  
The PAH proteins were fused to epitope tags in order to confirm and compare expression 
levels of each protein and determine a contribution of both mutants to residual PAH activity. 
In addition, the tags allow the study of protein interactions between the two mutants by co-
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immunoprecipitation. The subunits of each dimer contact and interact with the adjacent 
dimer. It was planned to purify Myc-tagged PAH proteins using a commercially available kit 
and immunoblot with anti-FLAG antibody. Under the assumption that interactions are strong 
enough to resist precipitation, the blot would have shown interactions by the two co-
expressed PAH mutants. In addition, the influence of the epitope tag on PAH activity 
remains to be evaluated, as well as the influence of the location of the tag. PAH mutant 
subunits should also be produced with C-terminally tagged proteins and co-expressed. The 
same range of activity for each mutant should result.   
As PAH is tightly regulated by the concentrations of Phe and BH4 (18, 46), both 
compounds need to be considered when assessing BH4 responsiveness. The co-expression 
system allows the fast determination of residual PAH activity in combination with presence 
or absence of BH4 and high or normal Phe levels. BH4-loading test protocols are not 
harmonized throughout the world and variation of Phe intake during the test often leads to 
inconsistent results. BH4-response may vary if a patient is on dietary restriction or not, as Phe 
levels interact with response and it is the ratio of BH4 and Phe that determines activation and 
inhibition of PAH. Some PAH mutants even reach their peak activity at higher substrate 
concentrations (19). Increased Phe levels may lead to increased enzyme activity and also 
favor conformational rearrangements promoting access of the cofactor (increased affinity of 
the mutant for the cofactor). Eventually only then an effect of BH4 in the more severe 
phenotypes is observed. Nevertheless, treatment by sapropterin facilitates diet compliance, 
increases Phe tolerance, and should be favored if possible. The previous evaluation in cell 
culture and comparison with a genotype database enables the development of a 
recommendation on BH4 responsiveness and may even prevent some patients from 
performing the loading test.  
The choice of BH4 or sepiapterin formulation and concentration was made considering 
previous studies (19, 20). The biosynthesis of BH4 was investigated in COS-1 cells (47). 
However, information on the presence of dihydrofolate reductase activity in this cell line, in 
order to synthesize BH4 from sepiapterin, was missing. For this reason, both BH4 and 
sepiapterin were tested in COS-1 cells. Hasegawa et al. (37) demonstrated that several 
cultured cell lines take up sepiapterin more effectively than BH4 resulting in increased 
intracellular BH4 concentrations. The intracellular BH4 pool was found stable after 
sepiapterin supplementation. In addition and as already mentioned, supplemented BH4 is 
readily oxidized to BH2 in the extracellular fluid (37). These data, together with the stability 
of sepiapterin at 37°C and less influence on β-gal activity, led to the conclusion that 
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sepiapterin supplementation is favorable, resulting in stable intracellular BH4 concentrations 
over the time of transfection. Moreover, in further experiments, Phe and BH4 concentrations 
in cell culture could be varied to study the detailed concentration dependence of these 
reagents. The time of addition after transfection to the cell culture medium may influence 
residual PAH activity as well and should be further investigated.   
Correlations of the genotype and prediction of BH4 responsiveness remain complex as 
long as there is no gold standard test for assessing sensitivity to BH4 and inconsistent results 
persist. However, the co-expression system described herein can be used for the analysis of 
many genotype combinations under various culturing conditions. The investigation of many 
different allele combinations will allow the establishment of dominance effects for each 
mutation and algorithms for the prediction of BH4 responsiveness.  
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Supplementary Table 
Primer sequences, used for site-directed mutagenesis generating PAH mutants (Table 5.2) for 
in vitro expression: 
Corresponding nucleotide change is marked in bold. 
Primer name Sequence 5’ "  3’ 
PAH p.R261Q fwd 
                          rev 
ggcctggccttccaagtcttccactgc 
gcagtggaagacttggaaggccaggcc 
PAH p.R408W fwd 
                           rev 
ggaactttgctgccacaataccttggcccttctcag 
ctgagaagggccaaggtattgtggcagcaaagttcc 
PAH p.E390G fwd 
                          rev 
ccctctattacgtggcagggagttttaatgatgccaa 
ttggcatcattaaaactccctgccacgtaatagaggg 
PAH p.R158Q fwd 
                          rev 
gtgtaccgtgcaagacagaagcagtttgctgac 
gtcagcaaactgcttctgtcttgcacggtacac 
PAH p.I65T fwd 
                      rev 
atgatgtaaacctgacccacactgaatctagaccttctc 
gagaaggtctagattcagtgtgggtcaggtttacatcat 
PAH p.R408Q fwd 
                          rev 
ctgccacaatacctcagcccttctcagttcg 
cgaactgagaagggctgaggtattgtggcag 
PAH p.L48S fwd 
                       rev 
cactcaaagaagaagttggtgcatcggccaaagtattg 
caatactttggccgatgcaccaacttcttctttgagtg 
PAH p.E280K fwd 
                           rev 
cccatgtatacccccaaacctgacatctgcc 
ggcagatgtcaggtttgggggtatacatggg 
PAH p.Y414C fwd 
                           rev 
ggcccttctcagttcgctgcgacccatac 
gtatgggtcgcagcgaactgagaagggcc 
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Since the discovery of PKU as a treatable genetic disease and the prevention of the 
harmful effects by a low-Phe diet, it is often described as a paradigm, which caused a shift in 
medical thinking about inherited disorders (1). The initiation of newborn screening and its 
later extension to other disorders is a great benefit for patients. Moreover, PKU constitutes a 
paradigm for protein misfolding diseases with a loss-of-function pathogenic mechanism (2). 
Still, PKU is a heterogeneous disease and highly complex at its enzymatic, metabolic and 
cognitive levels.  
The molecular bases of PKU and their implications at the metabolic level with focus on 
BH4 responsiveness were addressed in the present thesis. Results from initial patient-based 
studies were investigated in the laboratory by in vitro analysis and characterization of PKU 
mutations, including the establishment of a novel method tandem mass spectrometry method 
for assessing in vitro PAH activity. 
In the first two chapters of this thesis, a large-scale assessment of Turkish and Croatian 
PKU patients with critical examination of genotypes and response to BH4 challenge is 
described. The Croatian patients were selected for BH4-loading tests solely based on the type 
of mutation. However, the prevalence of BH4-responders among the group was lower than 
predicted and led to the conclusion that the complete genotype needs to be considered for 
more consistent prediction of BH4 responsiveness. The Turkish PKU patients’ dataset was 
larger and included the full genotype with in vitro residual PAH activities of both alleles and 
data from the BH4 challenge. A substantial in vitro residual activity was found to be required 
for BH4-response. Also, a high rate of homozygous genotypes was detected and in this group, 
BH4 responsiveness was also related to substantial residual PAH activity. The detection of 23 
novel PAH mutations highlights the importance of genotyping for better characterization of 
the phenotypes and heterogeneity in PKU disease.  
Moreover, the Turkish patient study revealed 19 patients with elevated Phe levels where 
no PAH mutations were detected. The DNA was further assessed for mutations in QDPR, 
PTS, and PCD genes. Four different QDPR mutations were identified, as well as three PTS 
and one PCD mutation. The details of these results will be described in a separate follow-up 
study. However, the Turkish study contributed to the correct diagnosis of a BH4-deficiency in 
these patients, as they require a different therapy than the low-Phe diet.  
In some cases only one mutant PAH allele was detected and some of these samples will 
be further assessed by MLPA analysis or next-generation sequencing. A second mutation 
leading to a PKU phenotype may be deeply buried in an intron, which is not assessed in 
conventional genotyping methods. Lymphoblast cell cultures were initiated from the patients’ 
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blood. They will be analyzed for aberrant mRNA splicing as well as sequenced using 454 
sequencing.  
The crystal structure of PAH is a valuable frame of reference in the molecular 
characterization of the large number of PAH mutations. It is still only a model, but in 
combination with in vitro expression studies, both provide valuable information for 
characterization of the mutations, the relation to the phenotype and prediction of BH4 
responsiveness. Several different in vitro PAH assay protocols have been reported in the 
literature with divergent results for identical mutations. Most of the time PAH activities are 
reported as percentage of the wild type. Quantification and detection limits, as well as 
coefficients of variation are generally not reported. The measurement of PAH in vitro activity 
is technically relatively difficult as two of the assay components, BH4 and oxygen, react with 
each other in the absence of enzyme. 
Chapter 3 focuses on the successful application of a LC-ESI-MSMS method for the 
quantification of Phe and Tyr in cell lysates and mouse tissues. The PAH activity assay with 
amino acid analyzer, as described in Chapter 5 and previously applied in this laboratory, was 
not sensitive enough to quantify Phe and Tyr in cell lysates. Therefore, a LC-ESI-MSMS 
method for the quantification and subsequent calculation of PAH activities was developed 
and validated. Mass spectrometry is a powerful technique with high sensitivity and 
specificity for quantification of compounds in complex biological matrices. The inclusion of 
stable isotopes of the analytes renders the method highly specific.  
The LC-ESI-MSMS method was successfully applied for the direct quantification of Phe 
and Tyr in mouse brain tissue without PAH activity measurements. The tissue was extracted 
from wild type and PKU mice in order to assess diet effects on amino acids and 
neurotransmitters in the brain. The tissues were homogenized and directly prepared by the 
EZ:faastTM kit and measured by MSMS. This constitutes a different application of the 
method described in Chapter 3. In this context, the method may be further extended by the 
quantification of Trp in mouse tissue. The only requirement for the extension of the method 
with other amino acids is the availability of stable isotopes of the corresponding amino acid.   
During the setup of the in vitro expression system, we aimed at high expression levels for 
more accurate quantification of amino acids. However, as the MS method is far more 
sensitive and specific than the amino acid analyzer, the new method can also be used be with 
systems of lower transfection efficiencies and protein expression levels than presented in 
Chapter 3.  
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Many exonic PAH mutations investigated biochemically were studied before the 
awareness that up to 50% of missense mutations may influence splicing regulation (3, 4) and 
the action of the splicing code for exon recognition (5). The contribution of exon splicing 
enhancers and silencers, as well as of splice sites was poorly appreciated. But this influence 
may overrule what is predicted based on amino acid substitutions. In Chapter 4, the detailed 
analysis of PAH mutations in exon 11 has shown that splicing mutations masquerade as 
missense mutations and that exon 11 recognition is especially vulnerable. The combination of 
in silico analyses and in vitro assessment of mutations is highly important. Computer-based 
predictions provide helpful tools before embarking the genetic analysis on RNA level, but 
they also have to be considered critically. They may produce contradictory predictions on the 
effect of a mutation. This was observed for c.1139C>T mutation that was found causing exon 
11 skipping by disrupting an ESE by ESEfinder 3.0. This was so far not confirmed in the 
patient cells and transfected minigenes.  
All other exon 11 mutations reported up to date should be analyzed by the minigenes 
presented in Chapter 4. The production of several transcripts leads to reduced protein 
amounts and therefore to lower residual PAH activity than predicted. The c.1144T>C 
mutation for example and in general mutations causing reduced levels of wild type transcript 
may not respond in a 24-hour BH4loading test. Low levels of protein with low residual 
activity may explain the delayed response. This will add to the consistency of genotype-
phenotype correlations and possibly eliminate the need for a BH4-loading test.  
Unfortunately, we were not able to conclusively identify the splicing regulatory proteins 
binding exon 11 by RNA affinity chromatography to clarify the splicing mechanism of PAH 
exon 11. The sequence recognition is controlled by coordinate regulation of positive and 
negative proteins, which adds complexity to the identification of one single factor. We 
considered mass spectrometric analysis of the protein complexes and studying RNA 
interference. However, without a clear candidate regulatory protein mass spectrometry might 
lead to more confusion by identifying too many potential interaction partners. Further RNA 
affinity purifications are therefore planned in order to elucidate a splicing factor with the 
artificial mutations introduced in the minigene.  
The new exon 11a detected upon overexpression of the splicing factors SF2/ASF and 
Srp40 in the minigenes will be further analyzed in a follow-up project. To our knowledge, it 
is the first report of a pseudoexon detected in PAH, even though it was generated under 
overexpression conditions of the splicing proteins. Eventually, the appearance of the 
pseudoexon could be triggered in the patient lymphoblasts by overexpression of the same 
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splicing regulatory proteins. Lymphoblast cell lines from PKU patients present a potent tool 
to study RNA processing (liver samples from patients are not available) and allow 
investigation of a mutation’s effect at the genomic DNA level. Attention should be warranted 
to technical artifacts of RT-PCR and especially the quantification of aberrant versus normal 
PAH transcript is delicate with very low levels of expression. However, confirmatory 
experiments as described in Chapter 4 added important value to the molecular pathology of 
the assessed mutations in PAH exon 11. Finally, the BH4 responsiveness of these missense 
mutations could be tested with the in vitro expression system outlined in Chapter 5.  
The transient co-expression of two PAH subunits in a eukaryotic cell system provides 
rapid results for residual activity of the heteromeric PAH enzyme. The establishment of a 
system closely mimicking the patient genotype allows the investigation of sensitivity to BH4 
and elevated Phe levels. The analysis of numerous mutation combinations by the same 
system will enable the establishment of algorithms for the calculation of genotype-based BH4 
responsiveness. Chapter 5 describes the evaluation of only a few genotype combinations, but 
they contributed to highlight a few important aspects of such a system.  
The comparison between two residual PAH activities must be controlled for variations in 
transfection efficiency, as seen for example by comparing absolute and normalized activities. 
The normalization of PAH activity with the activity of a co-transfected reporter plasmid is an 
advantageous method, as all parameters are measured in the same cell lysate. However, our 
method of choice, the β-galactosidase reporter assay, seems to be influenced by BH4, leading 
to inconsistent results. Ma et al. (6) emphasized on the rigorous controlling of subunit 
contributions to heteromeric complexes and the analysis of subunit stoichiometry in co-
transfection studies. An internal control consisting of quantitating a second mRNA produced 
by the same vector should be less susceptible to variation. An internal control is more 
favorable as upon co-transfection, the expression of both subunits in a significant population 
of cells is critical. It could be that a nonnegligible number of transfected cells express only a 
single PAH allele. An alternative to co-transfection of β-galactosidase reporter plasmid is the 
inclusion of a fluorescent protein-encoding transfection marker, which can be assessed by 
flow cytometry.  
Some PAH mutants are more susceptible to accelerated degradation, and as could be seen 
from the immunoblotting of different PAH mutations in Chapter 3, protein amounts are 
variable depending on the type of a mutation. Thus, residual PAH activities need to be 
correlated with these differences in expression. Antibodies are available against total PAH 
(anti-PAH PH 8), but also for against FLAG- or Myc-tag fused to mutants. This allows the 
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quantification of total PAH and the amount of each mutant to be normalized with residual 
activity. It is not clear, whether transfecting different cDNA ratios would correct for 
differences in expression levels. A possibility for equalizing transcription levels between the 
two mutants would be the use of an inducible expression system. Commercial plasmid 
vectors are available containing for example the tetracycline inducible expression system for 
regulated control of transgene expression. Genes of interest can be fused to green or red 
fluorescent genes for expression monitoring and assessed by flow cytometry. Such a system 
would omit the need for performing another enzyme assay and provides values for expression 
levels of each plasmid vector.  
The use of a bicistronic expression plasmid containing two PAH alleles, constitutes a 
further alternative approach. However, the introduction of two different PAH mutations in 
the same vector in the two PAH cDNA’s requires the mutagenesis to be performed in a 
separate expression vector. The two complete PAH cDNA’s then need to be replaced in every 
mutagenesis cycle in the final bicistronic expression vector.  
If one identical PAH mutation is to be co-expressed in numerous combinations with other 
mutations, a few stable transfected cell lines with single mutations could be generated. This 
would ensure stable expression levels of one mutation and the second mutation would be 
transiently co-transfected. This approach absolutely requires the quantification of protein 
amounts and normalization of residual PAH activity for each PAH subunit. 
As can be seen from above, the co-transfection of two subunits is a delicate approach with 
many parameters requiring adjustment. Advantageous for these mammalian expression 
systems is that proteins do not require purification and enzyme activities can be measured in 
the total protein extract. The in vitro experiments have shown that amounts of transiently 
expressed PAH proteins are high and stable enough for activity assay and immunoblotting.  
Interesting would be also a co-immunoprecipitation of Myc- and FLAG-tagged PAH 
mutants co-expressed in COS-1 cells to illustrate an interaction between the two subunits 
after co-expression in COS-1 cells. A fraction of precipitated protein could then also be 
analyzed by mass spectrometry. Protein analysis by MS nowadays requires little amounts of 
protein material and is sensitive enough to distinguish small differences in mass. It could 
deliver information on the composition of the precipitated heteromeric PAH proteins.  
PAH activity is tightly regulated by BH4 and Phe. The established co-expression system 
with optimization of constant and identical expression levels allows testing various 
concentrations of both substrates. Although it is not a high-throughput system as described 
by Staudigl et al. (7), it is more specific, with lower detection limits and no interferences by 
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other fluorescing compounds. The in vitro PAH assay has also been adjusted for higher BH4 
levels to account for the optimal PAH working range, mentioned by Staudigl et al. (7).  
In summary, a combination of standardized BH4 loading test protocol, and the 
investigation of BH4-response of known genotypes in a validated, eukaryotic cell system, is a 
highly powerful tool to clarify different aspects contributing to the diverse genotype-
phenotype correlations encountered. The co-expression system accounts for dominance 
effects of one mutation to the phenotype, but also to BH4-response, and deposit in a 
genotypes database like BIOPKU may greatly improve diagnosis and establish tailored 
treatment for the patient. 
 
190 Concluding Remarks 
 
 
References 
[1] Scriver, C. R. (2007). "The PAH gene, phenylketonuria, and a paradigm shift." Hum 
Mutat 28(9): 831-845. 
[2] Pey, A. L., Stricher, F., et al. (2007). "Predicted effects of missense mutations on 
native-state stability account for phenotypic outcome in phenylketonuria, a paradigm 
of misfolding diseases." American journal of human genetics 81(5): 1006-1024. 
[3] Lopez-Bigas, N., Audit, B., et al. (2005). "Are splicing mutations the most frequent 
cause of hereditary disease?" FEBS letters 579(9): 1900-1903. 
[4] Wang, G. S. and Cooper, T. A. (2007). "Splicing in disease: disruption of the splicing 
code and the decoding machinery." Nature reviews. Genetics 8(10): 749-761. 
[5] Barash, Y., Calarco, J. A., et al. (2010). "Deciphering the splicing code." Nature 
465(7294): 53-59. 
[6] Ma, Z. L., Werner, M., et al. (2007). "Quantitative analysis of cotransfection 
efficiencies in studies of ionotropic glutamate receptor complexes." Journal of 
neuroscience research 85(1): 99-115. 
[7] Staudigl, M., Gersting, S. W., et al. (2011). "The interplay between genotype, 
metabolic state and cofactor treatment governs phenylalanine hydroxylase function 
and drug response." Human molecular genetics 20(13): 2628-2641.
 191 
 
 
 
 
 
 
 
 
Acknowledgments 
 
 
192 Acknowledgments 
 
 
I am sincerely grateful to Prof. Nenad Blau for the opportunity of this PhD thesis in the 
Division of Clinical Chemistry and Biochemistry in the Children’s Hospital Zurich. Thank 
you very much for your supervision, your constant support, your confidence and advice, and 
the introduction to the field of inborn errors of metabolism. Thank you for the opportunity to 
learn many new techniques and enabling the research in Denmark.  
I am grateful for the opportunity to collaborate with Prof. Brage S. Andresen in Odense, 
Denmark.  Many thanks for inviting me to your lab for a great, valuable experience and 
thanks to your group members for their support. Thank you for introducing me to the 
interesting world of splicing and the research tools.  
Thank you Prof. Beat Thöny, for your support, constructive inputs and advice, providing 
answers and scientific discussions. Thank you also for participating in my thesis committee 
and contributing to the guidance of this thesis. 
I would like to thank Dr. Mübeccel Demirkol and Dr. Steven F. Dobrowolski for these 
fruitful collaborations and interesting projects. 
Many thanks are expressed to Prof. François Verrey for accepting the guidance of this 
PhD thesis, as well as to Prof. Marc Donath for participating in my thesis committee.  
I would like to thank Dr. Heinz Troxler for the good collaboration on the mass 
spectrometry project and his confidence in our project and myself for using the instruments. 
Many thanks go to present and former members of the MS group. And special thanks go to 
the Rita for help with samples and the Sciex2000, as well as to Daniela and Andreas for great 
technical assistance. In addition, I would like to thank Angela and Corinne for their help with 
the enzyme assay, and Anahita for HPLC measurements. Thanks also to the Clinical 
Chemistry Routine team for measuring the many samples at any time.   
Thanks to all former and present members of the Clinical Chemistry and Metabolism 
division for contributing to the pleasant working atmosphere, always trying to help out and 
technical assistance.   
I would like to thank the OP-U15 girls for the pleasant working atmosphere in the lab, 
helping out each other and the good times around. Thank you Sophia, Hiu Man, Imane, Dea, 
Vanessa, Magda, Adrienne, and Martin and to all the others in Clinical Chemistry, as well as 
in Metabolism and Hematology division for help and support, sharing ideas as well as 
enjoyable times at lunch and coffee breaks and outside the lab.  
Many thanks go to my friends in and out of Zurich, for enjoyable times outside the lab, 
making these unforgettable. In the end I would like to send special thanks to my family for 
their encouragement, their support, advice, patience and love. And finally, I would like to 
sincerely thank Stefan for always encouraging and supporting me, for your patience and 
comprehension during these past years.  
Thank you! 
 193 
 
 
 
 
 
 
 
 
Curriculum Vitae 
 
 
 
 
 
 
194 Curriculum Vitae 
 
 
Caroline HEINTZ 
 
Personal details 
 
 Born July 17, 1981 in Luxembourg 
 Nationality: Luxembourgish 
 caroline.heintz@alumni.ethz.ch 
   
Education 
 
04/2008 – 06/2012 PhD Thesis, University Children’s Hospital Zurich 
 
"MOLECULAR AND METABOLIC BASES OF 
TETRAHYDROBIOPTERIN-RESPONSIVE PHENYLALANINE 
HYDROXYLASE DEFICIENCY" 
Division of Clinical Chemistry and Biochemistry 
Supervision by Prof. Nenad Blau, University of Zurich 
10/2007 Master of Science ETH in Chemistry, ETH Zurich 
04/2006 – 07/2006 Master Thesis 
 
"DIRECTED EVOLUTION OF A MOLTEN GLOBULAR ENZYME" 
Prof. Donald Hilvert, ETH Zurich 
08/2006 – 09/2006 Research Project II 
 
"SYNTHESE VON NEUEN Β-SEKRETASE INHIBITOREN – DIE 
SUCHE NACH WIRKSAMEN ALZHEIMER MEDIKAMENTEN" 
Prof. François Diederich, ETH Zurich 
04/2006 Bachelor of Science in Chemistry, ETH Zurich 
04/2005 – 07/2005 Research Project I 
 
"IN VITRO CHARACTERIZATION OF IMPROVED E.COLI 
CHORISMATE MUTASE HINGE-LOOP VARIANTS" 
Prof. Donald Hilvert, ETH Zurich 
10/2001 Chemistry studies 
 ETH Zurich, Switzerland 
09/1993 – 07/2001 Diplôme de fin d’études secondaires 
 
Major in natural sciences (Type C) 
Lycée Michel Rodange Luxemboug 
Curriculum Vitae 195 
 
 
195 
 
Supervising Experience 
  
09/2008 – 12/2010 Assistance in practical courses in physiology for biology and 
medical students 
Department of Physiology, University of Zurich 
  
01/2008 – 02/2008 Supervising assistant for general chemistry laboratory course 
students 
Department of Chemistry and Applied Biosciences, ETH Zurich 
 
Publications (prior to the PhD) 
 
International  
  
01/2010 – 03/2010 Visiting Scientist, University of South Denmark 
Prof. Brage Andresen 
 
 
05/2007 – 06/2007 Internship - Scientific assistant to the research project 
"Molecular mechanisms leading to the inhibition of erythroid 
differentiation by mediators of inflammation" at ‘Laboratoire de 
Biologie Moléculaire et Cellulaire du Cancer, Luxembourg’ 
Supervisor: Dr. Marc Diederich 
  
09/1998 – 07/1999 Student exchange in USA 
High School stay in Augusta, Georgia 
 
 
 
 
1) Neuenschwander, M.; Butz, M.; Heintz C.; Kast, P.; Hilvert D.; A simple selection 
strategy for evolving highly efficient enzymes. Nature Biotechnology 2007, 25, (10), 1145 
– 1147. 
  
2) Buck, I.; Morceau, F.; Christofanon, S.; Heintz, C.; Chateauvieux, S.; Reuter, S.; Dicato, 
M.; Diederich, M. Tumor necrosis factor alpha inhibits erythroid differentiation in human 
erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 
downregulation and GATA-2 upregulation. Biochemical Pharmacology 2008, 76, (10), 
1229 – 1239. 
196 Curriculum Vitae 
 
 
Oral and Poster Presentations 
 
11th International Congress of Inborn Errors of Metabolism (ICIEM), San Diego, 2009 
Oral Genotypes and BH4 responsiveness in 600 Turkish PKU 
patients 
Poster Genotype-predicted BH4 responsiveness and molecular 
genetics in Croatian patients with phenylalanine hydroxylase 
(PAH) deficiency 
  
University Children’s Hospital, Zurich, 2009 
Poster Genotype-predicted tetrahydrobiopterin (BH4) responsiveness 
and molecular genetics in Croatian patients with 
phenylalanine hydroxylase (PAH) deficiency 
  
42nd European Metabolic Group (EMG) Meeting, Lisbon, 2010 
Oral Genotype-based prediction of BH4 responsiveness in 
phenylketonuria 
  
6th Zurich Center for Integrative Human Physiology (ZIHP) Symposium, Zurich, 2010 
Poster Molecular pathology of mutations in PAH exon 11, impact on 
mRNA processing, and potential impact on therapy with 6R-
tetrahydrobiopterin (BH4)  
  
Society for Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, 
Istanbul, 2010 
Oral Molecular pathology of mutations in PAH exon 11, impact on 
mRNA processing, and potential impact on therapy with 6R-
tetrahydrobiopterin (BH4) 
Poster Genotype-based prediction of BH4-responsiveness in PKU 
  
Society for Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, Geneva, 
2011 
Oral Quantification of PAH activity in cells and tissues using 
stable isotope dilution LC-MS/MS 
  
Tri-National Congress of Swiss Society of Clinical Chemistry (SSCC), Zürich, 2011 
Poster Novel Assay for Quantification of Phenylalanine Hydroxylase 
Activity by Isotope-Dilution LC-MS/MS 
  
1st Forschungszentrum für das Kind (FZK) Retreat, Halbinsel Au, Zürich, 2011 
Oral Molecular pathology of mutations in PAH exon 11, impact on 
mRNA processing, and potential impact on therapy with 6R-
tetrahydrobiopterin (BH4) 
  
4th European PKU Group Meeting (EPG), Rome, 2012 
Oral Molecular characterization and genotype/phenotype 
correlations in BH4-responsive PKU 
 
